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Within the European Union (EU) the use and sale of recombinant bovine soma-
totropin (rBST) has been banned until December 31, 1999. Within a few years, a 
new decision must be made on the future of rBST use in the EU. Two issues will be, 
in our opinion, decisive in the political process: a) the public attitude in the EU to-
wards rBST, and b) the socio-economic impact of using/not using rBST in EU dairy 
farming. These two issues are the main elements of the analysis in this report. 
From studies of public attitude towards biotechnology one may expect that the 
current negative attitude towards rBST will not easily change. Especially where this 
attitude is based on fundamental values and beliefs, for instance on the treatment 
of animals, no quick change can be expected. However, experiences in the USA 
show that consumer concern ex ante does not necessarily lead to adverse consumer 
behaviour once rBST is introduced. Adoption of rBST by American dairy farmers is 
mostly in line with ex ante adoption studies, with some differences in different 
states due to variation in the structure of the dairy industry. 
For the EU, the most decisive element in the decision making on the future of 
rBST use is the continuation or abolishment of the milk production quota system. 
Under four different scenarios we have studied the potential socio-economic im-
pact of rBST use. The distinguishing element in the scenarios are yes/no quota sys-
tem and yes/no rBST. Only when the production limitations are lifted, the use of 
rBST may become economically desirable, as it may help strengthen the competi-
tiveness of the EU dairy industry. Not only the reaction of EU consumers, but the 
reaction of consumers in the major EU export markets is important. 
Dairy Farming/Biotechnology/USA/European Union/Dairy Policies/Adoption/ 
Economics/Structure/Public Attitude 
The contents of this report may be quoted or reproduced without further permissi-
on. Due acknowledgement is requested. 
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PREFACE 
The development of biotechnology and its applications raises a number 
of important questions concerning its impact on people, society, and markets. 
The European Commission sponsors activities to study those impacts in its RTD 
programmes in the field of biotechnology, in particular its socio-economic im-
pact and public attitudes to biotechnology. The Commission services have par-
ticipated in the public debate through a number of ad hoc activities, like sup-
port to meetings and studies. 
The Commission's White Paper on 'Growth, Competitiveness, Employ-
ment' confirmed the importance of such activities and stressed that they should 
be continued and logically further developed. 
The debate on biotechnology often involves sophisticated argument. 
Differences in knowledge and perception of facts and data lead to misunder-
standings and lead to deadlocks in the debate. Therefore provision of accurate 
information and access to it are of primary importance. In this realm the 
Biotechnology programme launched a call for proposals for studies, to support 
experts working on specific subjects. Grants have been attributed to a wide 
range of subjects (risk analysis, education in biotechnology, public perception, 
industrial strategies, employment aspects, etc.). Their selection took place on 
the basis of a peer review evaluation. The studies collect relevant facts, discuss 
and explain them, and thereby generate information useful to the general 
public or for public policies. 
This particular study here deals wi th the future of recombinant bovine 
somatotropin (rBST) in Europe. It analyses present-day differences in public 
attitudes to rBST, the state of regulatory policies, and evaluates a number of 
scenario's for the EU dairy sector under different policy alternatives. 
This report represents the studied opinion of experts working on the sub-
ject. It is published as a contribution to the debate on biotechnology. Thus, this 
study is meant to be a valuable contribution to this debate, but does not reflect 
otherwise the position of the Commission. There might also be publications in 
this series in which other experts draw different conclusions about the same 
subject, and their comparison will only complete the picture of promises versus 
realities in the biotechnology field. 
This study has been carried out by the following experts: 
Berit Nygârd, of the Centre for Rural Research, University of Trondheim, 
Norway; 
Siemen van Berkum and Jos Bijman, of the Agricultural Economics Re-
search Institute (LEI-DLO), The Hague, the Netherlands; 
Marshall Martin, of the Department of Agricultural Economics, Purdue 
University, West Lafayette, IN, USA. 
Although the study has been a collaborative effort, some division of la-
bour was agreed upon. Berit Nygârd has mainly been working on the issue of 
public attitudes, while Jos Bijman and Siemen van Berkum have studied the 
economic and regulatory aspects. Marshall Martin has provided the informa-
t ion about rBST use in the USA. Together the researchers are responsible for 
the conclusions and the report as a whole. 
Integral to the project was a workshop held, on January 30, 1996, to dis-
cuss preliminary findings of the study with various stakeholders. At the work-
shop a good discussion took place about these findings as well as about 
broader socio-economic issues of agrobiotechnology. Wherever possible, the 
comments of the workshop participants have been incorporated into the main 
report. Appendix 1 gives a brief report of the workshop. 
The final text of this report has been written in February 1996. Therefore, 
changes in US farm commodity programs, as part of the 1996 Federal Agricul-
tural Improvement and Reform Act, have not been incorporated in the analysis. 
The researchers would like to thank all those who have directly or indi-
rectly contributed to this project. In particular, we are grateful to the workshop 
participants for their very constructive comments and suggestions. 
Agricultural Economics Research European Commission 
Institute (LEI-DLO) Directorate General XII 
Biotechnologies 
Zachariasse R. van Vliet and A. Klepsch 
The Hague/Brussels, June 1996 
SUMMARY AND CONCLUSIONS 
Within the European Union (EU) the use and sale of recombinant bovine 
somatotropin (rBST) has been banned until 31 December 1999. The December 
1994 Council decision was based on two considerations. First, the introduction 
of rBST would not be in line with reform of the Common Agricultural Policy 
(CAP), as it would negatively effect dairy and beef markets. Second, a strong 
aversion against the use of rBST existed among consumers. The Council feared, 
together with the European Commission and the European Parliament, that 
the consumption of dairy products and beef would decrease considerably and 
that the image of dairy products would be negatively affected. Another issue 
supporting an extension of the existing ban was the ongoing uncertainty about 
the impact of rBST use on the health of the cow. 
Within a few years, a new decision must be made on the future of rBST 
use in the EU. Two issues will be, in our opinion, decisive in the political pro-
cess: a) the public attitude in the EU towards rBST and b) the socio-economic 
impact of using/not using rBST on EU dairy farming. These two issues are the 
main elements of the analysis in this report. 
Besides the socio-economic impacts, other issues play a role in the societal 
debate about rBST, and about agricultural biotechnology in general. Although 
these other issues only receive minor attention in this report, it is useful to list 
them because they influence public attitude towards biotechnology. Discus-
sions on the merits of agricultural biotechnology usually deal with a) the safety 
of biotechnology products for human consumption; b) the short term and long 
term impact on the environment; c) the socio-economic impact on farming, 
particularly the changing structure of agriculture and the expected domination 
over agriculture by large agrochemical and pharmaceutical companies; d) the 
impact on health and welfare of animals; and e) ethical aspects. 
Regulation of rBST 
Historically there is probably no other agricultural technology that has 
aroused such large and broad social and political debate even before its intro-
duction as the case of rBST. Because biotechnology is a new technology, there 
has been uncertainty as to how this technology should be regulated. Should 
biotechnology products be assessed and approved under existing regulation, 
or is there a need for new legislation? 
The regulation that eventually resulted from the social and political de-
bate over rBST is a reflection of the influence of different interest groups, of 
the political sensitivity of the issue, of the latitude regulators have and of the 
decision making process itself. As these are country specific issues, different 
countries have come up with different regulation on rBST. While the USA and 
approximately twenty other countries have approved the use of rBST, the EU 
has placed a ban on its sale and use, and others, like Canada, have yet to make 
a decision. But even within countries, regional governments may implement 
additional regulations, as such labelling requirements in some states in the 
USA. 
Consumer acceptance and public attitude 
Consumers are increasingly critical about the quality of food products. 
Quality includes traditional characteristics like taste, appearance and price, but 
increasingly also encompasses the production methods used on the farm. Thus, 
in the case of milk derived from rBST treated cows, consumers not only are 
concerned about the food safety, but also about the impact of rBST use on the 
environment, on the health and welfare of the cow, and on the structure of 
European dairy farming. The quality concept also has an ethical dimension, in 
the sense that consumers prefer ethically justifiable production processes. 
No international comparative studies exist on how European consumers 
would react to rBST-derived dairy products. What is available, are the EU-12 
Eurobarometer studies on public attitude towards biotechnology. In the 1991 
and 1993 editions of the Eurobarometer, questions were asked about the 
knowledge and risk perception of biotechnology and genetic engineering. 
Although the Eurobarometer does not contain any specific questions on con-
sumer acceptance, the conclusions can provide some indication of the future 
acceptance of biotechnology products like rBST. 
From the Eurobarometer study it appears that the public is more likely to 
accept genetic engineering of plants and micro-organisms than genetic engi-
neering of animals. Although rBST has nothing to do with genetic engineering 
of animals, the combination of biotechnology and animals makes the average 
consumer wary. The Eurobarometer focused on knowledge of biotechnology 
and sources of information on biotechnology. There is a large variation as to 
the trust people put in different sources of information on biotechnology. Con-
sumer and environmental organizations receive the most trust, and they have 
been very critical about rBST. The biotechnology industry, such as producers of 
rBST, was not considered very trustworthy. 
Besides the general knowledge base of individuals, the public attitude is 
also influenced by the public discourse on biotechnology. The intensity of the 
discourse as well as the articulation of the different interests effect the national 
opinion on new biotechnology. While in Great Britain and the Netherlands the 
concern for animal health is especially mentioned as a reason to reject rBST, in 
Germany the expected negative consumer reaction is also a major reason for 
rejection. In Norway, Sweden and Finland, the farming community is strongly 
opposed to using rBST, as it conflicts with the current practices of small scale 
farming, strict disease control, restrictive use of antibiotics and no illegal use of 
hormones. The productivity enhancing effect of rBST is not considered very 
important in the Scandinavian countries, due to the relatively large govern-
ment protection of the dairy sector. 
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A large part of the differences in public attitude towards biotechnology 
can be attributed to cultural differences and variation in fundamental values. 
Recent studies indicate that people's attitudes towards modern biotechnology 
are based on fundamental values. In contrast to (scientific) knowledge, funda-
mental values remain relatively stable over time. 
Farm structure and adoption 
The structural features of dairy farming differ considerably in Europe. The 
average EU dairy farm has 19 cows. While Norwegian and Finnish dairy farms 
are much smaller, with 12 and 13 cows respectively, the average dairy farm in 
the Netherlands is much larger with 40 cows. The Netherlands, Germany, 
France and Denmark are the most important exporters of dairy products in the 
EU. However, farm structure is quite different in those countries. In Germany 
and France, more than 50% of the dairy farms also have other farming activi-
ties. In the Netherlands and Denmark most (about 70%) of the dairy farms are 
specialized dairy farms. In all European countries, dairy farms are becoming 
larger, while the number of farms is declining. 
The literature on adoption of new technologies suggests that larger and 
more productive farms, with younger operators and newer technologies in use 
are more likely to adopt rBST than smaller farms, with less productive cows and 
older farmers. The US experience with rBST so far seems to support this hypoth-
esis, but with two exceptions. First, adoption of rBST has lagged somewhat in 
California compared to the national average. This is due to the very large herds 
and the tendency to manage the herd rather than individual cows. Second, the 
experience in Wisconsin, the second largest dairy state, has been somewhat 
different than in other states. By November 1994, only 5.5% of Wisconsin dairy 
farmers were using rBST compared to 11 % nationwide. This relatively low level 
of adoption could be the result of the high level of politicization surrounding 
rBST in Wisconsin. Consumer concerns about the safety of rBST in milk, along 
with concern about the economic pressures for structural change in Wisconsin's 
dairy industry, has resulted in strong resistance to rBST adoption by Wisconsin's 
dairy farmers. The politicization of rBST in Wisconsin appears to demonstrate 
that economic as well as social forces can play a role in farmer adoption deci-
sions concerning emerging agricultural technologies. 
Dairy policies 
Dairy policies in the EU, the USA and Scandinavian countries used to have 
a lot in common, but also had major differences. On average, dairy farms in the 
EU receive substantially more support than dairy farms in the USA. Another 
difference is that in the EU and Norway milk production is restrained by a 
quota system, while such a system does not exist in the USA. If US dairy produc-
tion exceeds a certain level of surplus production, support prices are reduced 
and this would bring down production. In the EU, where price guarantees exist 
and production is higher than consumption, 'excess' production is sold with 
(export) subsidies. 
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EU dairy export 
The use of rBST may affect trade patterns and trade volumes. With a 
quarter of total world production, the EU is the most important milk producing 
region. The EU is by far the largest supplier of dairy products on the interna-
tional market, supplying almost half of all internationally traded dairy prod-
ucts. Still, the EU only sells about 11 % of its milk production to third countries. 
New Zealand, the second largest dairy exporter, sells 70% of its production on 
the world market. Major export markets for EU dairy produce are Saudi Arabia 
and other Middle East countries, USA, Switzerland, and Japan. 
The future of EU dairy export is determined by internal and external fac-
tors. The main internal factors are the developments in consumption and the 
future of the quota system. The external factors are international trade agree-
ments, the enlargement of the EU with Central and Eastern European coun-
tries, and production and consumption patterns in third countries. The OECD 
expects that world prices for dairy products will increase, due to diminishing of 
subsidized exports (as result of the GATT/WTO agreements), to falling surplus 
stocks and to growing demand in non-OECD area, notably Asia. Despite these 
positive market developments, it is not expected that the EU will maintain its 
current share of the world market, mainly because it has to reduce its subsi-
dized exports. 
EU dairy sector under four scenarios 
Whether rBST will be used in the EU in the next century is strongly related 
to the quota system, which also expires at the end of 1999. We have designed 
four scenarios for the dairy sector in the early years of the 21st century, with 
yes/no for the quota system and yes/no for rBST use as distinguishing elements. 
Scenario 1 is a continuation of the current situation, with a quota system and 
without rBST. This scenario is the baseline, used as point of reference for the 
other scenarios. Under scenario 1, production will remain unchanged, con-
sumption will increase slightly, new exports will decline due to GATT/WTO com-
mitments, internal real prices will be lower, the number of dairy farms will de-
cline and the number of cows per farm will increase following the current 
trend in concentration among dairy farms, while regional distribution of dairy 
production will not change. 
Scenario 2 combines a continuation of the quota system with the use of 
rBST. There will be no change, compared to the baseline, in production, con-
sumption, net exports and internal milk prices. The trend towards a larger 
number of cows per farm continues, but at a lower rate, because of the com-
bined effect of long term structural growth in the number of cows per farm 
and a decrease in the number of cows due to the productivity enhancing effect 
of rBST. There will be some regional concentration of production within EU 
countries. 
Under scenario 3 the quota system is abolished, while rBST is still banned 
from the EU market. The unrestricted production opportunities result in larger 
production, lower prices and thus a slightly higher consumption in the EU. 
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Lower prices will also enhance the EU export performance. The structural ad-
justment of the dairy industry will be reinforced, with fewer dairy farms, more 
cows per farm, and regional concentration of milk production in regions with 
the lowest production costs, like Niedersachsen (G), Bretagne (F), Lombardia (I), 
West England (UK), the Netherlands and Denmark. 
Scenario 4 represents the elimination of both the quota system and the 
ban on rBST. This scenario can be seen as a reinforcement of scenario 3, as rBST 
use gives a push to milk production. Internal prices will be lower, net exports 
will be higher. Internal consumption will only be slightly higher, due to low 
price elasticity of demand. Structural change will accelerate: more concentra-
tion of production on a farm as well as on a regional level. 
The abolishment of the quota system is expected to result in increased 
production and net exports, plus an accelerating of structural change in the 
dairy sector towards more concentration of production, on a farm as well as on 
a regional level. The adoption of rBST reinforces these effects: more production 
and exports, lower internal prices, fewer but bigger dairy holdings, and more 
regional concentration of production. Those effects may be socially negative 
if the pace and extent of structural change exceeds certain limits, i.e., if many 
farmers have to leave the sector. 
On the other hand, a scenario without a quota system and with rBST may 
contribute to improving the international competitiveness of the EU dairy in-
dustry, as it creates opportunities for profiting from economies of scale in milk 
production. Such a structural development may be necessary if the EU wants 
to maintain its level of production, but has to lower export subsidies. 
However, the competitiveness of EU dairy products also depends on qual-
ity aspects like food safety and animal welfare. In high income markets like 
Japan and Switzerland, consumers may not be willing to accept dairy products 
from rBST treated cows. It is expected that these high income export markets 
will become more important as export subsidies are reduced. Currently, there 
is little information on consumer attitude towards rBST in the major export 
markets for EU dairy products. Consumer research in these countries may pro-
vide that valuable information. 
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1. INTRODUCTION 
1.1 Introduction 
Bovine Somatotropin produced with the help of recombinant-DNA tech-
nology (in this report referred to as rBST), has been one of the main issues in 
the pubic debate on the merits of modern biotechnology. It is one of the first 
agricultural technologies to result from recombinant-DNA technology and, 
partly therefore, one the most controversial. Like all previous new technologies 
used in agriculture, rBST promised desirable, primary consequences as well as 
some unwanted, secondary impacts. But unlike other agricultural technologies, 
rBST has been a focal point in a much larger debate about the benefits and 
costs of using modern biotechnology in agriculture and food production. 
The debate on agricultural biotechnology has focused on many issues 
that surround biotechnology, but are not limited to agriculture and food. Be-
cause biotechnology deals wi th living organisms, broader issues on ethics, 
safety and environmental impacts have raised much controversy, especially in 
the early years of its development. Still, agricultural biotechnology has received 
more public attention than one would expect on the basis of the position of 
agriculture in modern society (§ 1.2). 
The development and introduction of agricultural biotechnology has 
raised questions about the safety for humans, animals and the environment; 
about socio-economic impacts; about how to regulate this new technology; 
about ethical issues; about intellectual property rights; and public perceptions 
(Baumgardt and Martin 1991). Most of these issues also are present in the soci-
etal debate on rBST (§ 1.3). 
The importance of rBST as one of the first products of agricultural 
biotechnology, together with the continuing uncertainties as to the impact of 
rBST use, resulted in a politicization of the rBST debate. While scientists contin-
ued to disagree on the exact impacts, interest groups differed considerably in 
their valuation of the expected impacts. Still, governments had to come up 
wi th regulations that could meet both social and economic interests and be 
science-based wherever possible (§ 1.4). 
The expected adverse socio-economic impact on European dairy farming, 
together with the fear that consumers would buy less milk and dairy products 
if cows are treated with rBST, was reason for the Council of Ministers of the 
European Union (EU) to ban the sale and use of rBST. This ban is valid until 
December 31, 1999. Whether, and on what conditions, rBST will be approved 
after that date depends on what happens with (1) public attitude towards agri-
cultural biotechnology in the EU, (2) the EU dairy policy, particularly wi th the 
production quota system, and (3) the international competitiveness of the Eu-
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ropean dairy industry, especially now that American dairy farmers are using 
rBST(§ 1.5). 
1.2 The debate over agricultural biotechnology 
Although the public debate about biotechnology is not only about agri-
cultural biotechnology, the latter has been disproportionately important, rela-
tive to its role in the world biotechnology industry, in stimulating and shaping 
that debate. The relative importance of agricultural biotechnology can be 
shown by some figures: in 1993 agbiotech companies invested about $85 mil-
lion in R&D, while biopharmaceutical firms invested more than $3 billion in 
R&D 1) (Bio/Technology, July and August 1994). Yet, many of the most contro-
versial aspects of biotechnology pertain primarily, if not exclusively, to agricul-
ture and food. These aspects include environmental implications of the release 
of genetically modified organisms, the awarding of intellectual property rights 
to life forms, food safety and regulatory concerns, ethical considerations and 
industrial concentration issues. 
This relatively large emphasis on agricultural biotechnology applications 
is caused by the sensitivity of agriculture and food matters. Consumers are in-
creasingly critical about both the quality of food products and the way they are 
being produced. First, with abundant food supplies and rising income in the 
industrialized countries, consumers are putting more emphasis on the quality 
and less on the price of food items. It is expected that quality issues will in-
crease in importance (Senauer et al., 1991; Steenkamp, 1992). It is difficult, 
though, to point out exactly what this means for individual products and mar-
kets, as food quality is a broad concept. The various dimensions of food quality 
can be categorized as follows: (1) physical characteristics like taste, appearance 
and freshness, (2) food safety, e.g., the absence of toxic substances, and (3) 
characteristics of the production process, particularly farming practices. Con-
sumers tend to favour animal production systems that take into account animal 
welfare aspects, and plant production methods that are less polluting. In food 
marketing, more and more attention is being given to the sustainability of 
farming methods. 
Second, in the perception of many, the (small) family farm structure of 
agriculture is the ideal structure for the well being of the farmer, who lives in 
harmony with the natural environment, and for producing good food prod-
ucts. Any new technology that may change the structure of agriculture is seen 
as a threat. 
A third reason for the sensitivity of agriculture and food is the cultural 
dimension of food consumption. Particularly in Europe, what you eat and how 
and where you eat are still important cultural phenomena and vary from re-
gion to region and from country to country. Any real or perceived threat to 
Both figures exclude R&D spending by large, established pharmaceutical and 
agrochemical companies. 
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current food consumption patterns is looked at suspiciously. Early stories about 
the revolutionary impact of biotechnology on food production and consump-
t ion have caused much anxiety 1). 
1.3 The issues in the debate on rBST 
A large part of the public debate about agricultural biotechnology has 
focussed on rBST. Not only because rBST is one of first commercial agbiotech 
products, but also because it combined many of the issues that were of impor-
tance in the larger debate. The following were/are the main issues in the rBST 
discussion (see e.g., Hallberg, 1992): health and welfare of the cow, safety of 
milk and dairy products, structure of dairy farming, environmental impacts, 
domination over agriculture by large agrochemical and pharmacentical compa-
nies, and ethical aspects. 
The perceived impact on the health and welfare of the cow has led to 
heated discussions. Hundreds of studies have been conducted. The majority of 
these studies indicate that no adverse health effects are to be expected. For this 
reason veterinary advisory boards in both the USA and the EU have approved 
the use of rBST. However, a few studies do indicate that there may be a nega-
tive impact on the health and welfare of the cow. Thus, the debate lingers on 
and a definite answer cannot be given. Part of the uncertainty results from the 
health effects that coincide with higher milk production itself, like a higher 
incidence of mastitis. One of the welfare (and ethical) issues in this debate is 
about the way rBST is administered to the cows: a fortnightly injection. 
As consumers have become more and more concerned about the safety 
of food, uncertainty about the safety of milk and dairy products f rom cows 
treated wi th rBST has long been a major concern. Now, most scientists and 
other observers agree that the use of rBST does not pose any threat to human 
health. Still, some scholars disagree on this conclusion. Particularly the higher 
concentration of insulin-like growth factor-1 (IGF-1) has worried some health 
scientists. The fact that rBST is a hormone caused additional health worries in 
Europe, even though BST naturally occurs in the milk. The existing ban on the 
use of any hormone in animal production, and incidents of illegal use of hor-
mones that are a health threat, has made European consumers very sensitive 
to the word 'hormone' itself; even though BST is a protein hormone and not 
a steroid hormone that has been a concern in meat production and consump-
tion. 
1) This is not to say that food consumption patterns do not change. Indeed they do 
change rapidly, particularly in Europe. But a change in consumption habits is an 
individual choice, while a change in production technology lies outside the scope 
of the individual consumer. 
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Another major concern is the impact on the structure of dairy farming 
and on rural communities. It was expected that the increase in milk production 
per cow of 10 to 15% would benefit large farms more than small farms. Since 
rBST is administered to a cow individually, its application is scale neutral. How-
ever, realization of the production increasing potential will require rather in-
tensive monitoring and management of feed rations, milk production, animal 
health, breeding programmes, and overall system coordination. These monitor-
ing and management activities and the equipment needed are not scale neu-
tral. Larger farms tend to have better management and are more likely to have 
computers for monitoring feed intake, health and production per cow. Many 
believe that rBST will increase the size and reduce the number of dairy farms. 
Since many small farms would go out of business, this process would also nega-
tively affect the viability of rural communities. Thus, a shift in production may 
occur from regions where production is more extensive to regions where pro-
duction is more intensive. In the European context, of course, the potential for 
such a shift is limited by the system of national production quota, but within 
countries a regional shift may occur. 
Although many ex ante studies have been carried out on the potential 
effect of rBST use on the structure of dairy farming, it is extremely difficult to 
arrive at definite answers. Most observers agree on the conclusion that rBST 
will intensify past trends in agriculture, like fewer and larger farms (Hallberg, 
1992: 298), but the exact figures depend on many social and economic factors, 
the management profile of the farmer, the size of the farm, the price of milk 
and the existence of a quota system. In the EU, with its quota system for milk 
production and its large surplus of dairy products in the late 1980s and early 
1990s, many people in the dairy industry have their doubts about the desirabil-
ity of a productivity enhancing technique like rBST, even if it reduces per 
kilogramme production costs. 
Some people have also been concerned about the environmental impacts 
of rBST use (this issue is related to the structure of agriculture issue). Because 
large farms, with intensive production methods, are more likely to adopt rBST 
and thus benefit from it, smaller farms, often with extensive production meth-
ods, would go out of business. Thus, the intensification of dairy production 
could lead to more concentrated emission of minerals and ammonia, and thus 
environmental pollution. It may also have a negative impact on the attractive-
ness of the landscape, an issue that is related to the growing importance of 
tourism. 
A further item in the discussion about agricultural biotechnology in gen-
eral was the fear for increasing domination over agriculture by large agro-
chemical and pharmaceutical companies. Although this domination is more an 
issue in the debate over plant biotechnology (e.g., the fear of package sale of 
seeds and agrochemicals), the development of rBST by a few large agrochemi-
cal and pharmaceutical companies was looked upon with suspicion. This feeling 
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may have been even stronger in Europe, since the companies developing rBST 
have been mainly American. 
In addition to the debate about the factual impact of rBST, there is also 
the issue of how to value these facts. This is basically an ethical discussion, 
where values and beliefs are important. According to Thompson (1992), the 
ethical aspects of rBST fall into three categories. The first group of ethical ques-
tions concern the impact felt by dairy farmers, particularly those farmers who 
are adversely affected. Will the costs and benefits of using rBST be fairly distrib-
uted? The second group includes the impact on dairy cows. If rBST is to have 
certain negative animal welfare implications, are we wil l ing to accept those? 
The third group of ethical questions include environmental impacts of the in-
tensification of the dairy industry. Will the adoption of rBST lead to new or 
exacerbate existing environmental problems? And how does this combine with 
the need to move towards a more sustainable agriculture? 
1.4 Politicization and regulation of rBST 
Historically there is probably no other agricultural technology that has 
aroused such large and broad social and political debate even before its intro-
duction as the case of rBST. Given the broad diversity of societal issues that 
were at stake in this debate, a wide range of interest groups entered into the 
discussion, at one time or another. Consumer organizations, church organiza-
tions, animal welfare organizations, trade organizations, various farmer groups 
and scientific societies all voiced their opinion on this new agricultural technol-
ogy. 
Proponents and critics not only fought each other, they also put pressure 
on government authorities. Because biotechnology, and therefore rBST, is a 
new technology, there was uncertainty as to how this technology should be 
regulated. One of the main issues in this political debate was whether 
biotechnology products could be approved under existing legislation, or that 
new legislation should be implemented, with both more strict and new criteria 
concerning the impacts. Both proponents and critics saw rBST as a test case for 
regulation of agricultural biotechnology in general. Because of this, the intro-
duction of rBST became a very politicized issue. 
According to Barham et al. (1995) the debate on rBST has ushered in a 
new era of politicization of agricultural technologies. The introduction and 
adoption of many (but certainly not all) new agricultural technologies may be 
accompanied by broad societal and political debate. Barham et al. give several 
reasons for this process of politicization. First, there is an increasing number of 
societal organizations that closely watch the introduction of new agricultural 
techniques and voice their concern if there are any potential negative socioeco-
nomic, ethical, environmental, health or animal welfare impacts. Second, as 
retailers are increasingly sensitive to consumer reactions to new agricultural 
techniques, they are more strongly voicing their opinion on the direction of 
technical change in agriculture. 
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Because of the politicization of agricultural biotechnology, and the differ-
ences of opinion even among scientists, regulating rBST has not been a 
straightforward issue. Government authorities had to account for the reserved 
public attitude towards agricultural biotechnology in general, for targeted 
critique by special interest groups, and for uncertainty over consumer reaction 
to the introduction of milk from cows treated with rBST. All the above listed 
issues in the rBST discussion had to be reckoned with. At the same time, gov-
ernment agencies dealing with the promotion of science and technology, sec-
onded by private biotech industry, did not want the development of 
biotechnology to be hampered by too strict regulation. 
The regulations that are resulting from the social and political debate 
over rBST are a reflexion of the respective influence of different interest 
groups, of the political sensitivity of the issue, of the latitude regulators have 
and of the decision making process itself. As these are country specific issues, 
different countries have come up with different regulation on rBST. While the 
USA and Mexico have approved the use of rBST, the EU has placed a ban on its 
sale and use, and others, like Canada, have yet to make a decision. But even 
within countries, regional governments can demand additional regulation, as 
the different labelling requirements in individual states of the USA show. 
The differences in national regulation of rBST, reflecting the cultural dif-
ferences between countries, may not be desirable from an economic perspec-
tive. Because dairy products are traded in an international market, country 
specific regulations can influence the competitiveness of the domestic dairy 
industry. Of course, this influence can be negative or positive, depending on 
the actual regulations compared to those of competing countries. The effect 
on competitiveness is reason enough for governments to closely watch foreign 
regulations and strive for harmonization. 
1.5 The future of rBST regulation in the EU 
In the EU, the sale and use of rBST has been banned until December 31, 
1999. Although there was broad political support for this decision by the Coun-
cil of Ministers, an interesting question is whether changing viewpoints by 
stakeholders in the EU, combined with positive experiences in the USA, may 
lead to pressure on the EU authorities to not extend the ban after the year 
2000. Two developments, in our opinion, may be instrumental to such pressure: 
(1) a gradual, but continuous change in European public attitude towards agri-
cultural biotechnology, towards a higher rate of acceptance, and (2) a deterio-
ration in the competitive position of the EU dairy industry, due to market 
liberalisation (under the GATT/WTO agreement) and to use of rBST in the USA 
(and other countries). Whether these changes may take place in the near fu -
ture and under what conditions, is the main focus of this report. 
Studies on public attitude towards (agricultural) biotechnology in the EU 
generally show low rates of acceptance. Low acceptance can have several rea-
sons, among which low knowledge and high risk perception are the most im-
portant. Studies on public attitudes have been conducted in the EU as a whole, 
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as well as in individual European countries. Even though most of these studies 
focused on biotechnology in general, often special reference was made to ap-
plications of biotechnology in agriculture and food production. Comparative 
studies on attitudes in different countries of the EU, notably the Euro-
barometer surveys (Marlier, 1992; INRA, 1993), showed that there are large 
differences in the knowledge of and opinion on biotechnology applications 
among inhabitants of the various EU member states. 
A change in European public opinion on agricultural biotechnology could 
result from several developments. First, more knowledge of biotechnology 
could result in higher acceptance of specific applications of biotechnology. It 
should be emphasized, however, that more knowledge does not automatically 
lead to higher acceptance of biotechnology products. It all depends on the 
specific application and product. Second, introduction of agricultural bio-
technology products in the coming years may make people more familiar or 
even enthusiastic about this new technology. Third, the commercial introduc-
tion of rBST, particularly in the United States, has created a new situation. Now, 
the adoption of rBST by farmers and the real impact on milk production and 
changes in the structure of the dairy industry can be monitored. Results of 
these studies can be compared with ex ante impact assessments. 
The other main question in this report focuses on the potential changes 
in competitiveness of the EU dairy industry. If the use of rBST really leads to 
lower production costs, farmers using rBST will improve their competitiveness 
compared to those that do not use it, both domestically and in third countries. 
Eventually, this may lead to changes in the competitive position of the various 
dairy exporting countries on the world market. For the European Union, as one 
of the main exporters of dairy products in the world, changes in the supply 
and/or the prices of competitors are important to monitor. 
Because rBST has only been marketed for a short period of time, there 
has been limited time for it to have had any significant impact on the (world) 
dairy market. Therefore, this study will look at expected changes under several 
scenarios. The United States have been using rBST since February 1994. Real 
changes in the dairy market are now beginning to emerge. Changes in the 
competitiveness will only result if prices of American dairy products are de-
creased, nationally and internationally. This study looks at expected, and not 
at observed changes, under several scenarios for the EU dairy industry. 
1.6 Outline of the report 
The report continues, in chapter 2, wi th a description of the regulatory 
background for the decision by the Council of Ministers to ban the sale and use 
of rBST until the end of 1999. One of the regulatory issues that may become 
important in the future is labelling: can one or should one label rBST-milk or 
rBST-free milk? As there does not exist a method to distinguish natural BST 
from rBST, labelling does not seem very useful (because the claim on the label 
cannot by controlled); still there are options for labelling rBST-free milk. 
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In chapter 3 the current and future public attitude towards biotechnology 
in general and rBST in particular is discussed. The discourse on biotechnology 
in five EU member states (UK, Netherlands, Germany, Sweden en Finland) is 
presented, along with the discourse on biotechnology in Norway. 
Chapter 4 discusses dairy farm structure in the EU, Norway and the USA. 
Rather large differences appear in the size of dairy holdings, in the productivity 
of the cow and in the rate of specialization of dairy farmers. These structural 
characteristics may give an indication of the rate of adoption and diffusion of 
rBST among dairy farmers. There are, however, factors indicating that tradi-
tional adoption patterns of agricultural technology may not be valid in the case 
of rBST, as European consumers have expressed their doubts about the desir-
ability of milk from cows treated with rBST. 
The dairy policies in the EU, Norway and the USA are described in chapter 
5. Particularly the future of the EU quota system for milk production is impor-
tant for this study. The profitability, and thus the adoption, of rBST is quite 
different under a quota system than without such a system. The future of rBST 
in the EU, therefore, depends very much on the future of EU dairy policy. 
In chapter 6 the current EU external trade in dairy products is described. 
The EU is the main player on the world dairy market. Changes in dairy policies, 
in production costs, in the availability and amount of export subsidies, all influ-
ence the competitiveness of EU dairy products. The perspectives for EU dairy 
exports are discussed, given several regional and global developments influenc-
ing the competitive position. 
Last but not least, chapter 7 presents several scenarios on the future of 
the EU dairy sector. The discriminating elements in the scenarios are yes/no 
rBST and yes/no quota system. These scenarios make clear what changes the EU 
dairy sector encounters under the assumptions of abolishing or extending the 
quota system and allowing or not allowing rBST. For each of the four scenarios 
the expected developments in production, consumption, price level, export 
level, farm structure and regional concentration of production are discussed. 
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2. REGULATION OF rBST 
2.1 Introduction 
The 1994 decision to ban the use of rBST in the European Union until the 
end of 1999 was preceded by several short term bans. For most stakeholders 
the decision making process has been rather obscure, with many issues simulta-
neously at stake. The discussions within the European Commission, the Euro-
pean Parliament and the Council of Ministers have been very politicized, wi th 
interests from various countries often conflicting. Even the regulatory path that 
a product like rBST has to follow before approval is not always very clear. Some 
observers (e.g., Bent, 1993a) even claim that the EU approval procedures for 
livestock productivity enhancers (including rBST) are extremely confusing and 
even contradictory. There seems to be no published comprehensive review of 
approval procedures. Several European institutions are involved, each repre-
senting different interests and with different powers. Some aspects of approval 
and control are executed at a Union level, others at a national level. Even if the 
procedures are clear for the moment, there is change over time 'as the Euro-
pean Community endeavours to balance political expediency with moves to-
wards rationalization and harmonization' (Bent, 1993b: 25). 
In the fol lowing, some key elements of the regulatory context of rBST 
approval in the EU will be presented. It is not the aim of this chapter or report 
to provide the comprehensive review on approval procedures. By presenting 
the key elements, the reader will hopefully get sufficient insights into the regu-
latory background to the (dis)approval of rBST use in the European Union. In 
the second part of this chapter the state of regulation in several other countries 
is briefly described. 
2.2 European Union 
2.2.1 Regulatory background 
Within the EU, productivity enhancers that are injectable and implantable 
substances with a hormonal activity are considered veterinary medical products, 
and thus fall under the supervision of DG-III-C (Internal Market and Industrial 
Affairs). The basic rules governing approval for marketing of veterinary prod-
ucts are contained in Directives 81/851/EEC and 81/852/EEC. These specify that 
the main criteria which should be taken into account by Member States are 
quality, safety and efficacy, and that tests conducted in compliance wi th Com-
munity requirements in order to obtain national approval need not be re-
peated at the Community level. Directive 81/851/EEC (with updates 87/20/EEC 
23 
and 92/18/EEC) set out the procedures to be adopted with respect to applica-
tions for authorization, renewal of authorization, manufacture of veterinary 
products and imports from non-EU countries, supervision and inspection of 
manufacturing and trading, and of labelling. The Directive also instigated the 
Committee for Veterinary Medicinal Products (CVMP), composed of representa-
tives of the Member States and the Commission. Directive 81/852/EEC (with 
updates 90/676/EEC and 90/677EEC) legislated for the approximation of Mem-
ber State laws relating to analytical, pharma-toxicological and clinical standards 
and protocols for the testing of these products. By implementing these two 
Directives, approval in a number of member states was facilitated, and proce-
dures for national approval were standardized. 
In order to approximate national measures for market introduction of 
medicinal products derived from biotechnology, a special Community proce-
dure was adopted in December 1986 (Directive 87/22/EEC). This procedure en-
ables questions relating to quality, safety and efficacy for these substances to 
be resolved at Community level within the CMVP before a national decision is 
reached. This Directive did not in itself introduce new criteria for the approval 
of substances. 
2.2.2 The decision by the Council of Ministers 
The Council of Ministers of the European Community (now European 
Union) decided, on December 19, 1994, to ban the sale and use of rBST until 
December 31, 1999 (Decision 94/936/EC). This decision is basically an extension 
of Decision 90/218/EEC (revised with Decisions 92/98/EEC and 93/218/EEC) that 
prohibited the sale and use of rBST in the Community. 
The decision was made on a proposal by the Commission (COM(93) 605). 
The Commission had chosen December 31, 1999, as the expiration date, be-
cause that is also the date on which the current milk quota system ends (Regu-
lation 3950/92/EEC). The Commission has given two reasons for the extension 
of the ban on rBST (COM(93) 331). This reasoning has been accepted by the 
European Parliament in their Advise on the proposal by the Commission (Bull. 
EC 12-1993, 1.2.21) and by the Council of Ministers, in their final decision. First, 
the introduction of rBST would not be in line with reform of the CAP, as it 
would lead to an uneven situation in the milk and beef sector. Because applica-
t ion of rBST would lead to higher productivity, holdings with a large quota 
would benefit more than holdings with a small quota, and thus milk produc-
t ion would concentrate in regions with intensive milk production at the ex-
pense of regions with extensive production. As more dairy cows would be 
slaughtered, the beef market would become disrupted. It would also lead to 
problems on export markets as most third countries prohibit the use of rBST. 
Second, a strong aversion against the use of rBST exists among consumers. If 
the use of rBST would be allowed, the consumption of dairy products and beef 
would decrease considerably and the image of dairy products would be af-
fected. The markets for dairy and beef products would be further disrupted, 
as no labelling system can repair consumer trust. Moreover, control and surveil-
lance of the use of rBST is very problematic. Thus, socio-economic issues have 
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been the main consideration behind the Council decision. Another issue that 
has favoured the current decision is the ongoing uncertainty about the impact 
of rBST use on the health of the cow. This issue particularly has been brought 
forward by several interests groups in the EC. 
Effects on human health have not been an issue in the discussions leading 
to the Council Decision. The Committee for Veterinary Medicinal Products 
(CVMP) of the EC has declared, in its advice of January 29, 1993, that rBST is 
safe for humans and animals. The assumed higher concentration of insulin-like 
growth factor-1 (IGF-1) was taken into account by the CVMP. 
It must be emphasized that the ban on the sale and use of rBST in the EU 
does not preclude the import of dairy products from countries that have ap-
proved rBST. Thus, the import of dairy products that are made with milk from 
cows treated with rBST is possible under the current regulation. Chances that 
European consumers actually buy dairy products made from rBST milk are cur-
rently not very large, as there is hardly any import of dairy products from the 
USA and other countries that have approved rBST, but could increase in the 
future as more countries around the world approve rBST use. 
2.2.3 The issue of labelling 
Labelling of products made with the help of genetically modified organ-
isms (GMOs) is one of the main demands from consumer organizations in Eu-
rope. So far, no EU regulation on labelling of GMO-derived food products has 
been decided. Thus, there is no labelling requirement for imported dairy and 
meat products from cows treated with rBST. Such products can be imported 
and sold in the EU without anyone knowing it. Labelling of imported dairy 
products from cows treated with rBST is not allowed under GATT/WTO rules. 
These rules state that countries are not allowed to require labelling if there is 
no scientifically substantiated reason to do so. The decision on scientific sub-
stance lies with the Codex Alimentarius. This body of experts has declared that 
both milk and meat from cows treated with rBST are safe for human consump-
t ion. 
Labelling GMO-derived food products has been under discussion in the 
EU for several years now. Differences in opinion on labelling have been a major 
hurdle in making a final decision on the Novel Foods Regulation, of which draft 
versions have been debated several times. The final draft regulation of the 
Council of Ministers was sent to the European Parliament in October 1995 (Bull. 
EC, No. C320 of 30/11/95). According to this proposal, labelling of GMO-derived 
food products will be required: 
if such products are substantially different from equivalent traditional 
products, in composition, in nutrional value or in intended use; 
if such products contain new compounds that are not present in equiva-
lent products and pose health risks for certain groups of consumers (e.g. 
in the case of allergenic compounds); 
if such products contain new compounds that are not present in equiva-
lent products and that may lead to ethical objections; 
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if such products contain genetically modified organisms, other than for 
modifying agronomic traits. 
Although some countries in the EU would have liked to see more strict 
labelling requirements, notably Germany and Austria, the Council of Ministers 
has agreed on this final draft, in order to establish the much needed EU wide 
legislation on the introduction of GMO-derived food products. As of January 
1996, the European Parliament still had not acted on this proposal. 
If this proposal for a Novel Food Regulation is accepted - and that is ex-
pected - the labelling requirement does not cover dairy products from cows 
that have been treated with rBST, both domestically as well as in third coun-
tries. Milk from rBST treated cows would be considered substantially equivalent 
to milk from cows that have not been treated. Thus, there is no legal basis for 
labelling milk from cows that have been treated with rBST. This still leaves 
room for some kind of labelling of milk from untreated cows. 
Even if there was a legal basis, labelling dairy products from cows that 
have been treated with rBST would be troublesome. As all cow milk contains 
BST (in variable quantities), and rBST is equivalent to naturally occurring BST, 
there is no way to detect in the milk or derived dairy products whether cows 
have been treated with rBST or not. Thus, there is no control device for differ-
entiating between milk with natural BST and with rBST. 
2.3 United States 
In the United States, new drug products (human pharmaceuticals and 
veterinary products) have to be approved by the Food and Drug Administration 
(FDA). Already in 1986 the FDA determined that milk and meat from rBST-
treated cows presented no increased health risk to consumers. The human food 
safety evaluation was based on several factors: BST is biologically inactive in 
humans, rBST is orally inactive, and rBST and BST are biologically indistinguish-
able (for details on safety assessment: Juskevich and Guyer, 1990). After this 
general safety evaluation, the FDA reviewed company requests for approval for 
commercial sale of rBST. Of the four major pharmaceutical companies working 
on rBST, to date only Monsanto has received FDA approval. This occurred on 
November 4, 1993. Due to Federal legislation that required a 90-day morato-
rium on rBST use following FDA approval, Monsanto could not begin sales to 
dairy farmers until February 4, 1994. This version of rBST is sold by Monsanto 
under the brand name Posilac™. The rBST version developed by Elanco (a divi-
sion of Eli Lilly) is still under evaluation by the FDA. 
Also in the USA the issue of labelling has been discussed extensively. The 
FDA has determined there is no legal basis to label milk products from cows 
treated with rBST, as there is no distinction between this milk and milk from 
untreated cows. A label saying that the milk is 'from cows not treated with 
rBST' is allowed, only if it is combined with the statement that 'no significant 
difference has been shown between milk from rBST treated and non-treated 
cows'. No safety or health claims are allowed. 
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Individual states in the USA have their own authority in regulating the 
marketing of food products, as long as they remain within the framework of 
federal regulations. Thus, individual states may allow the use of labels saying 
the milk is 'from cows not treated with rBST'. If states do so, they should evalu-
ate these rBST labelling statements. FDA recommends that companies making 
rBST claims be able to demonstrate that milk and all milk-derived ingredients 
are from cows not treated with rBST. This may include establishment of a third-
party certification programme to assure accuracy of the claims. If rBST claims 
are made, milk from non-rBST herds must be kept separate at every stage from 
other milk, as verified by a valid paper trail (FDA Notice on BST labelling, Febru-
ary 1994). 
Only a small number of states, notably Vermont, New Hampshire and 
Wisconsin, have implemented regulation on BST labelling. Vermont has actu-
ally demanded that all milk from cows treated with rBST be labelled as such. 
As this state regulation seems to be in conflict with FDA regulation, complaints 
have been brought forward by certain companies and organizations. In the 
state of Wisconsin, a voluntary labelling measure has been adopted by the 
state legislature (Barham et al., 1995). This measure allows processors to indi-
cate on the package that their milk products came from herds which had not 
been treated with rBST (in combination with the above mentioned FDA re-
quired disclaimer). 
2.4 Other countries 
Several countries around the world in recent years have approved the sale 
and use of rBST. Most of the these countries are developing countries and/or 
Eastern European countries. None of them are major milk producing countries. 
Of the main dairy producing countries, only the United States has licensed the 
sale of rBST. 
The fol lowing countries have approved the use of rBST: Algeria, Brazil, 
Bulgaria, Costa Rica, Czech Republic, Honduras, Jamaica, Malaysia, Mexico, 
Namibia, Pakistan, Romania, Russia (and other republics of the former Soviet 
Union), Slovakia, South Africa, South Korea, United States, Venezuela and Zim-
babwe. 
Posilac™, Monsanto's trade name for rBST, is being sold in Brazil, Czech 
Republic, Malaysia, Mexico, Russia, South Africa, United States and Zimbabwe. 
Besides the 15 member countries of the EU, the use of rBST is also not 
allowed in Australia, Canada, New Zealand and Norway. Australia and New 
Zealand have not approved rBST because its use is not considered to be very 
profitable under the production method of year round grazing on grassland 
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1). Moreover, these countries fear adverse consumer reactions in Japan if their 
dairy farmers start using rBST. In Canada, a moratorium on the sale of rBST 
expired in July 1995. Still, Health Canada (i.e. the ministry of health) has not 
approved the product. The delay is due to Health Canada's requests for more 
animal health data from the manufacturer Monsanto (The AgBiotech Bulletin, 
November 1995). In Norway, the use of rBST has not been approved, and it is 
not expected that it wil l be approved in the near future (see also chapter 3). 
The effect of rBST is largely dependent on the kind and quality of the feed; the 
better the feed, the larger the effect. rBST has the most effect when the cows 
are fed concentrated feed, and the least effect for grazing cattle that do not get 
concentrated feed (Sejrsen 1992:25). 
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3. PUBLIC ATTITUDES TO rBST 
3.1 Introduction 
If enhancing production is the main goal of innovation in the dairy indus-
try, then rBST could be expected to be of great importance as it can make milk 
production more efficient. However, in a time when the focus in agricultural 
production is shifting from quantity to quality, rBST is a controversial product. 
It must not only be evaluated from a technological and economic point of 
view, but also with reference to the social consequences of its use. Ultimately, 
the socio-economic impact of rBST depends on the farmers' willingness of use 
it, on the consumers' willingness to buy milk produced by cows treated with 
rBST, and on the regulation of rBST on a national and international level. The 
discussion of the public perceptions of rBST in this chapter will be linked to the 
broader debate on the use of biotechnology in food production. 
In the first part of this chapter, the importance of taking the consumers' 
attitudes into consideration when introducing a new product on the market 
is emphasized. In the second part, we present results from the Eurobarometer 
39.1 study, conducted in 1993, in which the public perceptions to different 
forms of biotechnology are investigated in several European countries. We 
assume that there is a connection between attitudes towards new bio-
technology in general and public perception of rBST in particular. In the third 
part of the chapter, we study how this could mirror the public discourse on 
biotechnology in some selected European countries 1). 
3.2 Method 
To get information about the public perception of biotechnology, we 
have used data from Eurobarometer 39.1 2), carried out during the spring of 
1993. Unfortunately the Eurobarometer studies have no questions directly con-
cerning rBST, but these studies offer comparable data from all EU countries 
about public opinion on biotechnology in general. Comparable data from two 
of the Nordic countries selected for this study are also available. Norway partici-
1) The countries discussed in this chapter are the UK, Germany, the Netherlands, 
Norway, Sweden and Finland. 
2) The Eurobarometer studies, conducted on behalf of the European Commission, 
are surveys of the opinions and knowledge of Europeans on a broad range of 
issues. They are carried out in all countries of the European Union. Several editi-
ons of the Eurobarometer, notably 35.1 (1989) and 39.1 (1993), have included 
questions on biotechnology and genetic engineering. 
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pated in the Eurobarometer 39.1 as the only country outside the EU, and seven 
of the fifteen biotechnology questions from the same study were asked in a 
national study in Finland (von Troil, 1994a). 
In Eurobarometer 39.1 there was a total of 14,000 respondents; 1,000 
from each country 1). The data are drawn from personal interviews carried out 
by national opinion polling organizations in each country. The Eurobarometer 
gives us extensive and comparative data about public opinion towards modern 
biotechnology. However, large quantitative interview studies of this type also 
have their limitations. In surveys where the respondents are asked to choose 
between different alternatives, the answers do not always measure the proper 
attitudes. Another problem one should be aware of is that the relationship 
between what people answer in a survey, and their actual behaviour, for exam-
ple when choosing between different products in a shop, do not always corre-
spond. The Eurobarometer is dealing with attitudes towards modern bio-
technology in general, and does not have any questions about specific food 
products produced with or containing genetically modified organisms. This 
makes it difficult to predict how these attitudes will influence consumer behav-
iour in the future. 
A problem with surveys conducted to determine public attitudes towards 
specific agricultural biotechnology products could be the information given to 
respondents (Smith and Warland, 1992). Responses can easily be biased by the 
use of value-laden language, by the information provided and the way ques-
tions are asked (Caswell et al., 1994). In the Eurobarometer, the various state-
ments about biotechnology are worded in a rather positive way. The main fo-
cus is on the potential and the positive aspects of the use of new bio-
technological methods in various areas. The immediate reaction is to agree that 
such research is worthwhile and should be encouraged. In order to have any 
objections, one would need to have thought about the questions in advance. 
This high level of awareness is found only in the countries of Northwestern 
Europe. In addition, comparative studies are problematic because of the con-
textual differences, which can lead to different understanding of the same 
question, depending on the association it gives. In spite of this, and the ab-
sence of specific rBST questions, the Eurobarometer study gives useful informa-
t ion on how the support for and the evaluation of risk of various forms of 
biotechnology vary among countries in Europe. 
In addition to the Eurobarometer studies, we have also used other 
sources to get more specific information about the attitudes to rBST. We have 
investigated whether the public attitudes could be mirrored from discussions 
at organizational level and from the media coverage of questions concerning 
new agricultural biotechnology in general, and rBST in special. In order to get 
information about the national regulation and official view on rBST in the dif-
ferent countries, we have been in contact with a number of key persons in 
1) Because of the great differences between Northern Ireland and the rest of the 
UK, and the former East and West Germany, these regions are treated individu-
ally in the analysis. 
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farmer organizations, government agencies, the dairy industry, etc. Due to 
their position, these people are valuable resource persons. 
3.3 Consumer attitude 
With consumers becoming more critical towards the quality of food prod-
ucts, the introduction of a new product requires that consumer attitudes are 
taken into consideration. Several studies have examined consumer acceptance 
of food-related biotechnology (Berrier, 1987, Hoban, 1989; Hoban et al., 1992; 
Hamstra, 1991; Hamstra, 1992; Hamstra, 1993). Among the consumer interests 
regarding food are food availability, food quality and acceptable prices. More-
over, the way food is being produced becomes increasingly important, as is 
shown by consumer interest in environmentally sound and animal friendly farm 
practices. If biotechnology can contribute to this, consumers are likely to accept 
it. With regard to biotechnology in food, consumers appear to be very sensitive 
to any possible safety risk. It is expected that consumers wil l only accept 
biotechnological foodstuffs, if there is a clear consumer benefit and if it is safe 
for human health and the environment (Hamstra, 1991). In her studies, 
Hamstra also found that consumers expressed their doubts about the distribu-
tion of benefits and the prevention and control of possible adverse effects for 
human health or the environment. When it comes to food, consumers often 
are concerned about different issues than those the experts are concerned 
about (Sjodèn, 1990). 
Knowledge, risk perception and ethical views all influence the degree of 
acceptability of biotechnology (Zechendorf, 1994). The knowledge base of an 
individual and his or her source of knowledge or information wil l help form 
public attitudes towards agricultural biotechnology and its products. The att i-
tudes among consumers depend on the kind of information provided, and are 
also related to basic values (Almas and Nygârd, 1994). Consumers may reject 
biotechnology-derived products if they feel that they are being denied the 
information needed to control their own food choices (Thompson, 1992). But 
the freedom of choice has two aspects. One is to have many possibilities, many 
alternatives to choose from. The other is the ability to make a choice among 
the alternatives (Kuitert, 1985). The more alternatives, the more difficult the 
choice, especially when the consumer lacks the capability to choose. 
The complexity of society is one of the most characteristic marks of our 
t ime (Beck, 1992). It is not easy for people to have their own opinions about 
everything. In many cases, people are dependent upon trusting experts for 
their opinions on what is new or unknown. In this way, people's attitudes are 
no longer only a question of their own knowledge, but to a great degree also 
a question of trust in those who are experts in the field (Beck, 1992). And ex-
perts do not always agree. The experts' opinions are divided on public health 
issues, animal welfare issues and the structural consequences of adopting the 
use of rBST. When experts disagree, non-experts are faced with uncertainty 
about whom to believe (Thompson, 1992:40). According to Thompson 
(1992:45), the matter of trust is the greatest and most serious ethical issue asso-
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ciated with rBST. The reality of disagreement among alleged experts creates a 
situation in which a member of the lay public, lacking even the evidence to 
make informed judgments about whom to believe, quite reasonably comes to 
regard all claims about the likely consequences of technical change with justifi-
able scepticism. Since it is logically impossible for all the experts who expose 
contradictory views to be speaking the whole truth, it is very reasonable to 
question the validity of claims that any expert makes about the true risk of a 
technology. 
In spite of the fact that several governmental agencies and advisory bod-
ies in the USA (e.g. NIH and FDA) and the EU (CVMP) have stated that milk 
from cows treated with rBST is safe for human consumption, there has long 
been and still may be uncertainty among consumers about food-safety issues. 
This uncertainty is evidence of a lack of confidence in science and in its institu-
tions. This development should be taken seriously, not only for science, but for 
the foundations of democratic institutions. Both commercial undertakings and 
political decision-making require a certain amount of trust. Trust must of 
course be won, and once won must be preserved. Whatever the causes, and 
however just or unjust the suspicion of science might be, the difficult discussion 
on the merits of rBST has probably not promoted trust in regulatory bodies. 
According to Thompson (1992:45) this was the largest and most serious ethical 
issue associated with rBST in the USA. 
Consumer groups who are reacting to the food-safety issue are not react-
ing to a health risk per se, according to Thompson (1992). He states that con-
sumer groups were reacting to uncertainty, to a problem in deciding whom to 
believe about rBST and milk. While the fact that an overwhelming majority of 
credentialed scientists see no health risk associated with rBST milk should count 
heavily in favour of rBST, the fact that some scientists are linked with private 
corporations and research institutions that stand to gain from sales of rBST 
weighs against it. The layman does not evaluate the risk of rBST as such. The 
layman must evaluate the risk of choosing the wrong expert (Thompson, 
1992:41). 
3.4 Results from the Eurobarometer studies 
If we fol low Beck's argumentation, people's attitudes towards modern 
biotechnology are no longer only a question of their own knowledge about 
the subject, but also to a great degree a question of their confidence in those 
who are the experts in the field. Results from the Eurobarometer studies indi-
cate that there is a definite variation between the sources of information and 
people's confidence in the various countries. Results from the Eurobarometer 
studies also show how support and risk perception of biotechnological research 
in different areas vary between various countries. We will now give a brief 
summary of the main findings of relevance to this study (for a more detailed 
description see Almas and Nygârd, 1995). 
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3.4.1 Whom to believe? 
Results from the Eurobarometer studies indicate that there is a large vari-
ation as to the trust people put in different sources of information. If we look 
at the average for all of the countries included in the study, we f ind that re-
spondents have the greatest confidence in environmental organizations (26%) 
(see appendix 2). While confidence in environmental organizations is rather 
high in countries such as West Germany (39%), and East Germany (31 %), the 
comparable numbers for Norway are only 14%. In Norway, this may be because 
there are other actors, such as several of the political parties and the ministry 
of environment, that also have significant legitimacy in the environmental po-
litical discourse. 
Very few name industry as a source of most confidence in telling the truth 
about modern biotechnology. None of the EU countries reports more than 2%, 
and in most of the countries, less than 1 % of respondents named industry as 
the source that they have most confidence in to tell the truth about 
biotechnology and genetic engineering. 
Norway differs the most from the EU countries in that the amount of 
confidence in public authorities is rather large (21 % in Norway, against 7% in 
the EU). The confidence in public authorities is also great in Denmark (18%), 
and probably we would have found the same in Sweden and Finland, as the 
Scandinavian countries are rather culturally homogenous. In comparison, only 
2% in Italy, and 3% in Belgium respond that public authorities are the source 
in which they have most confidence regarding information about bio-
technology and genetic engineering. The great amount of confidence in public 
authorities in the Nordic countries reflects the fact that they have a reputation 
for being relatively impartial and objective in difficult questions regarding reg-
ulation. 
3.4.2 Support for biotechnology research 
In the fol lowing we shall look at how support for biotechnological re-
search varies among different areas. From the Eurobarometer we have taken 
examples ranging from breeding plants, animals and micro-organisms, produc-
tion of food, to biotechnological research to develop new medicines and vac-
cines and to detect hereditary diseases in human beings. Each question has a 
short introduction that explains the field of application (see appendix 3). The 
respondents were asked whether they agree or disagree that 'such research is 
worthwhile and should be encouraged'. 
Biotechnological research for developing new medicines and vaccines has 
the greatest support in a majority of the countries (see appendix 4). In the 
Netherlands and West and East Germany, the greatest support is for research 
on the use of genetically altered micro-organisms for the breakdown of sew-
age and other waste products, together with the clean up of oil slicks. It seems 
reasonable to view this in the context of the strong environmental actors in the 
national discourse. West Germany distinguishes itself by having the least sup-
port for the statements supporting genetic engineering in all areas, except 
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when it comes to farm animals, where the Netherlands gave the lowest sup-
port. The historical background with racial experiments during World War II, 
together wi th the existence of strong environmental political actors helps to 
explain why this scepticism towards biotechnology is most strongly articulated 
in Germany. 
In the Netherlands, there has been a thorough discourse concerning ge-
netically altered farm animals. This could be partly explained by the strong 
environmental movement. While the Netherlands is the country which gives 
the least support to biotechnological research in farm animal breeding, they 
are the leading supporter when genetically altered micro-organisms to clean 
up oil slicks or other contaminants in the environment are in question. A great 
amount of knowledge is required to be able to differentiate about 'bad' and 
'good' use of the modern biotechnology. In Denmark, it was found that in-
creased knowledge about biotechnology resulted in a polarization between 
the sceptics and the supporters. The differentiation we find in the Netherlands 
might be a result of the same, indicating a relatively high information level 
concerning biotechnology and genetic engineering. 
On the whole, Belgium is the country with the highest support for 
biotechnology research. Except when it comes to farm animals, foods, and hu-
man beings, Belgium is the leading or second leading supporter. It has previ-
ously been suggested that there is a north/south division in attitudes; the opin-
ion in northern Europe appears to be more sceptical, while the southern Euro-
pean countries have a more positive attitude towards biotechnology 
(Zechendorf, 1994). According to our data, this pattern is not unambiguous, 
but seems to be correct when it comes to farm animals, foods and human be-
ings, wi th Spain and Portugal among the leading supporters. 
The use of new biotechnology methods in the breeding of farm animals 
as a goal of biotech research receives the lowest support in all countries. Para-
doxically, in all countries, there is greater support for research in genetic engi-
neering for human health purposes than for animals. This may perhaps be ex-
plained by the difference in the purpose. In the case of human beings and ge-
netically engineered production of medicine, the purpose is to save human 
lives. In developing transgenic animals, the commercial interests are more in 
the fore. As such, the motivation for this type of research is not primarily saving 
lives or improving the welfare of animals, but rather to increase productivity 
and profitability. 
3.4.3 Risk perceptions 
The respondents to the Eurobarometer studies were also asked to indi-
cate whether they agree or disagree that biotechnological research in the dif-
ferent areas could pose a risk to human health or to the environment. The con-
cern about risk varies a good deal between the different technologies (see 
appendix 5). The concern about risk is greatest for those technologies that re-
ceived the least support: biotechnology used on farm animals, food, and hu-
man beings. If we look at the variation between the different countries, we 
find that the concern about risk for all the technologies is consistently greatest 
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in Denmark (together with West Germany). This is interesting considering that 
Denmark is the country wi th the longest tradition of popular discourse on 
modern biotechnology, and that the Danes are probably the most knowledg-
able about modern biotechnology. Spain and Italy are the countries where the 
concern about risks is consistently low for all technologies. 
3.5 Country studies 
The degree of knowledge about biotechnology as well as the ability to 
influence its development correlate with the degree to which biotechnology 
has been the object of public discourse in the various countries. We assume 
that the strength of the various actors in the discourse will vary from country 
to country, depending on the strength of the hegemony of the technical-indus-
trial actors. In addition, cultural differences and variation in fundamental val-
ues will contribute to form people's attitudes towards modern biotechnology 
in various European countries. Recent studies indicate that people's attitudes 
towards modern biotechnology are based on fundamental values (Almas and 
Nygârd, 1994). In contrast to (scientific) knowledge, fundamental values remain 
relatively stable over time. 
3.5.1 The discourse on biotechnology in the UK 
In the UK there has been a quiet, limited discourse about genetic engi-
neering and biotechnology (Husted, 1992). In the same manner as in the USA, 
but far less dramatic, various interest groups have attempted to influence the 
federal regulation of new biotechnological methods. On the one side we find 
the associations for animal protection, environmental organizations, trade un-
ions, religious and ethical movements and representatives from small-scale 
farms. On the other side are the pharmaceutical companies, the agro-chemical 
industry and the food industry. These two parts present opposing views of the 
regulation and control of genetic engineering. The former pressure group 
wants governmental regulations that will slow down, limit, or prevent certain 
developments, while the latter, even if they see the need for some regulation, 
often take a stand for less regulation and for a relatively free market for the 
new biotechnological products and processes. 
British working groups that function as advisory and controlling organs 
on issues concerning genetic engineering are bound by secrecy. While in the 
USA the 'Freedom of Information Act' is discussed, it differs from the situation 
in Great Britain under the 'Official Secrets Act'. This is one of the reasons for 
difficulties that the sceptical groups have had in getting access to qualified 
information and opinions (Husted, 1992). 
In spite of this, there are several groups campaigning against rBST in 
Great Britain. The animal welfare organization Compassion in World Farming 
(CIWF) has campaigned long and hard against the use of rBST, believing it has 
a negative impact on animal health and welfare (D'Silva, 1994). Likewise The 
Farm Animal Welfare Council supported the continuation of the EU-morato-
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rium, wi th the fol lowing observation: rBST used at low levels in low yielding 
dairy cows may not have any adverse effects on cow welfare, but when used 
to induce high levels of milk production, rBST can have severe effects on wel-
fare, particularly in relation to the occurrence of mastitis and other diseases 
(The Veterinary Record, July 23, 1994). The evidence of mastitis in rBST-treated 
cows was the reason why the UK Veterinary Products Committee refused licen-
ces for rBST from Monsanto and from Elanco (Dixon, 1991). The National Farm-
ers Union (representing farmers and growers) also supports the EU-moratorium 
on the marketing of rBST. The British Ministry of Agriculture has supported 
findings demonstrating that rBST use is effective and poses no risk to human 
health or to the environment, but withheld approval because of insufficient 
data on animal health. 
3.5.2 The discourse on biotechnology in Germany 
From the Eurobarometer study, it appears that Germany (especially the 
former West Germany) distinguishes itself in comparison to the other EU coun-
tries in that it has the lowest support for the use of biotechnology in practically 
all the various contexts that were treated in the Eurobarometer (Almas and 
Nygârd, 1995). This makes it especially interesting to study what characterizes 
the discourse concerning biotechnology in Germany. According to Andersen 
(1992), the German discourse is marked by certain types of participants that are 
not found to the same degree in other countries. Well known actors are the 
'old' political parties, the representatives of industry and the representatives 
for research who also take part in the German discourse. In addition, are the 
many other important actors who have in some special manner contributed 
towards the characteristics of the German discourse. The political party 'Die 
Grünen' has made biotechnology a leading issue. There is a strong, organized 
and well founded critical expertise in Germany. Several independent institu-
tions outside the established research environment, for example 'Öko-Institut' 
and 'Forschungsstätte der Evangelishen Studiengemeinschaft' (FEST) have also 
participated in the discourse. In addition, the church, more specifically the 
Evangelical Lutheran Church, takes a much more active part in the discourse 
than it does in other countries. The German Organization of Veterinarians 
(Tierärztliche Vereinigung für Tierschutz) has stated its opposition against rBST, 
as there are still many animal health questions unresolved (Welt der Milch, 48, 
1994/3). 
3.5.3 The discourse on biotechnology in the Netherlands 
As already mentioned, the Eurobarometer shows that the Dutch have a 
differentiated view on various forms of biotechnology, indicating a relatively 
high information level concerning biotechnology and genetic engineering. 
There has been a thorough discourse concerning genetically altered farm ani-
mals, and the Netherlands give the least support of all countries on the state-
ment that such research is worthwhile and should be encouraged. Several stud-
ies on public opinion and consumer acceptance of food biotechnology were 
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also carried out in the Netherlands (Hamstra, 1991, 1992, 1993). 
Since 1986, farmers, consumers, animal welfare and environment organi-
zations in the EU have been demanding a ban on rBST and products derived 
via its use. The Dutch animal protection organization 'Nederlandse Vereniging 
tot Bescherming van Dieren' has had a central role in the campaign, as one of 
the member organizations of the 'Eurogroup for Animal Welfare - A united 
voice for animal welfare in the European Union'. A statement against rBST, 
signed by more than 300 European organizations, was sent to the European 
Council in 1994. 
In the Netherlands, the expected negative consumer reaction is the main 
reason why the dairy industry has taken a clear stand against the use of rBST. 
They have done so even though the use of rBST would clearly contribute to the 
reduction of costs in the production of milk, thereby increasing the ability of 
the Dutch producers to compete in the international market. Milk is regarded 
as a natural product, and this is the way the producers would like it to continue 
to be considered. The market for dairy products is a very international one. 
Thus, the main clients of the Dutch dairy industry are the Germans. German 
consumers are very sensitive about their food; it must be 'natural' and not pro-
duced wi th the aid of additives (Lager, 1994). 
3.5.4 The discourse on biotechnology in Norway 
From the Eurobarometer studies, we can see that the Norwegians are 
among the most sceptical. This is further illustrated by the Norwegian Gene 
Technology Act that was passed on April 2, 1993, which has been called 'the 
world's strictest law concerning genetic engineering' (White paper No. 8, 
1992-93). When deciding whether or not to grant an application of genetically 
modified organisms (GMOs), the Norwegian Gene Technology Act not only 
demands that GMOs should be safe to humans and to the environment (as is 
the internationally dominant approach to regulation of GMOs), it also includes 
that significant emphasis shall be placed on whether the deliberate release 
represents a benefit to the community and a contribution to a sustainable de-
velopment (White Paper No. 8, 1992-93, §1). The proposal for the Gene Tech-
nology Act, together with a White Paper on human biotechnology, were in-
strumental in encouraging a great media interest in biotechnology and genetic 
engineering in Norway in 1993 (Kraft, 1994). New biotechnology changed from 
being a special area of interest for very few, to be a topic that 'everybody' was 
to have an opinion on. 
Studies from 1988 and 1990 show that Norwegian farmers strongly op-
posed the use of productivity enhancing hormones in meat and milk produc-
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t ion, even if it were to become available (Almas, 1991) 1). In the first part of 
the 1988 study, 80% of the Norwegian farmers interviewed said that they 
would not use such hormones if they were available. In the same study, it is 
also shown that there is a strong consensus for considering the social and eco-
nomic consequences that biotechnological research might have on agriculture. 
At the same time, as many as 66% state that they have poor knowledge about 
the new technologies that might be considered for agricultural use. 
Lack of knowledge is often used as an explanation for why people are 
sceptical about various forms of biotechnology. It is very interesting then, to 
look at the results from the second part of the study, done in 1990. During the 
winter of 1988/89 an educational campaign called 'Ethics in the barn' was orga-
nized by three of the strongest national agricultural organizations. The educa-
tional campaign gathered exceptionally large nationwide participation (13,855 
participants divided into 1908 study groups). Approximately one third of the 
textbooks for the course were about general issues in biotechnology, so it 
could be expected that the level of knowledge about biotechnology would 
increase. One would also assume that the scepticism would decrease, since sev-
eral biotechnology products approached the final stage of development during 
the period of this campaign. For example, transfer of embryos to cows was 
being done on a research basis during this period. The results of the study in 
1990 show, to the contrary, that opposition to growth hormones became stron-
ger during the two years (Almas, 1991). In 1990, as many as 88% responded 
that they would not use growth hormones in meat and milk production even 
if they were to become available. These results show that there are other fac-
tors in addition to the level of knowledge about biotechnology that form peo-
ple's attitudes towards modern biotechnology. 
One of the main issues in the Norwegian rBST-debate, has been whether 
or not it will be possible to maintain the ban against rBST in Norway if rBST is 
approved in the EU. Under the European Economic Space (EES) agreement, it 
could be difficult to prevent rBST from being marketed in Norway if it is per-
mitted in the EU, even though Norway is not among the EU member states. 
Several animal welfare organizations, environmental organizations, and agri-
cultural organizations have signed an appeal against rBST. These organizations 
support the international campaign against allowing the use of rBST. 
3.5.5 The discourse on biotechnology in Sweden 
The discussion of gene ethics at the official level in Sweden can be illus-
trated by the activities in the parliamentary committee, which was initiated 
during the spring of 1990 (Nilsson, 1994). The committee presented its 'Gene 
technology - a challenge' in the autumn of 1992, and in 1993 there was a near-
It should be noted that those studies were concerned about hormones in gene-
ral, not rBST specifically. At the same time, there is no reason to believe that the 
attitude towards rBST is more positive than the attitude towards other growth 
hormones. 
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ing on this report. The committee on gene technology's major concerns are the 
issues of patent rights and questions of ecological risks regarding genetically 
modified organisms (GMO). Nilsson (1994) writes that the reactions to the re-
port in many ways reflect the lack of confidence that is found among the vari-
ous groups in the gene-ethic discussion. The motive for a comprehensive law 
for gene technology is to gain political influence in 'expert questions' that 
would otherwise be relegated to departments and professional authorities. 
Jonas Josefsson, philosopher at the University of Lund, and secretary for 
the Nordic committee for ethics in biotechnology (Nordic Council), informs us 
that in spite of his special interest in ethics, he cannot remember having ob-
served any discussion about rBST in the press or in any other area of the media 
in Sweden. It is possible that the question has been raised in special interest 
periodicals for agriculture and animal protection, but it cannot be said that 
there has been any general debate on the subject of rBST. In Sweden, the pub-
lic debate about modern biotechnology has concentrated mainly on the medi-
cal aspects, related to human health and reproduction. For example, a discus-
sion like the one in Norway about transferring genes from flounder to aspen 
trees has not taken place in Sweden. Nor has there been any discussion about 
Novel Foods (defined as food produced with the aid of, or containing, GMOs) 
in Sweden. 
The Federation of Swedish Farmers (LFR) took a stand in opposition to the 
use of rBST as early as 1988. Gunnela Stähle, from the LFR, points out that their 
rejection of rBST is based on several factors. It is assumed that the use of rBST 
wil l have a negative influence on animal health, since increased production 
leads to an increased risk of production diseases. The use of antibiotics will thus 
increase. The structural consequences of using rBST, leaving room for fewer 
cows, and the risk that farmers with small herds wil l be unable to compete, is 
another reason for LFR's rejection of rBST. The aspect of public health is also 
mentioned by LFR as an area they believe has not been given adequate atten-
t ion. 
3.5.6 The discourse on biotechnology in Finland 
In August 1993, a small study about the public opinion on biotechnology 
was carried out in Finland. The seven questions that were posed were taken 
from the Eurobarometer 39.1. A selection of 972 Finnish citizens ranging from 
15 to 69 years of age were interviewed. The results basically indicate that there 
is a relatively high support of, and low concern for risk regarding bio-
technology and gene technology in Finland (von Troil, 1994b). As in Norway, 
the most scepticism is connected with the fields of genetic engineering in re-
gard to farm animals, food, and human beings. The field of genetic engineer-
ing that has the greatest support in Finland is the production of medicine and 
vaccines, and genetically modified microorganisms in connection with the envi-
ronment. While gene technology applied in these areas is regarded as valuable, 
there is strong support for the idea that this must be regulated. As in the other 
Scandinavian countries, there is great confidence in public authorities in Fin-
land (von Troil, personal communication). 
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Like in Norway and Sweden, rBST is not a well-known topic for the lay-
man in Finland, and it has therefore mainly been discussed by those who are 
confronted with it by virtue of their jobs. Both the farm organizations and farm 
authorities have made it clear that rBST is an undesirable, unwanted product. 
Banning such hormones is seen as responsible policy, and because of the strong 
agreement on this, the debate surrounding rBST has calmed down during re-
cent years. No pressure groups wanting rBST to be allowed have let themselves 
be heard, and the fact that rBST is forbidden, contributes to keep the oppo-
nents relatively calm. 
Like in Sweden, most of the debate on bio-ethics in Finland has been 
about the application of biotechnology related to human health, medicine and 
reproduction technology (von Troil, 1994b). In the Finnish press new results 
about the medical accommodation of genetic engineering are reported wi th-
out actually being questioned. One of the reasons for this lack of public debate 
could be the deep economic crisis in Finland, as the problems brought on by 
this crisis have overshadowed all other debates. 
Olli-Pekka Väänänen of the Finnish agricultural organization 'Central 
Union of Agricultural Producers and Forest Owners' (MTK) states that they have 
taken a restrictive stand against rBST (Väänänen, personal communication). The 
same position has been taken by the Finnish organization for the protection 
of animals. 
3.5.7 Summary of country studies 
We have shown how national opinions about biotechnology in Western 
Europe are influenced by the manner in which its various elements have been 
articulated in the national discourse. The strength of the various actors in the 
biotechnology discourse vary from country to country. In all the countries se-
lected for our study, there are organizations opposing the introduction of rBST. 
The Eurodeclaration on rBST summarizes the arguments to continue the ban 
on rBST in six points: 1) Violation of Consumer Rights; 2) Harm to Dairy Farmers; 
3) Detrimental to the Health and Welfare of the Cow; 4) Not proven safe for 
Humans; 5) Increased Environmental Problems; 6) Opening the Door to Growth 
Hormones. 
While in Great Britain the concern for animal health especially is men-
tioned as a reason to reject rBST, in Germany and the Netherlands the apparent 
negative consumer reactions also are major reasons to reject rBST. German 
consumers are regarded being especially sensitive about their food. 
In Norway, Sweden and Finland there is also a strong support for the idea 
that rBST is an undesirable product. This is confirmed by information from cen-
tral sources in agricultural organizations and administrations. In Norway and 
Sweden, the farmers' organizations took a stand against rBST as early as 1986 
and 1988. The interest in rBST has decreased during the 1990's. The reason for 
this is apparently the regulation forbidding the use of hormones, and the 
strong agreement that this is an unwanted product. The negative attitude to-
wards rBST is not unexpected, due to the small-scale farming, strict disease 
control, restrictive use of antibiotics and no illegal use of hormones that has 
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characterized farming in the Nordic countries until now. The exceptional good 
health of farm animals in all the Nordic countries is among other factors a re-
sult of cold climate, a relatively small number of animals in each herd, orga-
nized f ight against diseases and effective control programmes. Farm animals 
are kept according to sound ethical principles, where the welfare of the ani-
mals is given high priority. Some of the reasons for this are the stringent con-
trol routines together with an official policy that have made it possible to carry 
on wi th small-scale farming. The fact that agricultural production in Norway, 
Sweden and Finland has been strictly controlled by federal regulations might 
possibly have brought the profitability aspect more in the shadow. There is a 
common belief that the general agricultural policy (and the quota system) wil l 
be more decisive for the possibility to continuing farming in the future, than 
an eventual increase in profitability by taking production enhancers like rBST 
into use. 
3.6 Discussion and concluding remarks 
New technology that increases productivity does not receive immediate 
acceptance on the part of the producers or the consumers in the selected Euro-
pean countries. For dairy farmers, it is important that milk production is profit-
able. One key question is whether the negative opinions about rBST held by 
farmers and consumers will lead to a definite ban of rBST in Europe. This will 
to a great extent depend on agricultural policy at the national and suprana-
tional level. If the conditions make it impossible to carry on with dairy produc-
tion in an economically feasible manner without using productivity enhancers 
like rBST, farmers' scepticism and expected negative consumer acceptance may 
not stop the introduction of rBST in the long run. On the other hand, it may 
appear to be a competitive advantage to be able to offer the consumer both 
meat and milk that have been produced without the use of any hormone, as 
consumers are exceedingly sceptical towards products that are produced wi th 
the aid of hormone supplements. 
A reduction in the price of dairy products may be of importance for the 
consumer. The effect is not unambiguous, however. In general the price elastic-
ity of demand for staple consumer products like milk is low. But it is higher 
than average for low income groups. For other socio-economic groups other 
aspects may be more important. Some segments of the public are placing 
greater weight on quality and safety than they did in the past. According to 
Caswell et al. (1994:20), a new ecological, environmental 'green' direction is 
growing among the consumers. Consumers are willing to pay higher prices for 
foods that offer enhanced qualities, such as improved nutrition, safety, flavour, 
and appearance. The quality concept also has an ethical dimension which in-
cludes that the production process has been worked out in an ethically justifi-
able manner (Lassen, 1993). The ethical questions have been a major issue in 
the discussion of organic products. Producers will respond to the changing con-
sumer preferences, and put more emphasis on these quality aspects. 
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The claim that milk from cows treated with rBST is safe for human con-
sumption may not be sufficient for consumers to accept, i.e., buy this milk. The 
strong emphasis that the product is no different from regular milk also tells the 
consumer that rBST does not provide the consumer with a product of higher 
quality. If rBST does not have any benefits, either quality-enhancing or 
price-reducing (depending on the future dairy policy, see chapter 7), there is 
not much reason for the consumer to accept it. Even if the risk is very small, 
why expose people to the risk, when there is no short supply of milk? There is 
still some disagreement whether an increased level of IGF-1 in the milk poses 
a risk. As long as this uncertainty exists, the health issue remains relevant. Con-
sumers may rationally see little risk in being deceived by rBST's opponents, and 
may be comparing this risk to a low-probability/high-consequence risk of being 
deceived by the majority of voices speaking in favour of rBST (Thompson, 
1992:41-42). As a result of the disagreement among the experts, science is put 
in a position of being both a threat and a guarantor against threats. 
From the Eurobarometer study it appears that consumers are more likely 
to accept genetic engineering of plants and micro-organisms than genetic engi-
neering of animals or humans (Almas and Nygârd, 1995). The opposition to-
wards rBST does not stem from the way it is produced, but rather from the 
consequences of its use. rBST is a product that has many controversial aspects 
reaching beyond the fact that it is produced by genetically modified organisms. 
For the biotechnology industry the rBST case is a difficult one. The low accep-
tance may do harm to the introduction of other biotechnology products. If rBST 
is going to stand as the first example of what products the new agricultural 
biotechnology is going to introduce in the EU, the biotechnology industry 
could be exposed to the very difficult task of convincing the public about the 
necessity of their activities. As such, many scientists think the rBST is a bad case 
to push and may harm the relations between the research community and the 
public. 
An important conclusion we can draw on the basis of the Eurobarometer 
is that people's confidence in representatives from industry is minimal. There 
is little enthusiasm for leaving the development of technology to commercial 
powers. This is a challenge to industry, but also to the EU Commission that has 
defined biotechnology and genetic engineering as a key technology for ensur-
ing the competitive ability of the EU. At the same time, there is reason to be-
lieve that environmental and consumer organizations, together with represen-
tatives for education and research will greatly influence the biotechnological 
discourse in Europe in the years to come. Religious groups and societies may 
start defining their profiles, especially regarding the patenting of life and ge-
netic engineering of human cells. This will ripen the biotechnological discourse 
in southern and central Europe and may alter the balance of power between 
the supporters and the opponents of new biotechnology. 
It remains to be seen how public attitudes towards biotechnology in gen-
eral, and to rBST in particular will develop in the near future. Given that peo-
ple's attitudes towards modern biotechnology are based on fundamental val-
ues, there is not much reason to expect any rapid change, as fundamental val-
ues, in contrast to (scientific) knowledge, remain relatively stable over time. On 
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the other hand, pressure from European producers to suspend the ban on rBST 
in the EU before the end of 1999, so that they can be more productive, could 
be seen as another scenario. We may have a situation that resembles the one 
described by Kvistgaard and Neimann-Sorensen (1992): the individual farmer 
feels pressured to use rBST, because he expects that all his colleagues wil l use 
it. This may happen in spite of objections from consumers, and in spite of the 
fact that it is in conflict with the individual's own values and norms (Kvistgaard 
and Neimann-Sorensen, 1992:98). Here lies a challenge to the policy makers to 
make it possible to keep on with profitable dairy production without adopting 
the use of rBST. This shows that the discourse about new agricultural 
biotechnology in general, and rBST in particular, is just as much a social and 
political question as a technological question. 
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4. FARM STRUCTURE AND ADOPTION 
4.1 Introduction 
This chapter focuses on a description of the structural features of the 
dairy sector in the countries under consideration. Farm characteristics are of 
major importance in assessing the potential adoption of new technologies, like 
the use of rBST (e.g. Caswell et al., 1994). The relation between farm structure 
and adoption is however not unambiguous, as other factors also play a role 
(see figure 4.1 on page 50). One of those other factors is the profitability or 
competitiveness of the farm, which is linked with the structure of agriculture. 
Attention will be paid to the economics of dairy farming in the EU and its rela-
t ion to structural features in section 4.3. The chapter will close wi th the 
confrontation of farm structure and profitability on the one hand and poten-
tial adoption of rBST on the other. 
4.2 Structural features of the dairy sector 
In 1995 there are almost 21 million dairy cows in the EU-12 (see table 4.1). 
About 70% of the herd is in Germany, France, United Kingdom and Italy. The 
total number of dairy cows has fallen drastically in recent years: compared to 
the herd of 1988 the number of dairy cows in 1995 is 20% less. The trend ob-
served in these figures did not start with the introduction of the quota system 
in 1984. Since 1968, when the common dairy policy was fully established, the 
number of dairy cows has decreased in all EU member states, except in the 
Netherlands and Ireland where in the period between 1968 and 1983 the dairy 
herd increased on average 2% per year. Since 1984, the number of dairy cows 
has fallen in all member states, most drastically in France and the Netherlands 
(CEC, Agricultural Situation Report, various years). The total number of dairy 
cows in the EU showed a substantial increase every time a new member state 
joined the Community. The 1995 enlargement of the EU with Sweden, Finland 
and Austria, has expanded the EU dairy herd with 1.7 million dairy cows. With 
this enlargment, the EU dairy herd counted 22.5 million cows. 
The United States (US) dairy herd is almost half the size of the herd of the 
EU-12. Compared to the reduction of the number of dairy cows in the EU in 
recent years, the decline in the US is less significant. In the period between 
1988 and 1995, the reduction of the number of dairy cows was only 6.7%, or 
on average less than 1 % per year (over a longer period of time the decline in 
the US is also considerable). The decline in the Norwegian dairy herd has been 
7.6% in the period observed, also much less than in the EU. More significant is 
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the decline of the dairy herd in Finland (-26%) and Sweden (-17%) in the pe-
riod being considered. 
Production per cow has been increasing year by year in the EU, USA and 
Sweden, while the yield per cow is rather stable in Norway and Finland. The 
level of productivity is highest in the USA. The production per cow in the EU is 
less than in the USA and in the Scandinavian countries. There are, however, big 
differences in productivity per cow between EU member states, in the range 
of 3.6 t/cow/year for Greece to 6.5 t/cow/year for Denmark, in 1993 (CEC, 1995). 
Table 4.1 Selected basic indicators of the dairy sector in the EU, USA and Scandinavian coun-
tries 
EU-12 
USA 
Norway 
Sweden 
Finland 
Dairy cows ('000) 
Yield (t/cow/year) 
Dairy cows('OOO) 
Yield (t/cow/year) 
Dairy cows('OOO) 
Yield (t/cow/year) 
Dairy cows('OOO) 
Yield (t/cow/year) 
Dairy cows ('000) 
Yield (t/cow/year) 
1988 
25,995 
4.6 
10,212 
6.4 
354 
5.6 
621 
5.5 
551 
5.0 
1990 
24,507 
4.8 
10,015 
6.7 
355 
5.7 
576 
6.1 
490 
5.7 
1992 
21,686 
5.2 
9,728 
7.1 
342 
5.7 
526 
6.1 
427 
5.8 
1994p 
20,959 
5.3 
9,528 
7.5 
331 
5.8 
517 
6.5 
408 
5.7 
1995e 
20,800 
5.3 
9,532 
7.5 
327 
5.4 
n.a 
n.a 
n.a 
n.a 
Source: OECD, Current situation, short term outlook and recent policy changes in the dairy mar-
kets of OECD and observed countries. AGR/CA/APM/MD(94)6, August 1994 and (95)5, October 
1995. 
Trends in the yield per cow differ between the EU and the USA. Since 
1992 a slowdown of the yield increase in the EU can be observed. In 1988-1990, 
production per cow went up 2.1 % per annum on average. Yield increase per 
year reached 4.2% in the 1990-1992 period, but the growth rate dropped in 
1993 and 1994 to somewhat less than 1.0% per annum. The yield per cow in 
the USA shows a more steady path with rather high growth rates of 2.3% per 
annum in the period 1988-1990, 3.0% for 1990-92 and 2.9% in 1993 and 1994. 
According to OECD estimates the yield per cow in the US will stabilize in 1995. 
Such a projection may be too conservative if the impact of the use of rBST is 
fully taken into account. 
The Netherlands, Germany, France and Denmark are the most important 
EU exporters of dairy products (see also chapter 6). Therefore, these countries 
are selected to look at more closely. 
In 1991, there were 1.2 million dairy farms in the EU (table 4.2). Out of 
these 1.2 million farms, about 40% are in Germany and France. In these two 
countries, 50% or more of the farmers with dairy cows also have other farming 
activities (other animals, crops); in Germany only 43% of the farms with dairy 
cows can be categorized as specialized dairy farms, while in France it is 52%. 
In the Netherlands and Denmark, the specialization rate is much higher 
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(around 70%, almost the same as in the USA). Compared to those in the Neth-
erlands and Denmark, the dairy farms in Germany and France fewer cows and 
about the same land area. So, dairy farming is less intensive in Germany and 
France than in the Netherlands and Denmark. The number of cows per dairy 
farm is increasing over time at the EU level as well as in all member states 
shown in table 4.2. As the smallest dairy farms leave the sector, this increases 
the average farm size in terms of number of dairy cows per farm. 
Table 4.2 Features of dairy sector in selected countries 
EU NL G F DK USA N S F 
Number of dairy farms ('000) 1,202 48 275 199 21 182 29 23 47 a) 
Specialized farms (%) 57 69 43 52 67 68 
Farm area (ha) 29.0 29.4 38.4 36.0 158 
Cows per farm 1991 18.4 40.1 17.3 25.0 35.8 54.0 11.6 22.0 10.5 a) 
Cows per farm 1987 15.7 37.6 16.0 20.0 30.4 44.0 11.2 18.0 8.6 b) 
Note: 1991 data; a) data 1990; b) data 1983. 
Sources: CEC, Agricultural situation report 1994,1995; Rabobank, 1995:10; Agricultural Statistics 
of Norway, Sweden, Finland. 
Compared to European dairy farms, US farms are large, both in terms of 
number of cows and hectares, and specialization. However, these data are all 
averages. There are significant differences between individual farms. Around 
14% of all US farms with milk cows are large dairy farms wi th 100 or more 
dairy cows. The largest farms are concentrated in the West and Southwest. Very 
large dairy herds of 700 to 1,500 cows are common in Southern and Central 
California, Arizona, New Mexico, Texas and Florida, but are rare elsewhere. 
Table 4.3 Farm structure of the dairy sector in selected countries (% of total number of farms) 
Farms <10 cows '92 
Farms <10 cows '87 
farms >50 cows '92 
farms >50 cows '87 
EU 
46.7 
53.3 
7.8 
5.8 
NL 
13.3 
16.6 
31 
28.9 
G 
35.0 
40.3 
3.5 
3.3 
F 
17.5 
28.6 
8.0 
4.9 
DK 
10.2 
16.3 
22.9 
16.8 
USA 
38 a) 
46 a) 
39 
30 
N 
40.1 
44.0 
0.2 
0.2 
S 
18.4 
26.5 
7.5 
3.4 
F 
49.0 
64.1 
0.1 
0.1 
b) 
c) 
b) 
c) 
a) % farms <29 cows; b) data 1990; c) data 1983. 
Source: CEC, Agricultural situation report 1994, 1995; Rabobank, 1995, p.10. 
The trend of increasing concentration of dairy farming is confirmed by 
data on small and large farms (see table 4.3). In 1987, more than 53% of EU 
dairy farms had less than 10 milking cows and only 5.8% of the farms had more 
than 50 cows. In 1992, these percentages changed so that the percentage of 
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smaller farms declined and the number of larger dairy farms had increased. 
These changes appear to be the general trend in the EU member states and in 
the USA (and in the Scandinavian countries too; see Nord, 1995). But the 
smaller dairy farms are still dominating the scene in the EU, contrary to the 
situation in the USA. Only 38% of US dairy farmers have less than 29 cows, but 
in the EU almost 80% of dairy farms are within this category. Also in this re-
spect there are big differences between EU member states and between re-
gions within member states (e.g. Habraken, 1994). 
Together wi th the increasing concentration in milk production at farm 
level, the number of processing plants has declined and the scale has ex-
panded. Since the introduction of the quota system in the EU in 1984, the struc-
tural change of the dairy processing industry, which had already started during 
the mid-sixties, has undergone an impressive acceleration. The number of busi-
nesses in the milk collecting and processing industry dropped from over 9,000 
in 1973 to less than 4,000 in 1993 (Rama and Pieri, 1995). This concentration 
trend has favoured the biggest companies whose position has been strength-
ened further. More than 60% of EU milk production is delivered to approxi-
mately 70 companies which make up less than 2% of the total number. The 
(three) biggest dairy processors are private companies while in most EU coun-
tries dairy cooperatives play a significant role too 
4.3 Economics of dairy farming in the EU 
The economics of milk production is difficult to analyse. On most dairy 
farms, except the specialized ones, milk production is mixed with other animal 
and/or crop production, with which it constitutes an integrated farming system. 
Milk production is inextricably bound up with beef production, as beef produc-
t ion accounts for a substantial contribution to total gross production value, 
even on the highly specialized farms in milk production. Therefore, allocation 
of costs on an output basis is complex and mainly done by using standard 
norms based on averages. Actual allocation of costs on a farm may differ from 
the averages used in the calculations. Moreover, there is a wide spectrum of 
methods in valuing unpaid cost items like owned land, family labour and 
owned capital. All this makes the specific consideration of milk production 
somewhat arbitrary. However, despite the methodological complexities, esti-
mates of production costs have been made and used by economists and policy 
makers for different purposes, like measures of productivity, to provide guide-
lines for farm operators and in setting target prices. Moreover, cost price com-
parisons between countries can play a role in the analysis of international com-
petitiveness of a sector. 
In the work of Rama and Keane (1993), production costs for milk in nine 
EU countries (and Poland) are estimated. Because of the methodological prob-
lems mentioned above, a ranking of countries by costs can not be found in this 
study. Instead, emphasis is put on the links between farm structure, milk utiliza-
t ion and production costs. It appears that a fairly clear relationship emerges 
between size of the herd and the total unit costs. Costs per unit tend to fall 
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with increasing herd size, but flatten out after a certain point. The main reason 
for the size economies is related to the high level of family labour resources on 
smaller dairy farms. Omitting family labour from the cost estimates leaves a less 
strong relationship between scale and unit costs. As the size increases, labour 
(and land) requirements per kilo diminish to a very great extent, because of 
greater mechanisation and computerisation possibilities. After reaching a cer-
tain level (in terms of number of cows), production costs per unit are increasing 
as total required capital (including land) goes up and additional labour has to 
be hired. Differences in costs between large and small farms are highly attribut-
able to family-provided inputs, like land, labour and capital. 
Production costs and profitability of dairy farming are affected by various 
interrelated factors, of which the size of the farm is but one. Other key factors 
affecting profitability of milk production are the breed of the cows (affecting 
yield per cow, nutritional content of milk, production costs, and revenues), and 
the level of intensification (Rama and Keane, 1993:119-121). A crucial factor is 
the management of the farm. These factors are farm specific, and therefore 
costs of production and profitability may differ considerably between farms 
even if they have a similar size. 
Using farm accountancy data from the EU FADN database, Habraken 
(1994) analyses the trends in farm size, net return, cost of production and fam-
ily income of highly specialized dairy farms in the EU member states. Appar-
ently, there are huge regional differences in costs and returns. Based on the 
assessment of cost of production and family income per farm, the six best per-
forming regions are Niedersachsen (G), Bretagne (F), Lombardia (I), West Eng-
land (UK), the Netherlands and Denmark. Compared to EU and country aver-
ages, the dairy farms in these regions have more cows and a higher livestock 
density (and milk production per hectare). 
4.4 Adoption and diffusion of rBST 
The socio-economic impact of the use of rBST on the dairy sector depends 
on the adoption and diffusion of this new technology. Adoption refers to the 
decisions of individual producers whether or not to use a technology, whereas 
diffusion is the rate and extent of technology adoption over time (Rogers, 
1992). Studies on adoption and diffusion are carried out before (ex-ante) and 
after (ex post) the new technology has been introduced. Studies on diffusion 
of technology provide important information for public policy makers, because 
after a minimum number of farmers have adopted the new technology starts 
to have industry-wide or even nation-wide (socio-economic) effects. 
The decision by farmers to adopt rBST is influenced by many factors. Since 
farming is an economic activity, the expectation that profits from adoption will 
be larger than profits that would be earned without adoption is an important 
driver behind adopting rBST. The profitability of rBST use is influenced by inter-
nal factors, i.e. farm and farmer characteristics, but also by factors that lie out-
side the direct influence of farmers. For instance, public policies and regulations 
often change the relative costs for inputs or the revenues that can be earned 
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by farming. And ultimately it is consumer demand for food produced with the 
use of biotechnology, that will determine whether the adoption of rBST wil l 
be profitable. 
In the USA, many ex-ante studies have been conducted on the adoption 
and diffusion of rBST (see Caswell et al., 1994, for an evaluation of 15 such 
studies). Three types of predictive approaches have been used: profit function 
models, which compare the costs and benefits of adoption for farms with dif-
ferent production conditions and management techniques; historical trend 
analyses, which examine previous agricultural technology adoption experiences 
and compare them with the current technology; and farm operator surveys, 
which ask farmers their use intentions, sometimes in several different ways to 
test the sensitivity of their responses to the information they have at hand 
(Barham et al., 1995). In the USA, at least a dozen producer surveys were un-
dertaken between 1986 and 1993, especially in the major dairy production 
states of California, New York, Texas, and Wisconsin, to elicit responses from 
producers on their intentions to use rBST. 
Caswell et al. (1994) summarized the results and methods of many of the 
American studies on the adoption and diffusion of rBST. They conclude that 
there is a wide range in the forecasts of adoption and diffusion rates. Estimates 
of adoption of rBST after the first year of commercialization ranged from 6% 
to 77% of either total farms or cows. No study predicted complete adoption by 
the entire dairy sector, even after ten years of availability. Most studies esti-
mated that the extent of final adoption would fall between 30 and 75%. There 
were no significant differences in ranges of estimates for different regions of 
the USA. An important reason for the wide range of forecasts is the uncertainty 
about the acceptability of the biotechnology-derived product among produc-
ers, dairy processing firms, and consumers. But also uncertainty about the level 
of production efficiency that can be achieved when the technology is applied 
under actual farm conditions, and about possible changes or adjustments in 
government dairy policy can lead to the large variation in estimates of the 
adoption of rBST. 
In analysing potential rBST use, most of the ex ante adoption studies look 
at farm-level determinants. This focus on the farm and farmer characteristics, 
with its implicit assumption that farmer decisions will be independent of over-
all industry conditions, is not uncommon in research on the adoption and diffu-
sion of new technology in agriculture. Barham et al. (1995) have compiled a list 
of explanatory factors used in ex ante rBST adoption analyses and the typical 
direction of their effect (see figure 4.1). 
The effects of the various farm and farmer characteristics on rBST adop-
tion, as listed above, can be explained as follows. Larger and wealthier farms 
are more likely adopters because of information economies associated with the 
adoption of new technologies, their lower aversion to risk, and/or their better 
ability to finance associated investments. Herd productivity and more 'skilled' 
farm management practices are seen as being positively correlated with adop-
tion. Also, human capital attributes of farm operators are seen to be positively 
related to adoption of new technology, in that they wil l contribute to the op-
erator's capacity to make use of innovations profitably. Age is negatively re-
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lated, because younger farms are often viewed as having a longer time-horizon 
with respect to the farm enterprise, and thus to the gains from adopting new 
technologies. In the miscellaneous category, the adoption outcome associated 
with group membership or industry-level type concerns can be either positively 
or negatively related to adoption, depending on whether farmers view them-
selves as unable to affect the outcome through individual decisions or as part 
of a larger group acting collectively or jointly. 
This focus on farm and farmer characteristics presents an incomplete pic-
ture of factors that influence adoption and diffusion. According to Barham et 
al. (1995), the American ex ante adoption studies do not account for the poten-
tially negative effect of consumer response on adoption outcomes. If ex ante 
studies of consumer attitudes showed significant reduction of milk consump-
t ion as rBST was introduced, more complete producer surveys should include 
questions about how producers might adjust their adoption decisions to differ-
ent scenarios of consumer response. However, such comprehensive studies are 
rare. 
Explanatory Factors 
1. Farm Structure 
Herd size 
Diversity of income sources 
Wealth 
2. Farm Management Practices 
Herd productivity 
Higher productivity (+) 
Dairy herd improvement association 
Use computers on farm 
Artificial Insemination 
Milking facilities 
3. Human Capital Attributes 
Age 
Years of formal education 
Dairy farm experience 
4. Miscellaneous Factors 
Membership in farm groups 
Concern about price impacts 
Predicted Effect 
(+ = adoption, - = non-adoption) 
Bigger herd (+) 
More diverse (-) 
More wealth (+) 
Participation (+) 
Computer use (+) 
AI use (+) 
Parlour (+) 
Younger farmers (+) 
More education (+) 
More experience (+) 
Information (+) 
Group pressure (-) 
Treadmill concern (+) 
Surplus (-) 
Figure 4.1 Predicting rBST use in ex ante adoption models 
Source: Barham et al., 1995. 
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To our knowledge, no detailed ex ante studies of adoption and diffusion 
of rBST use have been conducted in the EU. Given the quite different dairy 
farm structure in the EU compared with the structure in the USA, and even the 
large differences within the EU, adoption and diffusion of rBST might fol low 
a rather different course than in the USA. It may be useful to conduct such 
studies in order to be prepared for expected changes in production and indus-
try structure. Such studies should also include, as above suggested, potential 
consumer response. As the attitude of consumers in Europe is expected to be 
negative (although with differences among EU countries), adoption and dif fu-
sion studies will not be complete without the incorporation of the impact con-
sumer response may have on farmer behaviour. 
4.5 US farmers' experience 
Studies in the late 1980s (Fallert et al., 1987, Blayney and Fallert, 1990) 
suggested that, depending on the government milk price support levels, over 
a 7-year period from 45 to 70% of US dairy farmers would adopt rBST. They 
estimated a 10% adoption rate in the first year and from 20 to 33% adoption 
by the end of the second year. Current actual adoption rates for Posilac™ seem 
to be following the trend projected in these studies by the US Department of 
Agriculture (USDA). 
Previous studies expected milk prices to remain at government price sup-
port levels. However, in the 1990s annual average farm-level milk prices have 
been 20 to 30% above the government support price. Consequently, cow num-
bers have remained stable around 9.5 million head. Growth in domestic and 
export demand for dairy products, along with occasional weather related prob-
lems with the quantity and quality of forages, have contributed to profitable 
milk production. Except under a very high-price support, wi th rBST adoption, 
the USDA studies had expected herd size to decline over a 7-year period from 
about 10.4 to 9.4 million cows. 
The USDA studies had forecast that wi th rBST adoption, average milk 
production would increase about 3,000 pounds per cow over a 7-year adoption 
period, or about 430 pounds per year on average. USDA data for the 2-year 
period 1994-1995 suggest that milk production has actually increased about 
725 pounds per cow, or on average 363 pounds per year. It should be noted 
that Posilac™ was available for 23 months of this recent 24-month period, be-
ginning in February, 1994. 
Monsanto officials indicate that the most rapid adoption of their product 
has been in New York, Pennsylvania, California, New Mexico, and Idaho. 
Monsanto has not yet released any data for their second year of sales nor are 
there any national studies available on rBST use for the entire 2-year adoption 
period. However, economic studies have been published for two of the key 
dairy states. New York and Wisconsin. 
Three states, California, Wisconsin, and New York, represent about 36% 
of the dairy cows and 38% of the milk production in the United States. Califor-
nia is the leading dairy state with 12% of the cows and 16% of the production. 
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Wisconsin is the second leading state with 17% of the cows and 15% of the 
production. New York is the third leading state with about 8% of the cows and 
production. 
Adoption of rBST has lagged some in California because of the large herd 
size, the corporate style operations, and a tendency to manage the herd rather 
than individual cows. The average herd in California is 305 head wi th several 
farms having more than 1,000 head. In California, slightly more than 50% of 
the dairy farms report 100 or more cows. Hence, some California dairy farmers 
have been slow to adopt rBST since their employees have to milk large num-
bers of cows each day and can not easily monitor the performance of each cow 
as is done more easily on family farms with smaller herds. Also with the large 
volume of milk production per farm, and often long hauling distances to the 
limited number of processing plants, there has been a concern by some Califor-
nia dairy farmers that if they used rBST and their processors did not accept milk 
from rBST-treated cows, they might have some difficulty finding an alternative 
buyer. 
In contrast to California, adoption has been relatively rapid in New York 
for several reasons. In New York there are about 11,000 dairy farms averaging 
66 cows per farm with 55% of the farms reporting more than 50 cows and 17% 
reporting more than 100 cows. With moderate size herds, and mostly family 
farm operations, it is easier to administer rBST and monitor cow performance. 
Cornell University scientists have conducted extensive studies of rBST. 
Consequently, New York dairy farmers have confidence in the university staff. 
This has helped encourage rBST adoption. Also many dairy processing plants 
are available to process milk within relatively short hauling distances. If a few 
processors refuse to accept milk from rBST-treated cows, there are other pro-
cessing plants nearby that will accept milk from rBST-treated cows. This reduces 
the marketing risk for New York farmers who wish to adopt rBST. 
Knoblauch et al. (1995) studied 400 dairy farms in New York for the years 
1993 and 1994 (for details see appendix 6). Recall that Posilac™ first became 
available in February 1994.They divided the sample into four groups. The first 
group (137 farms with an average of 89 cows in 1993) included cows that were 
not treated with rBST. The second group (24 farms with an average of 100 cows 
in 1993) used rBST on less than 25% of the cows during the period February 
through December 1994. The third group (85 farms with an average of 237 
cows in 1993) used rBST on 25% or more of the cows during the same period. 
The fourth group (13 farms with an average of 135 cows in 1993) started and 
ceased the use of rBST. They made a comparison between the year before 
adoption and the year of adoption for farms using rBST. They also compared 
farms using rBST to the farms that did not use rBST in each of the two years. 
A summary of the results of the Knoblauch et al. study follows: 
for the herd not using rBST, the herd size grew by four cows, milk sold 
per cow remained unchanged, cost of production increased 0.17 cents per 
pound, and net farm increased by $2,789; 
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for the herd where less than 25% of the cows were treated with rBST, 
milk sold per cow increased by 689 pounds, cost of production increased 
by 0.42 cents per pound, and net farm income increased by $540; 
farmers who used rBST on 25% or more of their cows increased the herd 
size by 21 cows, increased milk sold per cow by 1,752 pounds, cost of pro-
duction increased by 0.22 cents per pound, and net farm income in-
creased by $20,568. In the period 1992 to 1993 these same farmers wi th-
out rBST use increased milk sold per cow by only 122 pounds, substan-
tially less than the following year when they used of rBST; 
for those farmers who tried rBST but did not continue its use, herd size 
increased by only three cows, milk sold per cow increased by only 106 
pounds, cost of production increased 0.60 cents per pound, and net farm 
income decreased by $6,987. 
From this economic analysis of a relatively large sample of representative 
New York dairy farms, it is clear that farmers who adopted rBST had, on aver-
age, large herds and were more profitable than other farmers. With the adop-
t ion of rBST they increased productivity per cow and net farm income. Feed 
cost per pound of milk sold decreased for farmers using rBST, while it increased 
for non-adopters. Adopting rBST use is relatively easy, but changes in feeding 
programmes and selection of animals to be treated with rBST requires addi-
tional management time. 
Dairy farmer experience in Wisconsin, the second largest dairy state, has 
been somewhat different than in California and New York. Herd size is much 
smaller in Wisconsin and farmers tend to be slower to adopt new technology. 
Many Wisconsin dairy farmers still are not members of the Dairy Herd Improve-
ment Association (DHIA) and many have not yet adopted the use of Total Man-
aged Rations (TMR) to improve herd nutrition and performance. 
Results of a survey of dairy farmers conducted by researchers at the Uni-
versity of Wisconsin was released in May 1995. The researchers document the 
attitudes and rBST adoption rates of Wisconsin dairy farmers (Barham et al., 
1995). According to this survey, by November-December 1994, about 10 months 
after the initial commercial sale of Posilac™ by Monsanto, only 5.5% of 
Wisconsin dairy farmers were using rBST compared to about 11 % nationwide 
as reported by Monsanto on January 31, 1995. About 1% of the Wisconsin 
farmers indicated that they anticipated using rBST within six months, while 
3.6% said they would wait at least six months before making a decision. Of the 
remaining 90% of the survey respondents, many (36%) said that they were 
unlikely to use rBST and a majority (54%) said that they would not use it under 
any circumstances. 
For the Wisconsin dairy industry, a growing gap in adoption rates be-
tween Wisconsin and the rest of the United States could hamper the long-run 
competitiveness of the state's dairy industry. However, anecdotal evidence sug-
gests that the Wisconsin dairy industry may undergo a substantial structural 
transformation over the next few years wi th the smaller and less competitive 
dairy farmers leaving the sector, while larger and more competitive farmers 
expand the scale of their operations. Based on the New York study, and other 
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studies of technology adoption, these large farmers with improved manage-
ment skills would be more likely to adopt the use of rBST. 
The authors of the Wisconsin study conclude that the relatively low level 
of adoption of rBST in Wisconsin is a result of the high level of politicization 
surrounding rBST in Wisconsin. Furthermore, this politicization process has 
been intertwined with underlying structural and organizational issues in 
Wisconsin. Thus, consumer concerns about the safety of rBST in milk that was 
fed by the news media, along with concern about the economic pressures for 
structural change in Wisconsin's dairy industry due to expansion of the dairy 
industry in other regions of the United States, has resulted in strong resistance 
to rBST adoption by Wisconsin's dairy farmers. The politicization of rBST in 
Wisconsin - and perhaps in Vermont, Maine, Rhode Island, and California, all 
of which have experienced some organized resistance to the introduction of 
rBST - appears to demonstrate that social forces can play a role in farmer adop-
t ion decisions concerning emerging agricultural technologies. 
Wisconsin dairy farmers, and non-adopters in other states, face a serious 
challenge as the more progressive operators, who generally manage larger 
herds, adopt rBST and expand milk production, and probably herd size. Under 
such competitive pressures, the non-adopters' strategies might include: increase 
the scale and technical efficiencies of existing dairy farms, develop alternative 
low-cost ways to compete in a market with declining milk prices, develop new 
markets for rBST-free products, and prepare to consider some changes in mar-
keting and processing as the adoption of rBST increases. 
MONSANTOS EXPERIENCE 
While Monsanto was awaiting FDA approval, it developed an extensive database on ap-
proximately 100,000 US dairy farmers. This database serves as a basis for its direct marketing 
programme. To order Posilac™, each dairy farmer must call a toll-free 800 number. The prod-
uct is manufactured in Austria and air freighted to Memphis, Tennessee, the national trans-
portation hub for Federal Express. Once the farmer has placed an order. Federal Express de-
livers the product to the farmer. The farmer then receives from Protiva, a division of 
Monsanto, a bill for the product plus shipping and handling. Monsanto currently has about 
75 field representatives who work with farmers to answer questions and help them use rBST. 
Protiva also maintains a 24-hour hotline for farmers to call for technical information. Con-
sumers also can call a toll-free 800 number if they have questions. 
Posilac™ is shipped in boxes of 25 single-dose syringes, each containing 500 mg, as a pro-
longed release product. The farmer should administer the product every two weeks begin-
ning during the ninth week of lactation. Assuming a 310-315 day lactation, this implies 18 
injections per cow over a 252 day period. Farmers can expect a five to 15-pound increase in 
daily milk production. The average experience has been about 10 pounds per cow per day. 
After injecting the cows, the used syringes are mailed back to Monsanto in a special con-
tainer provided by Monsanto. 
Response to the injection is fairly immediate. Increases in milk production usually are 
noted within two or three days of the injection. Data provided by Monsanto indicate that 
the response to Posilac™ increases after each administration, then plateaus at a sustained 
higher level as compared to the normal lactation curve. 
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Initially, Posilac™ was sold to the producer at $5.00 per unit (36 cents per cow per day). 
The current price is $6.60 per unit (47 cents per cow per day). The minimum order is 50 units. 
Each order, regardless of the order size, has a handling and shipping charge of $8.50. The 
bill must be paid by the 20th day of the month following the month in which the order was 
placed. Since dairy farmers receive a monthly milk check, this method of payment usually 
does not cause any cash flow problems for the farmer. 
Since cows will produce more milk, they must consume more feed. Monsanto estimates 
that to produce 10 pounds more milk per day, the cow requires an additional 3.1 Meal of 
energy. Feeding 4 pounds (dry matter) of a ration with 0.78 Meal per pound of dry feed 
could meet this requirement. If the ration cost is seven cents per pound, the feed cost would 
equal 2.8 cents per pound of milk response. Monsanto estimates administration costs at one 
cent per cow per day. This is based on 50 cows injected once every two weeks with labour 
at $14.00 per hour. Monsanto estimates that with the milk price at $1.25 per pound, farmers 
should receive $0.51 profit per day per cow producing an additional 10 pounds of milk as a 
result of the injection of rBST with a daily cost of 36 cents per cow ($5.00 per unit). On a 50-
cow farm, injecting rBST for 252 days of each cow's lactation would generate $6,426.00 in 
additional profit per farm. 
After six months, on September 14,1994, Monsanto had received more than 78,000 tele-
phone calls from consumers and other interested parties. They also reported that more than 
10,000 producers had treated 800,000 cows with 6.8 million doses of Posilac™. Of 95 reports 
of concern from producers, only 14 had concerns about mastitis, a common udder inflamma-
tion that normally clears up in four to five days. 
After one year of experience with Posilac™, Monsanto reported sales of 14.5 million units 
to about 13,000 dairy producers, approximately 11 % of all U.S. dairy producers. As of Febru-
ary 1995 Posilac™ had been administered to approximately 2.7 million dairy cows. Monsanto 
estimates that those farmers who purchased Posilac™ during the first year of sales managed 
approximately 30% of the U.S. dairy herd. According to Monsanto, more than 99% of their 
customers reported increases in milk production. The average reported increase per cow was 
about 10 pounds per day. 
Monsanto's data suggest that the size of herds supplemented with Posilac™ closely re-
sembles the distribution of herd sizes in the United States. Herds more than 100 cows are 
slightly more likely to be using Posilac™. However, according to Monsanto, 55% of the farm-
ers using Posilac™ manage herds of 100 or fewer cows. The usage rate on farms varies from 
five to 70% depending on individual herd management and stage of adoption. 
To help monitor any potential herd health problems, Monsanto has an active outreach 
programme. During the first year of sales there were more than 110,000 telephone inquiries 
from customers. Also, Monsanto works with a network of more than 120 veterinarians and 
animal nutritionists. 
During the first year of sale of Posilac™, from the estimated 2.7 million cows treated, 
there were only 806 reports of adverse effects. Follow up by the FDA found that there were 
121 reports of mastitis, 105 reports of increased somatic cell counts, 73 reports of udder 
swelling or abnormal milk, and 89 reports of reproductive disorders. Of the 806 reports, 496 
were possibly related to product use and 310 were unrelated. After careful review, the FDA 
did not find any cause for concern. The agency validated Monsanto's adverse drug reaction 
reporting system and investigated some reports with on-farm inspections. The FDA plans to 
continue to monitor Posilac™ use including an ongoing, two-year study of 24 dairy farms of 
various sizes in different regions of the United States. They will release the results from this 
study in 1996. 
Monsanto has plans to soon release an updated progress report on Posilac™ use after 
two years' experience with the product. In November 1995, officials in the Protiva division 
of Monsanto estimated that during 1995, depending on the season, from 15 to 25% of US 
dairy farmers had used Posilac™. These farmers manage between one-fourth and one-third 
of the total US dairy herd. 
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5. DAIRY POLICY IN THE EU, NORWAY AND 
USA 
5.1 Introduction 
In this chapter the focus is on dairy policies in the EU, Norway and the 
USA. First, EU dairy policy is characterized by describing the instruments used 
within the market organization for dairy products. As the milk quota system is 
an instrument of crucial importance for this market organization, attention will 
be paid to the impact of this system on the sector and to the discussion on the 
future continuation of this instrument in EU dairy policy. Then, Norwegian 
dairy policy is described. No attention is paid to dairy policies in Sweden and 
Finland as both countries are new EU member states; dairy policy in both Scan-
dinavian countries is comparable to EU dairy policy. The US dairy policy is char-
acterized by the dairy price support programme and the milk marketing order 
programme. This chapter ends up with some concluding remarks on differences 
and similarities between dairy policies in all countries under consideration. 
5.2 EU market organization for dairy products 
The basic management of the dairy products market was instituted in 
1964 by the first EEC dairy regulation. This involved the annual fixing of a tar-
get price for milk in each member state and, on the basis of this price, an inter-
vention price for butter (for skimmed milk powder an intervention price was 
established in 1968) and threshold prices for a list of twelve pilot products. 
Originally prices were not common between the six member states during the 
period up to 1968, but these differences were gradually phased out. Since July 
1968, a single-price market has existed (Tracy, 1989). 
The methods by which the appropriate price levels are secured are: 
the imposition of variable levels on imports of dairy products to prevent 
internal price levels being reduced below the threshold or minimum im-
port prices; 
the payment of subsidies on exports in order to bring prices of EU prod-
ucts down to the generally lower-priced international market level. Ex-
port levies may be applied in times of shortage, when world market 
prices are above EU prices; 
the protection of the domestic market against disruptions caused by sea-
sonal and structural surpluses through the guaranteed purchase and stor-
age of butter and skimmed milk powder; 
the payment of a subsidy on skim milk used for the manufacture of casein 
and caseinates and on skim milk and skim milk powder fed to livestock. 
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5.2.1 EU quota system 
In the early 1980s, a target for milk deliveries was set, which, if exceeded, 
would lead to a modest reduction in the price received by farmers for their 
milk. This did little to halt the expansion of milk production and budgetary 
costs of the milk sector, and so, in April 1984, the milk quota system was estab-
lished. Originally, the quota system was authorized for five years, but in 1988 
it was extended for another five year period. As part of the CAP reform, it was 
further extended from 1992 until the year 2000, with the quantity to be speci-
fied year by year. 
Originally, quotas were set for each member state at the level of 1981 
deliveries plus 1 %, with 1984/85 a transitional year with an extra 1 % added. In 
addition, a Community Reserve was established to supplement the quota in 
particular areas of difficulty. Overproduction of butterfat led to the system 
being tightened in October, 1986 by penalizing any increase in fat content 
above the 1985/86 level. This was not enough to prevent budgetary problems 
and quotas were reduced by 6% in 1987/88 and an additional 2.5% in 1988/89. 
Quotas were further reduced in 1991/92 by 2% as a result of a deteriorating 
market situation. On April 1, 1993, quotas were increased overall by 0.6%, 
while additional quota was given to Italy, Greece and Spain to ensure a proper 
application of quota in these countries fol lowing the revision of quota esti-
mates. 
Table 5.1 Total milk quotas, by member state and EU-12 level 
1986/87 1988/89 1993/95 
Belgium 
Denmark 
Germany (West) 
Greece 
France 
Ireland 
Italy 
Luxembourg 
Netherlands 
UK 
Total EU-10 
Former GDR 
Spain 
Portugal 
Total 
3,611 
4,883 
23,553 
583 
26,508 
5,599 
9,914 
291 
12,074 
15,790 
102,806 
-
5,400 
-
108,206 
3,326 
4,468 
21,558 
536 
24,303 
5,150 
9,133 
268 
11,053 
14,475 
94,270 
-
5,032 
-
99,302 
3,310 
4,455 
21,621 
631 
24,236 
5,246 
9,930 
269 
11,074 
14,590 
95,362 
6,244 
5,567 
1,873 
109,046 
Source: CAP Monitor, appendix 7 and 8. 
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The system has been continually refined and altered to f i t changing cir-
cumstances. The most essential elements of the current system are (CAP Moni-
tor, 28.2.95): 
a guaranteed total quantity (quota) specified for each member state (ta-
ble 5.1). No transfers of quota can take place across national borders; 
if this total quantity is exceeded, a levy is payable by individual milk pro-
ducers. The level is currently fixed at 115% of the target price; 
a member state can choose whether to collect the levy directly from pro-
ducers (farm level), or from the purchasers of milk (dairy processors), who 
wil l deduct any amount owed from individual producers through the 
price of milk or by other appropriate means; 
the levy is only payable to the Community if the total guaranteed quan-
tity for the member state is exceeded. Individual producers who exceed 
their quota are subject to the levy once allowance has been made for 
producers who have marketed less than their quota; 
individual reference quantities are allocated to each holding. If the fat 
content of a producer's milk varies from the base level (usually the level 
in 1985/86), the amount of milk delivered is multiplied by 0.18% per 0.1 
gram of fat per kilogramme of milk. This effectively means that quotas 
are fixed in terms of fat rather than in quantity of milk. 
Although quotas are linked to a producer's holding, they can be trans-
ferred from one farm to another through the sale, lease or inheritance of the 
farm, the lease of the quota itself, the purchase of quota by the governmental 
authorities of a member state, or the allocation of quota from a national re-
serve. Arrangements and rules for quota transfer vary considerably from one 
member state to another. To restructure milk production, governmental au-
thorities of member states can purchase quota from producers and reallocate 
it to other producers. 
5.2.2 1992 CAP reform and GATT agreement 
The 1992 CAP reform and the implementation of the GATT agreement 
have only limited implications for the EU dairy market organization. As part of 
the CAP reform package it was decided to reduce the target price for milk and 
to reduce milk quotas. The price cut was justified by the decline in feed prices 
as a result of a fall in cereal prices. Such a price reduction was achieved by the 
lowering of butter intervention prices in 1993/94 and also in 1994/95. The 
quota and price decisions have been subject to review. Sofar, no quota cut has 
taken place, but the butter intervention price was reduced more than originally 
foreseen in the Mac Sharry reform package. 
Under the GATT Uruguay Round, the EU has entered into commitments 
governing market access, export competition, and internal agricultural support. 
The commitments began on 1 July 1995 and will be implemented fully over a 
six year period. The market access provisions relating to dairy products are a 
reduction of tariffs by 36% (20% for skimmed milk powder (SMP)) compared 
to the average level of 1986-88, and creation of import opportunities repre-
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senting 3% of domestic consumption, rising to 5% by 2001. Provision will have 
to be made to enable the import of around 105,000 tonnes of cheese and some 
SMP and butter. The export competition commitments entail a reduction of 
36% in expenditures on export support and 21 % in the volume of subsidized 
exports, compared to the average level of 1986-90. The principal effects will be 
to reduce subsidised cheese exports (Van Berkum, 1994, see also section 6.4). 
Rules governing imports and exports had to be adjusted. EU variable import 
levies are replaced by ad valorem tariffs. Furthermore, a system of import and 
export licenses had to be implemented in order to monitor trade according to 
the commitments made in the GATT agreement. 
5.2.3 Alternatives for present policy 
The most crucial question for the EU dairy sector in coming years wil l be 
whether the quota system will be maintained after the year 2000. Abolishing 
the system of production rights may have large economic and structural conse-
quences for the EU dairy sector (see chapters 6 and 8). Here we focus on some 
effects of the quota system on the sector and discuss alternatives to the present 
policy. 
The impact of the introduction of the system of production management 
on market developments has been multifarious. Less production led to less 
excess supply and so to lower export and intervention stocks. The forced pro-
duction limitation resulted in higher farm level milk prices. Estimates indicate 
that - assuming unchanged budgetary outlays - without the quota system, the 
milk prices would have been 20% less. Milk prices have remained higher since 
1984 compared to average agricultural prices (which are declining). Partly this 
can be attributed to the quota system. Also, the quota system has had conse-
quences for feed prices. Because of the shrinking of the dairy herd, more green 
fodder per animal is available. Subsequently, demand for compound feed de-
creased and prices declined. In general, dairy farmers have benefitted from 
lower feed prices. Lower cereal prices in the EU resulting from the 1992 CAP 
reform also have affected favourably the feed costs for dairy farmers. 
Although the economic results for the primary dairy sector are relatively 
positive and will not be affected negatively by the 1992 CAP reform, discussions 
to change the dairy policy occur from time to time. In the discussion of policy 
alternatives, the unfavourable aspects of the present quota systems are high-
lighted. The processing companies are especially against limitations on produc-
t ion. In countries where the production rights are tradeable (like the Nether-
lands and UK), the system is cost increasing. Advocates for an alternative dairy 
policy indicate that the quota system slows structural adjustment in the sector. 
In the fol lowing three alternatives are sketched. 
A. A two-price system is mentioned regularly as an alternative for the quota 
system presently in force (e.g. Hubbard, 1992). In such a system the maxi-
mum amount of milk is allocated to each dairy farmer. That amount 
(quota) can be delivered against a guaranteed price, which is above the 
world market price level. For milk production exceeding the quota, the 
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farmer would only receive the world market price. A disadvantage of this 
approach is that the quota with the guarantee price will have to be 
about same as the internal sales on the EU-market which means that the 
present EU production will be cut by about 12-15%. 
B. Another approach is radical price liberalization. According to this idea, 
price supports and the quota system would be abolished and farmers 
would be supported only by direct income payments. This income support 
could be production-tied or de-coupled from production levels or animal 
numbers. Internal prices would have to be on the same level as those on 
the international markets and no production management would be 
endeavoured any more. Proposals in this direction are not welcomed 
enthusiastically sofar. For most farmers, the economic advantages of the 
quota system (assuring production and sales support) are considered to 
be larger than those of liberalization where the market mechanism 
would cause more price uncertainty. 
C. As a third alternative, a direct payment could be introduced together 
with price reductions and maintenance of the quota system. Such an al-
ternative could f i t well within the GATT commitments. It would help to 
realize the export reduction requirements relatively easily. In fact, this 
approach was under discussion in the 1992 CAP reform package through 
the proposal of the dairy cows premiums. However, the proposal was 
rejected because it would mean a steep rise in the budgetary costs of the 
dairy policy. 
For the time being there is no support for dismantling the quota system. 
EU countries are, however, split in their views on how to solve a decline in milk 
prices. The Netherlands and UK are at the forefront of those who believe that 
there should be continuing support price cuts, while Germany favours quota 
cuts and unchanged prices. In Germany, milk prices paid to dairy farmers have 
declined around 20% since 1990, due to overproduction and a strong D-mark 
affecting exports negatively. Price reductions would be supported by budget 
controllers within the Commission, who are alarmed at the failure of the quota 
system to curb over- production and reduce subsidy payments (Agra Europe, 
London, April 29, 1994:E/7). The EU member states have not taken any position 
yet in discussions whether the quota system should be extended after the year 
2000, and, if not, which alternative dairy policy should be pursued. Only the 
Dutch Minister of Agriculture has given his opinion by stating that the quota 
system is 'artificial' and therefore it should be abolished 'in the longer term' 
(LNV, 1995). 
5.3 Dairy policy in Norway 
In Norway, a quota system was introduced in 1983. The quotas are allo-
cated to individual farms and are firmly fixed to the land. Transfer of quota 
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f rom one farm to another is not allowed. The quota system is continued for 
one year at the time. In 1983, each farm was given a 'basis quota' based on the 
average production over the previous three years. Every year the quotas are 
adjusted to the market forecasts by multiplying the individual quota basis by 
a given factor. A dairy farmer may opt for a qualification as a special case and 
apply for extra quota. He will only be successful when his farm development 
is in accordance with the official guidelines. These guidelines for farm develop-
ment refer to investments in expansion of farm buildings, expansion of area, 
and labour available on the holding. Since 1983 the rules of quota distribution 
and the related subsidies have contributed to levelling the production struc-
ture. Less milk is produced on large farms while many farms that had a limited 
production in the early 1980s have expanded. An increasing share of total milk 
production is produced at semi-large farms (60-100 thousand litres; Jervell, 
1993). The distribution of the quota shows the general principle of Norwegian 
agricultural policy, which is more to keep rural areas economically viable and 
occupied than to pursue the cheapest possible production. 
Ever since 1982 the national target quantity has been 1.8 million tonnes 
annually. Since 1992 the quantity target has been reduced several times to 1.74 
million tonnes in 1994. A buy-out scheme was introduced in 1991 in order to 
minimise the consequences of the quantity reductions for the remaining milk 
producers. The buy-out quota was not redistributed to other farmers. A farmer 
participating in the buy-out scheme pledges not to produce milk on the farm 
for a period of seven years. A compensation is paid for income losses. The dairy 
farmers themselves finance the scheme by a lower average milk price. Due to 
limited producer response, the scheme ceased operation at the end of 1994. 
Norwegian dairy farmers receive relatively high price supports. Producer 
prices are about 60% higher than in the EU. For deliveries beyond the quota 
limit, very low prices are given (around 5% of the target price). Market price 
support is supplemented by direct income payments, which are differentiated 
according to region and farm size. Basically, farmers in the more disadvantaged 
areas with the smallest farms are most favoured by the system. Norway has an 
extensive system of deficiency payments and other forms of direct payments. 
In 1992, a complete list of these payments included more than 40 separate 
schemes, some of which are targeted to meet regional, environmental and 
rural development objectives (OECD, 1993:144). A dairy farmer could receive 
payments from several schemes. The new agricultural policy approved in Febru-
ary 1993 is aimed at establishing a less complex support system with fewer pol-
icy instruments. For the 1993/94 and 1994/95 production years administered 
prices were reduced for all products (OECD, 1995a). Spending on deficiency 
payments was further reduced, especially for milk. Other forms of direct pay-
ments wi th weaker links to production have also been reduced. 
5.4 Dairy policy in the USA 
Most of the current major public dairy policies in the USA stem from the 
legislation enacted in the thirties and the forties (Weimar and Blayney, 1994). 
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Many of the major public policies are directed towards milk pricing, but milk 
quality and safety also have been important public policy targets. The two 
main vehicles of US dairy policy are the price support programme and the fed-
eral milk marketing order programme. Through the price support programme 
the US government stabilises dairy farm incomes while reducing seasonal insta-
bility in milk prices by purchasing unlimited quantities of manufactured dairy 
products at established support prices. Until July 1995 import quotas were im-
posed to keep imports of dairy products from overwhelming the dairy price 
support programmes. Since that date import quotas have been changed into 
a system of tariffs according to the rules defined in the GATT Uruguay Round 
agreement. Since 1985 export support through the Dairy Export Incentive 
Programme assist US exporters of dairy products to enter foreign markets. Fed-
eral and State milk marketing orders provide additional pricing mechanisms for 
the price support programme and cover nearly all fluid-grade milk produced 
in the US. Federal orders set minimum prices for raw-grade milk according to 
its use that processors must pay to dairy farmers or their cooperative. Federal 
orders do not determine how the milk may be used or how much milk is pro-
duced or marketed (Manchester, Weimar and Fallert, 1994). 
The dairy price support programmes supports the milk prices received by 
the farmer through the purchase of butter, nonfat dry milk, and Cheddar 
cheese. These purchases are made by the USDA through the Commodity Credit 
Corporation (CCC). Processors offer butter, nonfat dry milk and cheese at an-
nounced prices. These prices are designed to return the support price to the 
farmer. The farm bill of 1990 sets an annual milk surplus target of 3.5 billion 
pounds of milk (1.6 billion tonnes), which provides a supply for government 
programmes and a cushion in case supplies are smaller or demand greater than 
expected. If USDA estimates a smaller surplus, price supports are raised. If an-
nual purchases of dairy products are anticipated to be greater than 5 billion 
pounds of milk equivalents, the price support will be reduced, while if they are 
between 3.5 and 5 billion pounds, no price support adjustment is made. 
Since the CCC purchases the final manufactured products in the market 
at the support price level, the prices actually paid by milk processors to the 
dairy farmer are not directly regulated by the programme. Price linkages be-
tween the price support programme and the Federal order system are shown 
in figure 5.1. Prices received by the individual dairy farmers depend upon many 
factors other than the support level, including plant location, product manufac-
tured, quantity of milk delivered, local competition, and plant operating effi-
ciency. The Federal order system sets minimum prices processors must pay dairy 
producers for Grade A (fluid-grade) milk. Milk is categorized into two groups 
and priced according to its use. Only Grade A milk can be used for beverage 
production, while Grade B milk can be used to produce only hard-manufac-
tured dairy products. The price paid to farmers for manufacturing-grade milk 
is competitively determined. A commonly used measure for manufacturing-
grade milk prices is the Minnesota-Wisconsin (M-W) price series. The M-W man-
ufacturing price is used as a base formula by all orders and is the minimum 
Class III price. Minimum Class II prices are calculated by adding a small differen-
tial to the M-W price. The minimum Class I price is the M-W price plus any dif-
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ferential based on sanitation costs, transportation costs, and supply and de-
mand conditions for milk. 
The Agricultural Act of 1949 incorporated the parity price guideline which 
provided for minimum and maximum levels at which farm milk prices were to 
be supported. From 1949 to 1981 the minimum support price was 75% and the 
maximum was 90% of parity. Since the Agricultural and Food Act of 1981 mini-
mum support prices are legislatively set in dollars per hundredweight (Weimar 
and Blayney, 1994). 
Support prices may be adjusted from year to year depending on market 
developments. Since 1981 the support price for milk has declined in nominal 
terms several times as CCC projected removals exceeded 5 billion pounds milk 
equivalents (Manchester, Weimar and Fallert, 1994). Several programmes have 
attempted to reduce surplus production. For this purpose, the Food Security Act 
of 1985 established a whole herd buy-out programme for dairy farmers (Dairy 
Termination Programme). Cows and heifers exiting dairying under this 
programme were exported or slaughtered. This measure to manage excess 
dairy production was later considered to be unnecessary and was abolished in 
1988. Since the late 1980s, growth of demand for US dairy products - domesti-
cally and internationally - has reduced excess supply. As a result, market prices 
for dairy products rose to a level above the support price. Since 1989 the farm 
level US support price has been US$ 0.101/pound and market prices has been 
US$ 0.11 to US$ 0.13 per pound to US farmers, what means that the price sup-
porting programme has not effectively supported the farm level price since the 
late 1980s. 
PRICE SUPPORT PROGRAMME MILK MARKETING ORDERS 
support price for milk 
4 
support purchase prices for dairy products Class I price = M-W + differential 
1 
wholesale prices for manufactured dairy products Class II price = M-W + 15 $ct 
I 
prices for n nanufactured grade milk Class III = M-W price 
Figure 5.1 Federal milk marketing orders' link with Federal price support programme 
Source: Manchester, Weimar and Fallert, 1994:5. 
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5.5 Concluding remarks 
Dairy policy in the EU, USA and Scandinavian countries has a lot in com-
mon. The most significant similarity is the high level of protection all countries 
offer to their dairy sector (see table 5.2). The Producer Subsidy Equivalent (PSE) 
- an indicator for protection developed at and widely used by OECD - measures 
the value of the monetary transfers to producers from consumers of agricul-
tural products and from taxpayers resulting from a given set of agricultural 
policies. As a rule, the PSE is expressed as the total value of transfers as a per-
centage of total value of production (valued at domestic prices). It appears that 
on average dairy farmers in OECD countries receive more than 60% of the pro-
duction value through all support measures considered. The EU support level 
is equal to the OECD average, while the indicator for the US dairy farmer has 
declined and is now substantially below the average OECD level. According to 
the PSE-indicator, Norwegian dairy farmers are receiving substantially more 
support than the average OECD level. The Nominal Assistance Coefficient (NAC) 
on production - also an OECD concept - is the ratio of the border price plus the 
unit PSE to the border price. This coefficient gives an indication of the ratio 
between internal and world market prices. The NAC is highest for Norway, 
least for USA, and the EU-12 equals the OECD average. All countries use price 
supports as a policy instrument, resulting in internal prices significantly above 
the international level, especially in Europe. In the USA, farm prices in the mar-
ket place are now well above government support prices and are determined 
by market supply and demand forces. To prevent an inflow of cheap(er) dairy 
products from other countries, the price support is linked to border measures. 
While EU and Norway rely on import tariffs, US dairy imports were restricted 
by import quotas. These US import quotas were abolished in July 1995, when 
they were changed into tariffs as agreed in the GATT Uruguay Round, and are 
gradually being relaxed. 
Table 5.2 Overview of support to milk producers 
EU-12 
USA 
Norway 
OECD 
PSE % 
Producer NAC 
PSE % 
Producer NAC 
PSE % 
Producer NAC 
PSE % 
Producer NAC 
1986-88 
64 
2.70 
64 
2.55 
79 
6.28 
66 
2.9 
1989-91 
63 
2.55 
57 
2.17 
80 
6.26 
63 
2.6 
1992 
65 
2.62 
54 
2.06 
83 
7.07 
63 
2.6 
1993(e) 
62 
2.48 
55 
2.10 
81 
6.04 
63 
2.5 
1994(p) 
63 
2.51 
54 
2.04 
81 
5.75 
62 
2.5 
Note: (e) estimate, (p) provision. 
Source: OECD, Monitoring and Outlook report 1995. 
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Despite the similarities in policies, there are also striking differences. The 
main difference is that in the EU and Norway milk production is restrained by 
a quota system, while such a system is not in force in the USA. If US dairy pro-
duction exceeds a certain level of surplus production, support prices are re-
duced, and this would bring down production again. Therefore, while in Eu-
rope production is bound to quota, production management in the USA seems 
to be strongly linked to price support levels. Futhermore, in recent years, US 
government owned stocks of dairy products are much lower than in the early 
1980s, and milk price supports have had little impact on prices farmers receive 
and consumers pay. 
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EU INTERNATIONAL TRADE POSITION AND 
PERSPECTIVES 
6.1 Introduction 
The use of rBST may affect trade volumes and patterns. Widespread use 
of rBST by milk producers could stimulate dairy production. This could lead to 
increased surpluses if the domestic market is not able to absorb the extra sup-
ply and subsequently to more exports, or it could reduce the import needs be-
cause of an increasing self-sufficiency rate. In both cases, the country where 
rBST is adopted and used on a huge scale affects the trading possibilities of 
other exporters, wi th possible consequences for prices on the international 
markets. Furthermore, it is conceivable that countries where opposition against 
rBST is strong, may try to demand the strictest import requirements for dairy 
products processed from milk from rBST-treated cows. In those countries, prod-
uct quality rules may be implemented and when such regulations differ be-
tween countries they may act as trade barriers. 
In this chapter the focus will be on the international trade position of the 
EU and the intra-EU trade between member states. The chapter will end wi th 
a discussion of developments that will affect the international perspectives of 
the EU dairy sector in the years to come, plus supply and demand projections 
for the world market until the year 2000. These developments will play a role 
in the scenarios discussed in chapter 7 wi th respect to regulation of the use of 
rBST. 
6.2 Position of the EU on the international dairy market 
The EU is the most important milk producing region in the world (table 
6.1). In 1994, a quarter of total world production of cow milk was produced in 
the EU-12. The EU is the world's major producer of cheese and dry milk pow-
der, wi th a share of around 40% of the world production of both dairy prod-
ucts. The former Soviet Union was an important producing region with a share 
of about 23% of total world production of cow milk in the second half of the 
1980s. In recent years, production in the CIS-states declined sharply because of 
the structural adjustments related to the political and economic upheaval. Still, 
the production within the region is 18% of the world's total. The US share in 
world milk production is slightly less (15%) than for CIS states in 1994 and has 
increased somewhat throughout the years. To indicate the level of concentra-
tion of milk and dairy production in the world, the figures for the EU and the 
USA together show that both areas account for 40% of world cow milk produc-
tion, for about 55% of world dry milk powder production and for 60% of total 
cheese production in the world. When the region of the former Soviet Union 
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Table 6.1 Cow milk and dairy production in selected regions of the world 
1980 1984 1988 1992 1993 1994 
World cow milk (mil. mt) 
production butter & ghee (1,000 mt) 
cheese, total (1,000 mt) 
dry milk, total (1,000 mt) 
Share in world production (%) 
EU (12) 
USA 
Area of 
ex-USSR 
Oceania 
Rest 
cow milk 
butter & ghee 
cheese, total 
dry milk, total 
cow milk 
butter & ghee 
cheese, total 
dry milk, total 
cow milk 
butter & ghee 
cheese, total 
dry milk, total 
cow milk 
butter & ghee 
cheese, total 
dry milk, total 
cow milk 
butter & ghee 
cheese, total 
dry milk, total 
Source: FAOSTAT. 
422 
6,927 
1,518 
6,995 
28.2 
32.7 
35.7 
52.8 
13.8 
7.5 
19.6 
12.9 
21.4 
20.0 
13.0 
7.7 
2.9 
4.9 
2.3 
6.0 
33.6 
34.9 
29.3 
20.7 
452 
7,491 
12,739 
7,820 
27.7 
32.5 
36.7 
48.4 
13.6 
6.7 
20.1 
12.9 
21.6 
21.2 
13.1 
9.9 
3.0 
5.2 
2.1 
7.2 
34.2 
34.3 
28.1 
21.6 
471 
7,399 
14,272 
7,584 
25.0 
26.3 
35.7 
43.8 
14.0 
7.4 
20.7 
14.2 
22.5 
24.4 
13.9 
13.3 
3.0 
4.6 
2.1 
7.8 
35.5 
37.3 
27.6 
20.9 
463 
6,934 
14,650 
7,343 
24.2 
23.0 
37.7 
42.0 
14.8 
9.4 
22.5 
15.2 
19.5 
20.4 
11.6 
11.7 
3.3 
5.3 
2.3 
9.6 
38.3 
41.9 
25.9 
21.6 
461 
6,884 
14,740 
7,435 
24.1 
22.9 
38.3 
42.3 
14.8 
9.1 
22.4 
14.6 
18.8 
19.6 
11.1 
11.2 
3.5 
5.5 
2.4 
10.3 
38.8 
42.9 
25.8 
21.6 
459 
6,712 
14,880 
7,457 
24.1 
22.9 
38.6 
42.4 
15.2 
9.2 
22.7 
15.9 
18.0 
18.3 
10.3 
10.2 
3.6 
5.6 
2.8 
11.2 
39.0 
44.1 
25.5 
20.3 
is included, 10 to 20% can be added to these shares. Asia - as part of the rest 
of the world - produces around 15% of total world production. India provides 
around half of this production. Oceania (Australia and New Zealand) account 
for an increasing part of total world production but their share was only 3.6% 
in 1994. Although Oceania is a relatively small production region, it exports a 
major part of its production. Therefore, developments in milk production in 
Australia and New Zealand are relevant for the international dairy markets. 
The EU is by far the biggest supplier of dairy products on the interna-
tional market, followed at a distance by New Zealand and Australia (see table 
6.2). The EU accounts for almost half of the world's dairy exports and the EU, 
New Zealand and Australia together had a share of 88% in 1994. New Zealand 
and Australia are extremely dependent on the international market as dairy 
exports account for almost 70% and 50% of their milk production, respectively. 
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Table 6.2 Export position of major suppliers on the world market for dairy products in 1994 
(in milk equivalents) 
EU a) 
New Zealand 
Australia 
USA 
EFTA-countries b) 
Canada 
Total c) 
Export quant i ty 
(mill ion tonnes) 
12.0 
5.8 
4.0 
1.1 
1.5 
0.3 
24.7 
Export as % 
of wor ld exports 
48.6 
23.5 
16.2 
4.5 
6.1 
1.2 
100 
Export as % of 
country's product ion 
10.8 
69.2 
48.0 
1.6 
10.1 
3.9 
11.2 
a) EU external trade; b) Norway, Sweden, Finland, Austria and Switzerland; c) Total of countries 
mentioned. 
Sources: PZ, World Trade in Dairy Products 1994, p. VIM; FAO Agrostat. 
The EU and EFTA export 10% of their dairy production to the world market in 
1994. Only a very small part of US dairy production is exported. The same is the 
case with regard to Canadian dairy production. 
EU exports to third countries mainly consist of cheese and whole milk 
powder (WMP) (table 6.3). In some years the export of skimmed milk powder 
(SMP) accounts for a big share too, but the export of SMP fluctuates strongly 
from year to year. The export of condensed milk and butterare in terms of milk 
quantities of minor importance. 
Looking at the trends since 1984, cheese exports as a share of total dairy 
exports declined until 1988, have increased since then, and accounted for 
somewhat more than one-third of dairy exports in the 1990s. Whole milk pow-
der was, in terms of milk equivalents, the biggest export product in 1984, and 
its position has become even stronger. In 1994, WMP accounted for 40% of the 
EU export package. SMP exports account for about 25-30% of total dairy ex-
ports in normal years within the period under consideration. Big export quanti-
ties in 1988 were possible because of EU efforts to reduce the large stocks built 
Table 6.3 Composition of EU dairy exports to third countries (in mil. tonnes of milk equiva-
lents) 
1984 
1986 
1988 
1990 
1992 
1994 
Cheese 
3.9 
3.1 
3.6 
4.0 
4.4 
4.5 
WMP 
4.1 
3.9 
4.7 
3.9 
4.7 
5.0 
Condensed 
1.1 
0.9 
0.8 
0.7 
0.7 
0.7 
SMP 
3.4 
2.9 
6.4 
3.0 
3.8 
1.6 
Butter(-oil) 
0.4 
0.3 
0.6 
0.2 
0.2 
0.5 
Total 
12.9 
11.1 
15.8 
11.5 
13.2 
12.3 
Index 
(1984=100) 
100 
86 
122 
89 
102 
95 
Sources: PZ World Trade in Dairy Products 1994 (part 1), p. VI. 
68 
up in the EU. SMP export was encouraged by targeted export supports to sell 
the product on the world market. Since stocks were low in 1994, exports of 
SMP were also limited so that the export share of this product dropped to less 
than 15% of total EU dairy exports. 
EU dairy exports f ind their way to other regions all over the world. The 
most important destination, in terms of milk quantities, is Asia (table 6.4). 
Within Asia, the Middle East region (Saudi Arabia, Iran) and some countries in 
the Far East are primary customers of EU dairy products. Asia was more impor-
tant for the EU in the 1980s than in more recent years. The share of total dairy 
exports to Africa, the second important destination of EU dairy products, is also 
declining. Still, the densely populated North African countries are very impor-
tant clients for the EU. The emerging markets for EU dairy export appear to be 
the other European countries, like Central and Eastern Europe, the former So-
viet Union, and Latin America. 
Table 6.4 Destination of EU-12 dairy exports to third countries (in million tonnes of milk 
equivalents and in % of total exports) 
Other Europe 
Africa 
North America 
Latin America 
Asia 
Oceania 
Total third countries 
1984 a) 
1.0 (8) 
3.7 (29) 
0.6 (5) 
1.9 (15) 
5.4 (42) 
0.1 (1) 
12.8 (100) 
1988 
2.3 (15) 
4.1 (26) 
0.6 (4) 
2.4 15) 
6.4 (40) 
0.1 (1) 
15.7 (100) 
1992 
1.9 (14) 
3.4 (26) 
0.7 (5) 
2.7 (20) 
4.5 (34) 
0.1 (1) 
13.3 (100) 
1994 
1.8 (15) 
2.5 (21) 
0.8 (7) 
2.4 (20) 
4.4 (36) 
0.1 (1) 
12.0 (100) 
a) 1984 refers to EU-10, other years refer to EU-12. 
Source: PZ, World Trade in Dairy Products (several years). 
Table 6.5 Major markets for EU dairy products outside the EU (export value in million ECU) 
Product (total export value Most important markets 
to non-EU countries) 
Cheese (1,406) USA (252), Switzerland (138), Japan (106) 
Saudi Arabia (88), Austria (72) 
WMP (1,117) Algeria (141), Saudi Arabia (118) 
Taiwan (57), Russia (52), UAE (33) 
Condensed milk (327) Saudi Arabia (48), UAE (21), Hong Kong (20) 
Libya (20), Nigeria (17) 
SMP (435) Mexico (131), Algeria (56), Malaysia (24), 
Indonesia (18) 
Butter(-oil) (313) Russia (43), Egypt (35), Saudi Arabia (34), 
Mexico (16), Algeria (14) 
Source: Eurostat Trade Statistics (EXMIS/LEI-DLO). 
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Looking at the export value of EU dairy products in 1993 for the most 
important markets of EU countries outside the EU, some observations can be 
made. Cheese and whole milk powder (WMP) are by far the most important 
dairy export products, as both products together account for about 70% of 
total dairy export value. Major markets for EU cheese are countries wi th high 
income levels, while other dairy products from the EU mostly go to markets in 
developing countries (table 6.5). The USA is by far the most important market 
for EU cheese. The cheese exports to the USA, Switzerland and Japan ac-
counted for 35% of total cheese exports in 1993. WMP finds its way mainly to 
North Africa (Algeria) and the Middle East (Saudi Arabia and UAE). Saudi Ara-
bia appears to be a major market for all products except for SMP. Russia, Alge-
ria, and Mexico are important markets for more than one EU dairy product, 
too. 
6.3 Intra-EU trade in dairy products 
Most exports of EU Member States find their way to other Member States 
of the EU. In 1994, EU countries exported 34 million tonnes of milk(equivalents) 
of which 22 million tonnes had a destination within the EU. 
The intra-EU dairy trade is dominated by four suppliers; Germany, France, 
the Netherlands and Belgium/Luxembourg (table 6.6; appendix 7 gives a more 
detailed table). These four countries have a share of around 75% in the total 
intra-EU dairy exports (11,964 million ECU in 1993). The main exporting coun-
tries are also important in the intra-EU imports. The countries just mentioned 
have a 60% share in the intra-EU imports of dairy products. In addition to these 
countries, Italy is also a large importer. 
The fact that Germany, the Netherlands and Belgium/Luxembourg are 
among the main exporting, as well as among the main importing, countries 
shows that there is a lot of mutual trade. For instance, Germany has a 3 1 % 
share of total Dutch dairy imports, while the Netherlands have a 44% share of 
total German dairy imports. Germany has a 56% share of the very large Italian 
dairy imports (Kelholt, 1995). 
Table 6.6 EU-intra trade in dairy products in 1993 (million ECU) 
Product Total value 
of exports 
Main exporters 
country value 
Main importers 
country value 
Dairy total 11,964 Germany 3,129 
France 2,467 
Netherlands 2,242 
BelgAux. 1,421 
Germany 2,240 
Italy 2,124 
Netherlands 1,691 
Belg./Lux. 1,527 
Source: Eurostat Trade Statistics (EXMIS/LEI-DLO). 
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Having a large share in the intra-EU dairy exports does not necessarily 
mean a high export surplus in the intra-trade. The countries wi th the highest 
surplus (in descending order) are: France (1,063 million ECU), Germany, Ireland, 
the Netherlands and Denmark. All the other EU-countries are net importers. 
Italy has by far the largest import surplus (1,680 million ECU) in the intra-EU 
dairy trade. 
Cheese is the most important product in the intra-EU dairy trade (5,022 
mill ion ECU in 1993). Its share in the total intra-trade value in dairy products 
has risen from around 35% in 1984 to 42% in 1993. After the introduction of 
the quota system, not only the share of milk processed into cheese rose, but the 
absolute quantity of milk processed into cheese increased also. The dairy indus-
try produced more cheese and developed several new types of cheese to gener-
ate more value added. 
The Netherlands, France and Germany are the leading exporters. Al-
though Germany is among the leading exporters, its intra-EU trade balance for 
cheese is negative. In the Italian cheese market, it has a share of over 40%, but 
this does not compensate for its imports (mainly from France and the Nether-
lands). The type of cheese that Germany exports to Italy is also different from 
the types of cheese that are imported from France and the Netherlands. 
The internal market for fresh dairy products and ice-cream has more than 
quadrupled since 1984. This market segment (877 million ECU in 1993) also has 
a potential for new products that generate value added. France, Bel-
gium/Luxembourg and Germany are the main exporting countries. 
The internal market for fresh milk (1,627 million ECU in 1993) is domi-
nated by one exporter (Germany) and one importer (Italy). 
The internal EU markets for butter, whole powder, skimmed powder and 
condensed milk together represent around one third of the total internal dairy 
market. Although these products are still very important, there have been little 
or no new developments. It may be expected that in the future they will be-
come less important. 
6.4 Perspectives for EU on the international dairy market 
World cow milk production stabilized in 1994 after several years of de-
cline. The production in Europe went down by 1 % while production increased 
in the USA (2%), Asia (3%) and Oceania (5%). Prices in the international dairy 
markets increased because of limited supply. During the first half of 1995, 
prices for milk fat rose steeply due to the sudden demand for butter in Russia 
in early 1995. World production of skimmed milk powder went down, while 
consumption remained at much the same level pushing international prices 
upward. Increased demand for cheese has been matched by increased produc-
t ion. In addition to these factors of supply and demand, the upswing in US 
dollar prices was accentuated by the weakness of that currency (OECD, 
1995b:5-8). The future EU position in the world dairy market depends on all 
those factors affecting supply, demand and international prices. Numerous as 
71 
they are, attention will be paid to what are considered to be the most impor-
tant factors affecting future perspectives for EU dairy industry. 
The most important factors playing a role in the analysis of international 
market perspectives for EU dairy are the future international trade policy 
shaped by GATT/WTO agreements, the enlargement of the EU with Central and 
Eastern European countries, and market developments inside and outside the 
EU with respect to central regions of supply and demand. Besides these factors, 
the present and future EU dairy policy is of prime importance to the market 
perspectives for EU dairy. Market organization may change in level as well as 
in the use of instruments. Furthermore, due to environmental concerns, polit i-
cal support may change too. Environmental policies also may have an impact 
on the development of the dairy sector. Production circumstances (farm man-
agement, processing techniques) as well as product supply (diversification, 
quality, etc.) may be affected by technological changes. All these aspects men-
tioned are related to each other and affect each other. This has to be kept in 
mind in discussing the factors below. 
6.4.1 International trade policies 
The EU has made commitments in the GATT agreement of 1994 to im-
prove market access and reduce export restitutions. For its international trade, 
a reduction of export support may have major consequences. The impacts wil l 
concentrate on the export of cheese, and to a lesser extent on skim milk pow-
der and butter. Because of the reduction of subsidized cheese exports by the 
EU and an increasing demand for cheese in the world due to economic growth, 
international prices may increase in the years to come. The general expectation 
is that such price developments will stimulate production in Australia and New 
Zealand (OECD, 1995b). It has to be noted however, that the potential growth 
of cheap production in these countries has its limits too. A production decline 
in the EU is foreseen by the OECD, mainly because of less export support. An 
increase of the internal EU demand could prevent a production decline but 
market saturation may occur in the medium-term. Furthermore, more competi-
t ion on the internal market from foreign suppliers is to be expected in the 
years to come, because of the reduction of import barriers. An increase in ex-
ports to non-EU countries without the support subsidies would relieve the pos-
sible oversupply on the internal market. Most important is, if and how the EU 
can make use of the opportunities the international dairy markets will offer. 
6.4.2 Developments on the international dairy market 
Because of the changes in the export regime due to the GATT agreement, 
competition on international dairy markets will increase for EU countries. First 
of all, EU countries are competing among each other for a decreasing budget 
for export support and on foreign markets. Secondly, competition with non-EU 
countries will increase, especially with countries where production circum-
stances are beneficial for milk production. Countries like Australia and New 
Zealand are the first to be mentioned in this respect. Large potentials for an 
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increase in milk production in the former Soviet Republics are probably not to 
be developed fully in the short to medium term because of the huge problems 
milk producers face in these regions. The US dairy industry is growing, but is 
still mainly focused on the large internal market. Growth in demand wil l be 
strongest in regions where purchasing power and population growth are high-
est. This will be in (Southeast) Asia and, to a lesser extent, in Latin American 
countries. North Africa, Central and Eastern Europe, and the former Soviet Un-
ion. In most of these regions, consumption patterns are changing rapidly and 
becoming more Western. Because of the geographical proximity, and the tradi-
tional trade contacts, EU sales perspectives will be affected mainly by demand 
developments in North Africa, Central and Eastern Europe, and the former 
Soviet Union. 
6.4.3 EU enlargement with Central and Eastern European countries 
Present competitiveness of the dairy industry in Central and Eastern Euro-
pean countries is rather weak in the international markets. Since the upheaval 
caused by the breakdown of the communist system in 1989/90, production and 
exports did fall significantly in the whole region. In the years to come, supply 
of milk and dairy products from Central and Eastern European countries wil l 
stay at a low level, mainly because of the structural adjustment problems these 
countries still face. Competition from the countries at the eastern border wil l 
therefore be limited. Furthermore, because of the border protection, EU mem-
ber states still have a preferential position on the EU market. Border protection 
will be abolished, however, when new member states from the East join the EU 
and there will be one internal market. The question is whether the dairy sector 
in the EU-12 can stand the competition from these new member states. Much 
depends on the way these countries use available resources in the years to 
come to strengthen their dairy sector. The process of political and economic 
structural adjustment in the former East Bloc countries will take time. The 
shrinking herds and declining production, which the dairy sector within the 
Central and Eastern European countries had to face during the last five years, 
may be history in the near future. However, to develop a modern dairy industry 
that may play a role in the international markets one needs capital and knowl-
edge, both scarce resources in these countries. In the meanwhile, the EU dairy 
industry may be able to strengthen its market position in these candidate mem-
ber states. It is expected that due to increasing purchasing power, the dairy 
consumption in Central and Eastern European countries will grow. 
6.4.4 EU dairy policies 
From the very start in the 1960's, the market and price policies of the CAP 
have been the object of almost permanent renegotiation. The present post-
Mac Sharry CAP is also very much under discussion. The evaluation of the Mac 
Sharry reform, the implementation of the GATT Uruguay Round Agreement 
and the future enlargement of the EU with Eastern European countries may 
induce new adjustments in the common market organizations, which may be 
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reinforced by EU environment policy. The Mac Sharry reforms of 1992 left dairy 
policies about unchanged. Moreover, the milk quota system is to be main-
tained until the year 2000. What will happen after that date, however, is un-
clear. Abolishment of the dairy quota system may have significant impacts on 
the structure, location and competitiveness of the EU dairy industry (see also 
chapter 7). The industry may also be affected by changes in agricultural policies 
aimed to respond to environmental concerns. Such changes may imply a reori-
entation of support towards production methods making use of land and other 
resources (except labour) less intensively than is common nowadays. An inte-
gration of environmental objectives in the agricultural policies may change the 
international competitiveness of the sector and its structure. Furthermore, envi-
ronmental policies formulated outside the sector will affect its competitive 
position as these policies focus on the use of scarce production resources and 
therefore may set important limits to the agricultural sector. Looking at all 
these factors presently playing a role in discussions about the future agricul-
tural policy, it is very likely that the CAP which can be seen in operation today, 
will change. Much is undefined about the future CAP, but apparently there will 
be less support for agricultural production forcing the EU dairy sector to in-
creasingly orientate itself towards the market. 
6.5 Projections of future developments on the world dairy market 
According to OECD's (1995b) medium term outlook for dairy markets, 
world milk production will increase between 1995 and the end of the decade. 
In OECD countries the annual growth will be modest, and by the year 2000 the 
production will exceed the 1990-94 average by 4.7%. This increase should be 
largely due to the US, where output is expected to rise with the use of rBST, to 
Australia, where exports should increase following the GATT Uruguay Round 
Agreement and to Mexico, which has several milk production support 
programmes. Milk production in the rest of the world (except former Soviet-
Union and Czech Republic, Slovak Republic, Poland and Hungary) is projected 
to grow more rapidly than in the OECD area. 
Projections made by the OECD indicate that world dairy production will 
focus more and more towards cheese production and less towards bulk prod-
ucts such as butter and skimmed milk powder. Cheese production in the OECD 
is projected to rise by about 15%, to meet higher demand in the OECD area. 
Each of the OECD countries will see output rise. New Zealand and Australia will 
show the strongest growth in relative terms while the US and the EU will expe-
rience the highest growth rates in absolute terms. Butter production in the 
OECD countries is expected to fall (-2%) due to a sharp drop in output in the 
EU. Production in non-OECD countries is expected to rise steadily so that overall 
world butter production in 2000 will be somewhat higher than the average for 
1990-94. World butter consumption is expected to rise, mainly due to increased 
demand in the non-OECD countries. Also consumption in the US and Australia 
is expected to go up. World production of SMP is expected to fall (-15%), most 
significantly affected by the drop in output in the EU. Consumption in the 
74 
OECD area wil l fall largely due to declining consumption in the EU owing to 
the reduction in subsidies for animal-feed products. The decline expected in the 
rest of the world is likely to be offset by a rise in the consumption of whole 
milk powder. 
As a result of these supply and demand trends, trade patterns wil l 
change. The exports of butter and SMP from OECD countries are expected to 
decline. A further increase in the demand for cheese is expected to boost trade 
among OECD countries. Because of these trends, major exporters are likely to 
see a change in their market shares between 1994 and 2000. According to 
OECD estimates, the EU is likely to see its market share fall for SMP and cheese. 
With respect to butter, EU exports are likely to decline, just as exports of other 
major exports decline, so that the EU should register virtually no change in its 
market share. Australia's shares are expected to rise on all three dairy commod-
ity markets. 
As a result of the above trends (declining subsidised exports following the 
Uruguay Round agreement, falling surplus stocks, high demand in the non-
OECD area - notably in Asia, and shrinking world production of SMP), world 
prices in current terms for butter, SMP and cheese are forecast to rise between 
1995 and 2000. SMP and cheese prices should rise steadily over the period, 
whereas butter prices should level out between 1998 and 2000. 
The future increase in world market prices is expected to be largely due 
to an adjustment in the supply and demand balance for dairy products. The 
GATT Uruguay Round Agreement is primarily expected to reduce subsidized 
exports from the EU and increase US, Canadian and Japanese imports of dairy 
products between 1990-94 and 2000. However, the rise in exports from New 
Zealand and Australia to meet the greater export opportunities generated by 
the agreement is expected to dampen the beneficial impact on prices. Price 
levels are expected to be increasingly affected by demand from non-OECD 
countries, which is largely income-related. The position of the EU on the inter-
national dairy markets - at present more than substantial in the markets of all 
dairy products - is projected to decline. The OECD does not give its opinion to 
what extent such a decline will occur. 
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7. EU DAIRY SECTOR UNDER DIFFERENT 
POLICY ALTERNATIVES: FOUR SCENARIOS 
7.1 Introduction 
In this chapter, we will elaborate several policy scenarios for the EU dairy 
sector after the year 2000. Until the turn of the century, there will not be much 
room for policy adjustments. The current quota system for EU milk production 
will last until 2000. The ban on the use of rBST within the Union will not expire 
before December 31, 1999. The Mac Sharry reform measures are currently be-
ing implemented and will be fully in place in the year 1996. Finally, the agree-
ments made in the GATT Uruguay Round will be fully effectuated in 2000. 
Apart from these, no fundamental changes in the CAP are expected until the 
end of 1990s. Therefore, the year 2000 is taken as the starting point for future 
dairy market scenarios. In the next century, external circumstances such as the 
enlargement of the EU with Central and Eastern European countries or interna-
tional agreements to further liberalize international trade may force the EU to 
adjust its agricultural policy again. We do not want to take into account all 
implications of these external drivers to policy changes. Assuming that further 
agricultural policy adjustments after the year 2000 will take time to materialize, 
the period for our projections runs only between 2000 and 2005. 
The policy scenarios focus on the quota system and rBST. The quota sys-
tem is a core element in EU dairy market organization and will be maintained 
at least until 2000. A debate about the continuation of this policy is about to 
begin and will definitely intensify when the expiration date comes nearer. The 
same is likely to happen to the ban on the use of rBST: discussions on the pros 
and cons of rBST use will intensify when a decision has to be taken whether to 
extend the ban into the 21st century or not. For the time being, there is no 
major support in the EU member states for dismantling the quota system. How-
ever, dairy farmers, processing industries, policy makers and politicians may 
change their positions if markets for dairy products decline and policy adjust-
ments are considered necessary to adapt to the changing circumstances. If eco-
nomic conditions in the dairy sector deteriorate, then also farmers' skepticism 
about the benefits of using rBST may disappear. Crucial in the sector's position 
in such a case is whether consumers will accept dairy products from milk of 
rBST-treated cows. Presently, EU consumers' attitude towards rBST is negative. 
The resistance to eliminate the quota system and to allow the use of rBST 
presently seems to be rather strong in the EU. Therefore, it may appear to be 
rather premature to outline scenarios in which there is no quota system 
anymore and rBST-use is permitted. Still, it is useful to think about the possible 
implications of such policy alternatives, as it may contribute to the process of 
preparation of all involved. The qualitative impact assessments of the four sce-
narios outlined in the following sections are affected by assumptions, exclu-
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sions and simplifications. Therefore, the analysis surely does not pretend to be 
comprehensive enough to tackle all problems involved or show all possible 
impacts. However, this scenario approach can be helpful in clarifying the possi-
ble impacts of the policy alternatives discussed. 
Alternatives Quota rBST 
Scenario 1 (baseline) continued not allowed 
Scenario 2 continued allowed 
Scenario 3 eliminated not allowed 
Scenario 4 eliminated allowed 
Figure 7.1 Policy options 
In the following sections, the four policy options, shown in figure 7.1, are 
elaborated. We start with scenario 1, in which no policy changes compared to 
the current situation are projected. This is the baseline scenario, and serves as 
a point of reference for scenarios 2, 3 and 4. For each scenario, the fol lowing 
variables will be assessed: production and consumption of milk within the EU, 
export of dairy products to third countries, internal price level, and structure 
of EU dairy sector, e.g. number of dairy farms, number of cows per farm, and 
regional concentration of milk production. 
7.2 Scenario 1 (baseline) 
The baseline projection of developments in the EU dairy market to 2005 
is based on the estimated impact of full implementation of the 1992 CAP re-
form and of the GATT agreements on external trade in agricultural products. 
It is assumed that there will be no major changes until the year 2005 in the 
dairy policies after the full implementation of the Mac Sharry reforms. The 
quota system wil l be maintained and rBST use is not allowed in EU countries. 
This baseline projection builds mainly on the ECAM-projection of the Mac 
Sharry reform package (Folmer et al., 1995), supplemented with estimated im-
pact assessments of future developments from other sources. Internal and ex-
ternal price developments are part of the baseline projection (for international 
prices, see section 6.5). 
The 1992 CAP reform implied very limited changes in the dairy market 
organization (see section 5.2). Policy changes focus on small price reductions for 
the intervention products butter and skimmed milk powder. For the period 
beyond 1995, Folmer et al. assume further price declines in real terms, but the 
impact of those price adjustments on the milk production is absent: the annual 
growth rate of dairy production is estimated to be zero for the period 1992-
2005 (Folmer et al., 1995:186-188). The milk quota regulation continues to con-
strain EU milk production. 
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According to the model simulation, consumption of dairy products in the 
EU is expected to increase slightly during the period until 2005 (Folmer et al., 
1995:191). Total human consumption and intermediate use of dairy products 
may grow with 0.3-0.6% annually. This projection of consumption growth of 
dairy products does not correspond to the Commission's view and OECD projec-
tions towards 2000 on most likely developments in the EU-15. Both the Com-
mission (CEC, 1994) and the OECD (1995b) state that the consumption of butter 
and skimmed milk powder will decrease in the years to come, due to a decline 
in the use of animal/milk fats and a reduction in subsidies for use of SMP in 
animal feed. Cheese consumption, however, is expected to continue to increase 
but at a slower rate than before. Total dairy consumption is assumed to be 
more or less stable in the near future. 
The projections for production and consumption according to Folmer et 
al. result in less excess supply in 2005 compared to 1992. Net exports of butter 
remain negligible throughout the period though there are some gross imports, 
since the EU has a commitment to import butter from New Zealand. Total net 
export of all dairy products decreases and falls according to model calculations 
by about 25% in the simulation period (Folmer et al., 1995:193). The Commis-
sion's and OECD's view on most likely consumption trends in the Union imply 
that the EU's net trade position would not change significantly. 
The commitments under the GATT agreement may have a serious effect 
on the net export position of the EU. Export support has to be reduced in terms 
of subsidized volume (minus 21 %) and in terms of outlays for export subsidies 
(minus 36%) in the period 1995-2000. As subsidized cheese exports have in-
creased considerably during the late eighties and early nineties, a reduction of 
export support may have a major impact on the EU cheese market (Van 
Berkum, 1994). With reference to the export volume of 1991-92, subsidized EU 
cheese exports have to be reduced by 20,000 tonnes (i.e. 4.75% of total cheese 
exports of 1991-92) annually during the period 1995-2000. If EU consumption 
of cheese continues to increase, the internal market may be an alternative for 
export to third countries. However, competition from non-EU suppliers may 
increase because of the GATT requirement to enhance market access. When 
reduced export support leads to declining exports of EU cheese, cheese prices 
may go down, forcing processing companies to reduce their cheese production 
and change their production pattern towards other products. Such an adjust-
ment in the processing industry may lower milk prices paid to EU dairy farmers. 
EU exports to third countries are dependent on subsidies rather than on 
supply and demand conditions in the world market. International dairy prices 
are expected to increase in the coming years, mainly because of reduced subsi-
dized EU exports and a continuous increase in world demand (see section 6.5). 
Higher international prices will help the EU to fulfi l l GATT requirements as 
lower subsidies wil l be needed for EU cheese exports. Because of the GATT 
guidelines for minimum access commitments - 5% of 1986-88 consumption in 
the year 2000 - some quantities of butter (2,000 tonnes), skimmed milk powder 
(69,000 tonnes) and cheese (104,000 tonnes) may be imported under more 
favourable conditions. Although import tariffs are subject to a reduction under 
the GATT agreement, substantial EU market protection remains; the level of 
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the tariffs appears to remain high enough in the period until 2000 to prevent 
(further) downward pressure on internal prices, caused by market access com-
mitments (Van Berkum, 1994; Folmeret al., 1995:222). 
Changes in dairy farm structure will occur through changes in the number 
of dairy farms and number of cows per farm. Parallel wi th the general trend 
of a declining number of farmers, the number of EU dairy farms is diminishing 
year by year. In 1973 there were about 2.4 million dairy farms in the EU-9. 
Twenty years later, in 1993, only 800,000 dairy farms were left in those nine 
member states; about two thirds of the dairy farmers went out of business. 
Besides economic pressure to quit dairy farming, induced by technological and 
policy changes, demographic factors affect the restructuring process. In all EU 
member states, a significant proportion of farmers are aged 55 and over (EU 
average is 30%; CEC, 1995). In the baseline scenario it is expected that the cur-
rent trend in farmers discontinuing their operation will continue into the 21st 
century. Most likely, the smallest dairy farms are closed first because they are 
the least profitable and/or have minimal economic prospects. 
This trend of a declining number of farms also has consequences for the 
average number of cows per dairy farm. Due to technological advances, milk 
production per cow is increasing 1) wi th fewer cows needed to produce the 
(fixed) quota. Hence, the number of cows per dairy farm may fall. However, as 
dairy farms staying in business take over production rights from those who 
leave the sector, they will most likely expand their herd size. The number of 
cows per dairy farm has increased in the period 1985-1991 (see chapter 4). It is 
assumed that this trend will continue under the baseline scenario. 
Under the baseline scenario, the quota system is continued until 2005 (or 
beyond). Since the division of quota between countries is assumed to remain 
unchanged, there wil l be no shifts in the shares of EU member states in total 
EU milk production. On a national level, some shifts of production from regions 
with less attractive features towards regions with more favourable conditions 
for dairy farming have occurred. Such shifts depend on the tradeability of the 
quota between farmers located in different parts of the country. Under the 
baseline scenario, no further change in regional concentration of dairy farming 
within countries is assumed to occur in the period under consideration. 
7.3 Scenario 2, 3 and 4 
In scenario 2, the milk quota system is extended beyond the year 2000, 
while dairy farmers are allowed to use rBST. These policy choices lead to the 
same total milk production in the EU as under the baseline scenario because 
the quota system constraints growth of production. However, the consumption 
level may be affected by consumers' negative attitude towards milk from cows 
treated with rBST. In this scenario, it is assumed that the decision to allow milk 
1) Folmeret al. (1995:189) expect the average dairy cow to produce 16.5% more 
milk in 2005 than in 1992. 
79 
producers to use rBST, is based on consumer acceptance of milk from cows 
treated with rBST. Therefore, we assume no changes in EU dairy consumption 
patterns compared to the baseline scenario. This assumption builds on the ex-
periences in the US where, since the introduction of rBST in February 1994, milk 
consumption has not declined. In fact, US dairy consumption (especially cheese) 
continues to grow. Since dairy production and consumption are assumed to 
show the same pattern as in the baseline scenario, the EU net export position 
wil l also be the same. EU internal prices would fol low the same downward 
trend as in the baseline scenario. 
The use of rBST will have an impact on the structure of the dairy sector. 
The use of rBST increases the yield per cow and will therefore affect the size of 
the farms, as a dairy farmer needs fewer cows to produce the quantity of milk 
he is allowed to produce. Compared to the developments described under the 
baseline scenario, the number of cows per farm is still expected to increase, 
though at a slower rate. This slower growth rate is due to the combined effect 
of long term structural growth in the number of dairy cows per farm and a 
decrease in the number of cows per farm due to rBST use. With lower per unit 
production costs, rBST adopters will have an incentive to purchase quota from 
non-adopting neighbours, thereby speeding up the process of structural 
change. The less efficient non-adopters will sell their quota and leave the sec-
tor. As a consequence, the number of farms is expected to decline slightly more 
than the trend. Some regional concentration of production may occur. There 
will be no shifts in production concentration between countries since no 
change in the operation of the milk quota system is assumed and quota cannot 
be traded among member states. Within countries, the probability of regional 
shifts in production depend on the possibilities for quota trade. This may be 
restricted in some member states, because the production rights are tied to the 
land. For the EU as a whole, the impact on further regional concentration of 
production are expected to be limited. 
In scenario 3, dairy farmers are not allowed to use rBST but the quota 
system is abolished. Market prices are expected to go down because of a rise 
in production, caused by increased supply from producers wi th lower produc-
t ion costs. Those producers with relatively high production costs will not be 
able to continue their business when milk prices go down. The net effect wil l 
be that total milk production will increase, and milk prices will be lower than 
under the baseline scenario. Only a small increase in domestic consumption is 
expected due to the rather low price elasticities of demand. Lower prices will 
strengthen EU's competitive position on international markets, and therefore 
net EU exports of dairy products are expected to be somewhat higher than 
under the baseline scenario. 
Structural adjustments will occur under this scenario: the decline in the 
number of dairy farms is accelerated and there is an increasing concentration 
of cows on farms (more dairy cows on fewer dairy farms). Furthermore, a shift 
in regional concentration will result. Milk production will be concentrated in 
the most profitable production regions of the EU. The most favourable regions 
for dairy farming, i.e. the regions with the lowest production costs and highest 
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family income, are Niedersachsen (G), Bretagne (F), Lombardia (I), West Eng-
land (UK), the Netherlands and Denmark (Habraken, 1994). 
Compared to scenario 3, the fourth scenario includes the use of rBST. 
Using rBST will give a push to milk production. Thus, prices wil l go down more 
than under scenario 3. Production growth will likely exceed increases in con-
sumption. Consumption is expected to be stimulated by lower prices but, given 
the low price elasticities of demand, the effects will be rather limited. Conse-
quently, there is a need to expand exports. With GATT commitments restrain-
ing export support, an increasing effort to export pushes internal prices down-
wards. This price development will induce a reorganization of the dairy sector. 
Structural adjustments as described under scenario 3 will accelerate under this 
scenario: fewer dairy farms and on average more cows per farm. Production 
will become even further concentrated in the regions most favourable for dairy 
farming. 
According to our scenario projections, the abolishment of the quota sys-
tem is expected to result in an increase of production and net exports, and in 
an acceleration of structural change in the dairy sector towards more concen-
tration, on a farm as well as on a regional level (scenario 3+4, see figure 7.2). 
The adoption of rBST reinforces the effects assumed under the no quota sce-
narios: more production and exports, lower internal prices and fewer, but big-
ger dairy holdings, more regionally concentrated (scenario 4). Elimination of 
the quota system and/or introduction of rBST will accelerate structural change, 
wi th possibly profound social consequences. On the other hand, structural 
change may be considered to be inevitable if markets decline, prices go down, 
and the economic performance of the sector deteriorates. In such a situation, 
a policy wi th rBST and without a quota system may be an option in order to 
strengthen the competitive position of those who are able to stay in business 
Scenario 
Production 
Consumption 
Net export 
Internal real price level 
Number of da ry farms 
Farm size in number of cows 
Regional concentration 
1. (baseline) 
quota 
no rBST 
stable 
up/stable 
down/stable 
down 
decline 
increase 
stable 
2. 
quota 
rBST 
0 
0/0 
0/0 
0 
+ 
-
+ 
3. 
no 
no 
+ 
+ 
+ 
+ 
++ 
+ 
++ 
quota 
rBST 
4. 
no quota 
rBST 
++ 
+ 
++ 
++ 
+++ 
++ 
+++ 
Figure 7.2 Summary of scenario outcomes for EU dairy sector 
0 = no change with respect to scenario 1; + = reinforcement of development under scenario 1; 
- = weakening of development under scenario 1. 
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under less market protection. The question is whether rBST is an appropriate 
instrument for improving EU's competitive position in international dairy mar-
kets. 
7.4 Will rBST improve the position of EU dairy on the international 
market? 
The future EU position in the international dairy markets depends on 
several issues, of which the most important are reviewed in chapter 6. A conclu-
sion from that chapter was that the international position of the EU in interna-
tional dairy markets will decline, mainly due to the GATT commitment to re-
duce subsidized exports. Generally speaking, price competition seems to be-
come much more important for selling in the international markets, although 
for exporting high value-added products, the price level may not be the deci-
sive competitive factor. In this situation, EU exporters will have to consider low-
ering their prices for dairy commodities to be sold in the international market. 
This will lead to a downward pressure on milk prices in the EU. Dairy farmers, 
processors and trade will have to reduce their costs as much as possible in order 
to improve their competitiveness. Both elimination of the quota system and 
approval of rBST could contribute significantly to lower production costs. 
If rBST is allowed in the EU, consumers' attitudes with respect to rBST in 
the EU export markets must be taken into account. If consumers in these coun-
tries do not accept dairy products from cows treated with rBST, the EU could 
lose customers. EU's most important export markets are developing countries 
in North Africa and in the Middle and Far East (see table 6.4). However, some 
important markets for EU cheese are countries with high income levels, like the 
USA, Japan and Switzerland. It is important to know the consumers' attitude 
in all these countries towards dairy commodities produced with the help of 
rBST. 
In the USA, experiences since the introduction of rBST appear to show 
that the vast majority of the consumers accepts dairy products processed from 
rBST milk. There is no reason to suppose that US consumers would refuse to 
buy EU cheese produced with rBST. In Japan and Switzerland, consumers feel 
very strongly about food quality and safety. In both countries, dairy farmers are 
not allowed to use rBST. Consumers could be strongly opposed to imports of 
dairy products produced from rBST milk, although information about this is 
scarce. The attitude of consumers in developing countries seem to be different: 
concern is more about food availability than about quality and safety. In a 
number of developing countries rBST is permitted (see chapter 2), which may 
indicate that consumers accept dairy products produced with rBST. Exports 
from the EU to important markets in North Africa and the Middle East would 
therefore not be under pressure from negative consumer reactions. The same 
could hold for Russia and probably also for most countries in Central and East-
ern Europe. In some of these countries, dairy farmers are allowed to use rBST. 
Information about the application rate of the hormone is lacking. Also, con-
sumers' attitude towards rBST milk in Central and Eastern European countries 
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is unclear because no results are known of any research on this topic. There is 
still a lot of uncertainty about the acceptance of rBST in EU's most important 
export markets. Recent experiences of US dairy trade might throw some light 
on this issue. 
The most important US dairy export markets are Canada, Mexico, and 
East Asia, especially Japan and Taiwan. The most important dairy export prod-
ucts of the USA (in value) are cheese and nonfat dry milk powder. US cheese 
exports in 1994/95 were higher compared with the previous year. Shipments 
mostly went to Canada, Mexico, Japan and South Korea. Shipments of butter, 
nonfat dry milk and dry whole milk under the Dairy Export Incentive 
Programme (DEIP) were much larger in 1994/95 than in the previous year be-
cause of high demand. Mexico and Algeria have been the principal export mar-
kets for US nonfat dry milk. Also the South-East Asian region is a customer of 
US SMP. Sofar, there has been no indication that consumers in the importing 
countries would not accept US dairy products from rBST milk. 
Competition between the US and the EU could increase in the years to 
come in markets where rBST is (most likely to be) accepted. Looking at their top 
markets, the EU and the US seem to compete mainly in North Africa (Algeria) 
and in Japan. In North Africa, purchasing power is very low, so the region can 
be considered a dump market: in selling EU dairy products, trade can be real-
ized mainly because there is enough export support available from the EU. EU 
exports to North Africa are rather volatile from year to year. The same holds for 
US dairy exports to countries like Algeria and Egypt. Most of the transactions 
are supported by the DEIP. Competition between the EU and the US depends 
very much on the availability of funding for export support. Both countries 
have to reduce export subsidies under the GATT agreement. This may result in 
less support for exports from the EU as well as from the US to North Africa in 
the years to come. An increase in commercial exports from the EU and/or US 
could offset this decline, but depends on the development of purchasing 
power in this region. As already noticed above, acceptance of rBST is very likely 
in this region. This could strengthen US competitive position in these markets. 
Japanese consumers are requesting food products of highest quality and 
are willing to pay for that. In volume, Japan is an important importer of cheese: 
it has the second position (after the USA) as the world's largest non-EU import-
ers of cheese. Around two-thirds of total cheese imports comes from Oceania, 
while imports from the EU cover around 15-20% and those from the USA only 
1-2%. Cheese consumption in Japan has increased by almost a quarter since 
1990, boosting imports to around 30%. Consumption per capita is, however, 
still rather low compared to other high income countries: only 1.4 kg, which is 
around 20% of the consumption level in countries like Australia and New Zea-
land, and no more than 10% of the EU and US levels. These consumption f ig-
ures indicate that Japan can be considered as a growing market for dairy prod-
ucts, especially for cheese. The OECD expects a significant increase of SMP and 
cheese consumption between 1994 and 2000, together wi th an almost stable 
milk production (OECD, 1995b:35). As a consequence, Japanese cheese imports 
are projected to increase by 20% in the period under consideration. Most 
likely, Oceania will be able to benefit mostly from this consumption growth; 
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the already strong position of Australia and New Zealand in the Japanese mar-
ket shows that these countries are very competitive. EU exports to Japan may 
grow too, but can be endangered when rBST is allowed in the EU. Experiences 
of US dairy exports to Japan do not give indications strong enough to draw 
conclusions on that. US dairy exports to Japan have been increasing strongly 
since the beginning of the 1990s, but the USA is still a very small player in the 
Japanese market. Perhaps for this reason, import of US dairy products made 
from rBST milk is not really in discussion in Japan. 
The net effect of rBST use in the EU on its international position also de-
pends on the extent the productivity enhancer is used in other countries than 
the USA and the EU in the next century. In around 20 countries, rBST is licensed 
for sale, while rBST is being sold already in 8 countries (section 2.4). Excluding 
the USA, within the latter group of countries, the use of rBST is still, as far as 
known, very limited. However, in the years to come, adoption of rBST could 
become much more widespread. If so, milk production is stimulated in these 
countries, of which some of them may explore attributed export potentials. The 
result may be an increasing competition on international markets. Presently, 
in important dairy exporting countries like Australia, New Zealand and Canada, 
rBST is not permitted. Of these three countries, Canada could well change its 
position shortly, as the moratorium on the sale of rBST has ended in July 1995. 
However, no final decision has been made as of February 1996. The possible 
benefits to the EU dairy industry from using rBST would be limited if more 
countries adopt rBST in the near future. At the same time, if the productivity 
enhancer is adopted more widely, the EU may be forced to allow rBST use be-
cause of the threat that its exports might decline. However, the EU could also 
benefit from extending the ban on rBST use, if consumers in their major export 
markets insist on rBST-free dairy products and are will ing to pay for that. Be-
sides carefully examining all possible effects on the internal market and the 
structure of the sector, the decision whether to use rBST or not in the EU has 
to be taken by scrutinising the possible reactions by consumers on the export 
markets and the policy in other countries wi th respect to rBST use. 
7.5 Concluding remarks 
The abolishment of the quota system is expected to result in increased 
production and net exports, plus an accelerating structural change in the dairy 
sector towards more concentration of production, on farm as well as on re-
gional level. The adoption of rBST reinforces these effects: more production 
and exports, lower internal prices, fewer but bigger dairy holdings, and more 
regional concentration of production. Those effects may be socially negative 
if the pace and extent of structural changes exceed certain limits, i.e., many 
farmers have to leave the sector. The introduction of rBST may also have envi-
ronmental effects, but these are not unambiguous. The use of the hormone 
may induce less intensive farming if the increase in the yield per cow results in 
less milk cows per hectare. However, the need for more feed concentrates may 
counteract such a positive environmental effect. Furthermore, an increase in 
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concentration of dairy farming is expected when rBST is used and this may rein-
force depopulation of rural areas. Fear for such possibly negative developments 
may cause policy makers to refrain from milk quota abolishment and rBST use. 
On the other hand, a scenario in which no milk quota system exists and 
rBST is allowed, may contribute to an improvement of the international com-
petitiveness of the EU dairy, as it creates opportunities for increasing operation 
of scale, inducing more efficient dairy farming with lower production costs. 
Such a structural development seems to become more and more necessary as 
agricultural support changes from product-tied support to other forms. More 
specifically, export support has to be reduced under GATT commitments. How-
ever, the EU's international trade position in dairy markets also depends on 
aspects of food quality, food safety and animal welfare, all aspects that can be 
related to the use of rBST. If the EU introduces rBST, it has to be sure that its 
exports are not endangered by consumers who do not accept products pro-
cessed from rBST milk in the importing countries; especially in certain high in-
come countries, consumers may have a strong resistance to accept dairy prod-
ucts produced with rBST. These high income export markets will grow in impor-
tance as export support is reduced. Presently, there is too little information 
about consumers' attitude towards rBST in countries of importance to EU dairy 
exports to have a clear idea of the risks involved. Further research on consum-
ers' attitude in the major EU export markets may provide the information that 
is now lacking. 
85 
REFERENCES 
Almas, R. (1991) 
Norske ofamerikanske bonders syn pà bioteknologi i landbruket (Norwe-
gian and American farmers view on agricultural biotechnology); Centre 
for Rural Research, Trondheim; Report 1/91 
Almas, R. and B. Nygârd (1994) 
European Values and the new Biotechnologies. Post-materialism or a 
New Arena of Rural-Urban Conflict?; Paper to the XVth European Con-
gress of Rural Sociology, August 2-6,1993; Wageningen, the Netherlands, 
Centre for Rural Research, Trondheim; Paper 4/94 
Almas, R. and B. Nygârd (1995) 
New Biotechnologies: Attitudes, Social Movements and Regulation. A 
comparative Analyses of a European discourse; Paper to the XVIth Euro-
pean Congress of Rural Sociology; Prague, Czech Republic, 31 July - 4 
August 1995; Centre for Rural Research, Trondheim; Paper 2/95 
Andersen, S. (1992) 
Debatten om bioteknologi i Tyskland (The debate on biotechnology in 
Germany); In: Bioteknologi og etik i den offentlige debat; Kobenhavn, 
TeknologiNaevnet; Report 1992/3 
Baumgardt, Bill R. and Marshall A. Martin (eds.) (1991) 
Agricultural Biotechnology. Issues and Choices. Information for Decision 
Makers; West Lafayette, IN, Purdue University Agricultural Experimenta-
t ion Station 
Barham, Bradford L. et al. (1995) 
The Political Economy of rBST Adoption in America's Dairyland; ATFFI 
Technical Report No. 2; Agricultural Technology and Family Farm Insti-
tute, College of Agricultural and Life Sciences, University of Wisconsin, 
Madison, Wl 
Beck, U.(1992) 
Risk Society: Towards a New Modernity, London, Sage Publishers 
Bent, Martin (ed.) (1993a) 
Livestock Productivity Enhancers: An Economic Assessment; Wall ingford, 
CAB International 
86 
Bent, Martin (1993b) 
The European Approval Procedures for Livestock Productivity Enhancers; 
In: Bent, 1993a; pp. 24-42 
Berkum, S. van (1994) 
Gevolgen van het GATT-akkoord voor de EU-landbouw (Consequences 
of the GATT agreement for EU agriculture); The Hague, LEI-DLO; 
Mededeling 505 
Berrier, R.J. (1987) 
Public Perceptions of Biotechnology, In: L.R. Batra and W. Klassen (eds.), 
Public Perceptions of Biotechnology; Bethesda, Agricultural Research 
Institute 
Blayney, Don P. and Richard F. Fallen (1990) 
Biotechnology and Agriculture: Emergence of Bovine Somatotropin (bST); 
Washington, DC, United States Department of Agriculture, Economic 
Research Service, Commodity Economics Division; Staff Report AGES 9037 
Caswell, M.F., K.O. Fuglie and CA. Klotz (1994) 
Agricultural Biotechnology. An Economic Perspective; Washington, DC, 
United States Department of Agriculture; Agricultural Economics Reports 
No. 687 
CEC- Commission of the European Communities (CEC) (1994) 
Report on the market situation for milk and dairy products; Brussels, CEC; 
COM(94)64 def. 
CEC - Commission of European Communities (1995) 
The Agricultural Situation Report 
Dixon, B. (1991) 
No more Shallow Alarms; Bio/Technology, Vol. 9, No 1 
D'Silva, Joyce (1994) 
The cynical abuse: BST - A welfare analysis; Petersf ield, UK, Compassion 
in World Farming 
Fallert, Richard et al. (1987) 
bSTand the Dairy Industry: A National, Regional, and Farm-level Analysis; 
Washington, DC, United States Department of Agriculture, Economic 
Research Service; AER No. 579 
Folmer, C, M.A. Keyzer, M.D. Merbis, H.J.J. Stolwijk and P.J.J. Veenendaal (????) 
The Common Agricultural Policy beyond the Mac Sharry Reform; Amster-
dam, Elsevier Science Publishers 
87 
Habraken, R. (1994) 
fen verkennend onderzoek naar de ideale vestigingsplaats in de EG voor 
een melkveehouderijbedrijf; The Hague, Den Bosch, LEI-DLO/Agrarische 
Hogeschool 
Hallberg, Milton C. (ed.) (1992) 
Bovine Somatotropin & Emerging Issues. An Assessment, Westview, Boul-
der, CO 
Hamstra, A. (1991) 
Biotechnology in foodstuffs, towards a model of consumer acceptance; 
The Hague, SWOKA Institute for Consumer Research; SWOKA Research 
Report No. 105 
Hamstra, A. (1992) 
Consumer research on biotechnology, In: John Durant (ed.). 
Biotechnology in Public: A Review of Recent Research; London, Science 
Museum, for the European Federation of Biotechnology 
Hamstra, A. (1993) 
Consumer Acceptance of Food Biotechnology, The relation between 
product evaluation and acceptance; The Hague, SWOKA Institute for 
consumer research; SWOKA Research Report 137 
Hoban, T. (1989) 
Anticipating Public Response to Biotechnology; The Rural Sociologist, 
Vol.9, No.3, pp. 20-23 
Hoban, T., E. Woodrum and R. Czaja (1992) 
Public opposition to Genetic Engineering; Rural Sociology, Vol.57, No.4, 
pp. 476-493 
Hoop, D.W. de et al. (1988) 
Economische effecten van het gebruik van Bovine Somatotropine; The 
Hague, LEI; Publikatie 1.21 
Hubbard, LJ. (1992) 
Two-tier pricing for milk: a re-examination; Journal of Agricultural Eco-
nomics, September 
Husted, J. (1992) 
Debatten om bioteknologi i Storbritannien (The debate on biotechnology 
in Great Britain); In: Bioteknologi og etik i den offentlige debat; 
Kobenhavn, TeknologiNaevnet; Report 1992/3 
88 
INRA(1993), 
Eurobarometer 39.1; Biotechnology and Genetic Engineering: What Euro-
peans think about it in 1993; Brussels, Commission of the EC 
Jervell, A.M. (1993) 
Farmers' attitudes to milk quota policy in Norway, Sociologia Ruralis, 
Vol. XXXIII (3/4), pp. 365-382 
Juskevich, Judith C. and C. Greg Guyer (1990) 
Bovine Growth Hormone: Human Food Safety Evaluation; Science, Vol. 
249, pp. 875-884 
Kelholt, H.J. (1994) 
Ontwikkelingen in de melkverwerking en intra-EG-handel in 
zuivelprodukten Trends in Milk Processing and Intra EU Trade in Dairy 
Products; The Hague, LEI-DLO; Interne Nota 426 
Knoblauch, Wayne A. et al. (1995) 
Dairy Farm Performance with bST Supplementation; Unpublished manu-
script; Ithaca, New York, Department of Agricultural, Resource, and Man-
agerial Economics, Cornell University 
Kraft (1994) 
Bioetisk debatt i Norge 1993 (Bioethical debate in Norway 1993); In: J. 
Josefsson (ed.), Bioetisk debatt i Norden 1993; Copenhagen, Nordic 
Committe for Ethics in Biotechnology, Nordic Council; TemaNord 
1994:550 
Kuitert(1985) 
Genetische manipulatie: waar willen we ermee naartoe?; Christen 
Democratische Verkenningen 9/85, pp. 435-442 
Kvistgaard, M. and A. Neimann-Sorensen (1992) 
Sa m menfattende vurdering af anvendelse af BST (Summarized apprecia-
t ion of the use of BST); In: Sejrsen and Vestergaard (red): 
Kvaegvaeksthormon; Kobenhavn, TeknologiNaevnet; pp. 89-103 
Lager(1994) 
EU drofter hormonbruk (EU discusses the use of hormones); Bondebladet 
14 September 
Lassen, J. (1993) 
Food Quality and the Cunsumers; Ârhus, Denmark; MAPP Working Paper 
No. 8 
Lewis, H. W. (1990) 
Technological Risk; New York, NY, Norton & Company 
89 
LNV(1995) 
Dynamiek en vernieuwing; beleidsvoomemings op het gebied van 
Landbouw, Natuurbeheer en Visserij (Dynamics and renewal; policy plans 
on the field of agriculture, nature management and fisheries); The 
Hague, SDU 
Manchester, A., M.R. Weimar and R. Fallert (1994) 
The US dairy pricing system; USDA/ERS, Washington, DC; Agriculture In-
formation Bulletin Number 695 
Marlier, Eric (1992) 
Eurobarometer 35.1: Opinions of Europeans on Biotechnology in 1991; 
In: John Durant (ed.); Biotechnology in public: a review of recent re-
search; London, Science Museum, pp. 52-108 
Nilsson(1994) 
Bioetisk debatt i Sverige 1993; (Bioethical debate in Sweden); In: J. 
Josefsson (ed.), Bioetisk debatt i Norden 1993; Copenhagen, Nordic 
Committe for Ethics in Biotechnology, Nordic Council; TemaNord 
1994:550 
Nord (1995) 
Yearbook of Nordic Statistics 1995 (Vol 33); Copenhagen, Edited by the 
Nordic Statistical Secretariat, Nordic Council of Ministers 
OECD (1993) 
Agricultural policies, markets and trade; Monitoring and Outlook; Paris, 
OECD 
OECD (1995a) 
Agricultural policies, markets and trade; Monitoring and Outlook; Paris, 
OECD 
OECD (1995b) 
OECD Agricultural Outlook, 1996 edition; Paris, OECD 
Rabobank, (1995) 
Internationale concurrentiekracht in de melkveehouderij; Utrecht, 
Rabobank 
Rama, D. and M.J. Keane (eds.) (1993) 
Production costs for milk in European countries; Milan, FrancoAngeli 
Rama, D. and R. Pieri, (1995) 
The European dairy industry: consumption changes; vertical relations and 
firm strategies; Milan, FrancoAngeli 
90 
Rogers, E.M. (1992) 
Diffusion of Innovations; New York, NY, Free Press 
Sejrsen, K. (1992) 
Forogelse af maelkeydelsen ved anvendelse afBST (Increase in milk pro-
duction wi th the use of BST); In: Sejrsen og Vestergaard (red); 
Kvaegvaeksthormon; Kobenhavn, TeknologiNœvnet; pp. 20-26 
Senauer, Ben, Elaine Asp and Jean Kinsey (1991) 
Food Trends and the Changing Consumer, St. Paul, MN, Eagan Press 
Sjödèn, P.O. (1990) 
Oro och uppfattningar bland konsumenter, Vâr Föda, Vol. 42, Nr.3, 
s.176-185 
Smith, B. J. and Warland R. H. (1992) 
Consumer Responses to Milk from BST-supplemented Cows; In: Milton C. 
Hallberg (ed.) 
Steenkamp, J.E.B.M. (1992) 
De Europese Consument van Voedingsmiddelen in de Jaren '90; 
Assen/Maastricht, Van Gorcum 
Thompson, P. B. (1992) 
Ethical Issues and BST; In: Milton C. Hallberg (ed.) 
Tracy, M. (1989) 
Government and agriculture in Western Europe 1880-1888; New York, 
Harvester Wheatsheaf 
Troil, H. von (1994a) 
Bioetisk debatt i Finland 1993; In: J. Josefsson (ed.), Bioetisk debatt i 
Norden 1993; Kobenhavn, Nordic Committee for Ethics in Biotechnology, 
Nordic Council; TemaNord 1994:550 
Troil, H. von (1994b) 
Bio-ja geeniteniikan tiedotustarve Suomessa (The need for information 
on bio- and genetechnology in Finland); Unofficial report to the Ministry 
of the Environment in Finland 
Weimar, M.R. and D.P. Blayney (1994) 
Landmarks in the US dairy industry, Washington, USDA/ERS; Agriculture 
Information Bulletin Number 694 
91 
White paper no. 8 (1992-93) 
Om lov om framstilling og bruk av genmodifiserte organismer (The Nor-
wegian Gene Technology Act); Oslo, Miljoverndepartementet; Ot Prp nr. 
8 
Zechendorf, B. (1994) 
What the Public Thinks About Biotechnology, Bio/Technology, Vol. 12, 
No.9, pp. 870-875 
92 
APPENDICES 
93 
Appendix 1 Workshop report 
Introduction 
As part of the project on SOCIO-ECONOMIC ASPECTS OF MODERN 
BIOTECHNOLOGY IN THE EUROPEAN UNION: THE CASE OF rBST, a workshop was held 
at LEI-DLO, The Hague, the Netherlands, on Tuesday, January 30, 1996. 
This workshop had several objectives. The first was to present preliminary find-
ings of the project to representatives of various stakeholders. Secondly, these represen-
tatives were asked to give their comments on these findings, in order to improve them. 
All participants were asked to present and discuss comments and to suggest modifica-
tions and additions to the findings. Thirdly, the workshop participants were asked to 
give suggestions for a useful research agenda for future socio-economic impact studies 
of agricultural biotechnology in general, and of rBST more specifically. 
This workshop report consists of the following parts: 
the programme of the workshop; 
the participants; 
a summary of presentations and discussion; 
suggestions for future research on socio-economic aspects of agricultural bio-
technology. 
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w o r k s h o p programme 
socio-economic aspects of modern 
biotechnology in the European 
Union: 
the case of rBST 
Tuesday January 3 0 , 1996 
at LEI-DLO, The H ague 
9.00 Welcome and opening by chairman Hans van der Kooi (Dutch Ministry of Ag-
riculture) 
9.15 Introduction of participants 
9.30 Outline of research project on 'Socio-economic aspects of modern 
biotechnology in the European Union: the case of rBST, by Jos Bijman (LEI-
DLO) 
10.00 Experiences in the USA, by Marshall Martin (Purdue University, USA) 
10.30 Questions 
10.45 Coffee Break 
11.00 Public acceptance in the EU, by Berit Nygârd (University of Trondheim, Nor-
way) 
11.30 Questions 
11.45 First round of reactions, by consumer organization, farmer organization, dairy 
industry, producer of rBST, animal welfare group, government 
Plenary discussion 
13.00 Lunch 
14.00 International trade aspects, by Siemen van Berkum (LEI-DLO) 
14.30 Questions 
14.45 Second round of reactions, by consumer organization, farmer organization, 
dairy industry, producer of rBST, animal welfare group, government 
Plenary discussion 
15.30 Research agenda for future socio-economic impact studies of agricultural 
biotechnology 
16.15 Conclusions, by chairman 
16.30 D r i n k s 
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Participants of the workshop on 'Socio-economic aspects of modern biotechnology in 
the European Union: the case of rBST 
Mr. R. Almas 
Mr. S. van Berkum 
Mr. W.J. Bijman 
Mr. P. Einarsson 
Mr. E.M. Epstein 
Mr. A. Haslinger 
Mr. H. van der Kooi 
Mr. R. Lang-Ree 
Mr. M. Linskens 
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Mrs. A. van der Neut 
Mrs. B. Nygârd 
Mr. C. Oldenbroek 
Mr. B.J. Pastoor 
Mr. B. Staes 
Mr. H. de Vriend 
Mr. J.M. Vrij 
Mr. P. Wit lox 
Centre for Rural Research, University of Trondheim, Norway 
Agricultural Economics Research Institute (LEI-DLO) 
Agricultural Economics Research Institute (LEI-DLO) 
Ecological Farmers of Sweden 
Arbeitsgemeinschaft der Verbrauchersverbände 
(Cooperative of Consumer Associations), Germany 
Ministry of Sience, Research and Art, Austria 
Dutch Ministry of Agriculture 
Norwegian Cattle, Norway 
Eurogroup for Animal Welfare, Brusssels 
Department of Agricultural Economics, Purdue 
University, USA 
Dutch Ministry of Agriculture 
Centre for Rural Research, University of Trondheim, Norway 
Institue for Animal Science and Health (ID-DLO), 
the Netherlands 
COPA-COGECA (European Farmers Organizations), Brussels 
European Parliament, Brussels 
Stichting Consument en Biotechnologie (Foundation 
for Consumer and Biotechnology), the Netherlands 
Netherlands Dairy Organization (NZO), the Netherlands 
Produktschap voor Zuivel (Commodity Board for Dairy 
Produce), the Netherlands 
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Summary of presentations and discussions 
No full text of the presentations will be given here. The information that was 
presented can be found in the main report. Below, the reader will find the highlights 
from the individual presentation, the discussion that followed each presentation and 
the general discussion. 
OUTLINE OF RESEARCH PROJECT 
by Jos Bijman (LEI-DLO) 
Bijman gave an outline of the history, the goals and the organization of the full 
project. It was carried out for the European Commission, as part of the BIOTECH 
programme, subprogramme on socio-economic impacts of biotechnology. The research 
team was put together to incorporate knowledge on European public attitude towards 
biotechnology (Centre for Rural Research, University of Trondheim, Norway), on rBST 
adoption in the USA (Department of Agricultural Economics, Purdue University, USA) 
and on dairy policies and competitiveness of the EU dairy industry (Agricultural Eco-
nomics Research Institute, the Netherlands). Subsequently, Bijman briefly presented the 
main issues in the societal debate on agrobiotechnology: safety of biotechnology prod-
ucts for human consumption, environmental impact, socio-economic impact on farm-
ing, animal health and welfare aspects and ethical aspects. Finally, Bijman stressed that 
the future of rBST in Europe depends on two main issues: (1) public attitude towards 
biotechnology in general and towards rBST in particular, and (2) the competitiveness 
of the EU dairy industry, given the GATT/WTO commitments and the use of rBST by 
major competitors. 
Discussion 
The short discussion that ensued the presentation by Bijman, focused on the 
limitations of the project. It was stressed by Bijman that this was only a small project, 
and that many issues that may play a role in the European debate on rBST were not 
explicitly taken up in the study. Thus, in this project, no specific attention has been 
given to animal welfare issues. They are considered to be part of the larger public atti-
tude issue. It is acknowledged, though, that perhaps the main topic underlying the 
public attitude towards rBST is the impact on animal welfare. This is still a worry of the 
European Commission, although many studies on animal health and welfare suggest 
their is no significant impact. Also the human health issue was not incorporated in the 
study, because the authorities have repeatedly stated that rBST is safe for human con-
sumption. 
A connection was made to the European conference on the use of hormones in 
animal production, held in Brussels, in November 1995. At this conference, most scien-
tists stated there are no significant human or animal health reasons to ban the use of 
certain hormones. However, despite this scientific evidence, almost all non-governmen-
tal organizations present expressed their concern and disapproval over the use of hor-
mones in animal production. 
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EXPERIENCES IN THE USA 
by Marshall Martin (Purdue University, USA) 
Martin gave a presentation on the experiences with rBST in the USA. His presen-
tation included information from Monsanto, from the FDA and from several university 
studies (for detailed information, see chapter 4). 
After several years of controversy and national debate, the Food and Drug Ad-
ministration approved, in November 1993, the commercial use of Posilac™, the version 
of rBST developed by Monsanto. Commercial sales began in February 1994. Now with 
two years of experience with its use, slightly more than one in ten US dairy farmers, 
representing some what more than one fourth of the US dairy herd, are using rBST. 
Based on available farm-level economic studies, rBST use does increase productiv-
ity about 10 pounds per cow per day during the final 250 or so days of the lactation. 
At current market-determined milk prices, these studies suggest that adopters of rBST 
can expect increased profits per pound of milk produced and per farm. 
To date there is no evidence of any significant adverse consumer reaction in the 
United States, despite the debate in the news media before the approval of rBST, and 
efforts by some activist groups to create fear among the public about potential adverse 
impacts of rBST on food safety and family dairy farms. In fact, both milk production 
and consumption have continued to increase. Government stocks of dairy products 
remain at historic low levels. Milk prices at the farm level remain at or slightly above 
levels of the period just before the approval of Posilac™. Moreover, these market de-
termined milk prices are about 20% higher than the government support price. In fact, 
farm-level milk prices have been consistently above the government price support level 
since the mid-1980s. 
While there may be some resistance to rBST adoption by dairy farmers in some 
traditional states such as Wisconsin and some New England states, farmers in the rest 
of the United States seem to be willing to use this new product of genetic engineering. 
rBST adoption rates seem to be following those projected by researchers in the ex ante 
studies conducted by the USDA in the late 1980s. 
For Americans, the debate and controversy over rBST appears to be essentially 
over. Furthermore, US government agencies have now approved several genetically 
engineered crops with insect or herbicide resistance including soybeans, canola, corn, 
cotton, and potatoes. They will be planted on a commercial basis in 1996. Thus, the 
United States, after huge private and government investments in the research and 
development of agricultural biotechnology, is beginning to see the adoption of these 
new technologies and a return on these private and public investments. 
There are several key questions that must be addressed at this conference. What 
will happen in the European Union with rBST in particular, and biotechnology in gen-
eral? How long will the ban on rBST use last in the European Union? Will educational 
and informational efforts, decisions by regulatory agencies, and actions by farmers, 
processors, and consumers permit adoption of these new technologies in the European 
Union? Will Europe lag behind the United States and experience a comparative tech-
nological disadvantage in terms of higher production costs, slower gains in improved 
product quality, slower rates of productivity gains, and possibly less environmentally 
friendly ways to produce food and fibre? 
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PUBLIC ACCEPTANCE IN THE EU 
by Berit Nygârd (University of Trondheim, Norway) 
Nygârd gave a presentation on public acceptance of agrobiotechnology and of 
rBST in several countries of the EU, as well as in Norway. Most of her findings on 
agrobiotechnology in general were based on the Eurobarometer studies, regularly 
repeated public opinion polls carried out in all countries of the EU. The conclusions on 
the public acceptance of rBST are based partly on the Eurobarometer information and 
partly on more specific information on the rBST debate in the individual countries. 
The content and intensity of the public discourse on biotechnology in European 
countries is rather different. Two aspects are of great importance: knowledge of 
biotechnology and fundamental values. First, the degree to which biotechnology has 
been an object of public discourse correlates with the degree of knowledge about 
biotechnology as well as the ability to influence its development. There has been con-
siderable discourse in those countries for which the Eurobarometer shows relatively 
high responses for knowledge of biotechnology. 
Second, cultural differences and variation in fundamental values contribute to 
forming people's attitudes towards modern biotechnology. Recent studies have shown 
that these attitudes are based on fundamental values. In contrast to (scientific) knowl-
edge, fundamental values remain relatively stable over time. 
In all countries selected for this study, there are organizations opposing the in-
troduction of rBST. While in the UK the concern for animal health especially is men-
tioned to reject rBST, in Germany and the Netherlands the expected negative consumer 
reactions are also major reasons to reject rBST. German consumers are especially sensi-
tive to the product and process characteristics of their food. In Norway, Sweden and 
Finland there is also strong support for the idea that rBST is an undesirable product. 
In all these countries, hardly anyone can be found who is in favour of using rBST. Only 
the biotechnology industry is in favour. However, according to the Eurobarometer 
results, people's confidence in information coming from industry is very low. 
Given that the current opposition to rBST is large, that the attitude towards 
biotechnology is for a large part determined by basic values, and that these values 
remain relatively stable over time, there is no reason to expect that the public attitude 
towards rBST will dramatically change in the near future. 
Discussion 
The discussion after Nygârds presentation focused on the value of the 
Eurobarometer studies. As it is the only public opinion survey available for the EU as 
a whole, the comparisons are very useful. However, some participants expressed their 
doubts about the value of the answers, as most questions and the added information 
are stated in a rather positive way. Another limitation of the Eurobarometer is the very 
general character of the biotechnology questions. From national public and consumer 
attitude studies is has become clear that people, in their opinion on biotechnology, 
make important distinctions between various applications of biotechnology. 
Transgenic animals, for instance, are rejected by almost anyone, while genetically mod-
ified plants with enhanced disease resistance are welcomed by most. One participant 
stressed that for assessing the future attitude on rBST it is more important to look at 
the debate on hormones in animal production than to the debate on biotechnology. 
Many people object to rBST because it is a hormone supplemented to cows, and not 
because it is made with the use of modern biotechnology. 
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First round of general discussion 
In the first round of reactions to the presentation the discussion focused on the 
public attitude and consumer behaviour aspects of rBST. The fol lowing points were put 
forward: 
Europe is culturally a very diverse continent. Therefore it is difficult to compare 
public and consumer attitudes in the USA wi th those in the Europe; 
Ex ante surveys of public att i tude do not always measure eventual consumer 
behaviour after a technology has been introduced. The US experience has shown 
that large public opposition to rBST did not lead to a large number of consumers 
rejecting milk from cows treated wi th rBST; 
for the acceptance of a biotechnology product it makes a big difference whether 
there is a need for such a product (i.e., new drugs), and whether there is a clear 
advantage for the consumer, the environment or the farmer (and not just for 
the company selling the new biotechnology product); 
rBST wil l have a small impact on the ongoing structural change in agriculture. 
It very much depends on the individual values how this structural change is per-
ceived. Moreover, the advantages and disadvantages of structural change are 
felt by different groups; 
according to studies on the impact of rBST use on milk prices, the economic ad-
vantages of rBST use wil l eventually be felt by the consumer, mostly the low 
income consumer. However, normally only a part of the decrease in milk prices 
at the farm gate will be transferred to the consumer. The other part of the price 
decrease is taken as extra profit by processors and retailers; 
consumers are increasingly interested in the way food is produced. Therefore, 
one should be very careful in introducing new farming technology that is criti-
cized by consumers; 
in assessing the expected consumer behaviour towards milk products from cows 
treated wi th rBST one should take into account the increasingly differentiated 
dairy market. Some consumer primarily look at prices and therefore they may 
accept milk f rom cows treated wi th rBST, while others are more interested in 
quality, and therefore reject such milk. 
COMPETITIVENESS OF EU DAIRY AND INTERNATIONALE TRADE ASPECTS, 
by Siemen van Berkum (LEI-DLO) 
Van Berkum, in his presentation on the international trade and competitiveness 
aspects, focused on the EU perspectives on the international dairy market and dis-
cussed the impact on EU's competitiveness of an abolit ion of the quota system and a 
lift of the ban on rBST use. The EU plays a very important role on the international 
dairy market: it is the most important production region in the world (25%) and by far 
the biggest supplier of dairy products on the international market (50%). However, 
future perspectives are not so promising. Due to binding GATT-commitments to reduce 
export subsidies emerging markets in far-away Asia where the EU has a relative weak 
position, and to possible changes in EU dairy policy (also related to eastward enlarge-
ment of the EU), the position of the EU on the international dairy market is projected 
to decline. In order to stay competitive. Van Berkum stated that the EU dairy industry 
may press for lifting the ban on rBST use. In pointing out some policy alternatives that 
focus on the issues of the quota system and rBST use. Van Berkum concluded that rBST 
is economically much more attractive to farmers once the quota system is eliminated, 
al though structural changes and regional concentration of EU dairy industry are ex-
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pected to be most pronounced under that scenario. Van Berkum stressed that the po-
tent ial positive contribution of the rBST use to EU dairy competitiveness depends 
strongly on the consumer attitude, not only in the EU, but also in the major export 
markets. 
Discussion 
In the discussion following Van Berkums presentation one participant asked why 
so much emphasis should be put on the competitiveness of EU dairy products on the 
world market. Another participant answered that for several EU countries, notably the 
Netherlands, the export of dairy product to third markets is of great importance. 
Once again it was stressed that consumers are increasingly searching for quality 
products. In Sweden and Denmark there has been a rapid expansion of the market for 
biological (or organic) dairy products. rBST does not f i t into this trend. 
If prices decline due to the abolishing of the quota system and the l ift ing of the 
ban on rBST use, consumption of dairy products wil l change. The amount of change 
depends on the price elasticity of demand for dairy products. 
Second round of general discussion 
In the second round of general remarks, the discussion focused on the economic 
aspects of using or not using rBST. The following gives the highlights of the discussion: 
the future of rBST use in the EU is closely related to the future of the quota sys-
tem. Under the quota system, the advantages of rBST use are much smaller than 
wi thout the production limitations; 
rBST is just one of the issues that determine the future of the dairy industry in 
the EU. Therefore, it should be assessed in relation to other issues like the envi-
ronment, product and market development, and more emphasis on quality in-
stead of quantity; 
rBST can be seen as an threat but also as an opportunity. If approved, it wi l l 
probably stimulate the growth of biological (organic) dairy products, whi le it 
also supplies cheaper dairy products for those who have low income; 
in looking at the adoption process in the USA, we may learn for our own near 
future: does the EU look like California (very large dairy herds), Wisconsin (many 
small family farms) or like New York (average size, modern dairy farms). 
Suggestions for future research on socio-economic aspects of rBST and other 
applications of agricultural biotechnology 
The fol lowing suggestions for future research on socio-economic aspects of 
agrobiotechnology and rBST were made during the workshop. These suggestions can 
be categorized according to the five dimensions of socio-economic impact studies men-
t ioned by Bijman is his presentation at the workshop. These five categories are: 
safety of biotechnology products for human consumption; 
environmental impact; 
socio-economic impact on farming (changing structure of agriculture, multina-
tionals dominating farming, patenting, etc.); 
animal health and welfare aspects; 
ethical aspects. 
101 
1. On animal health and welfare aspects: 
- carry out large scale field trials, for comparison of rBST treated cows with a 
control group; 
- carry out forecasting studies. 
2. The eventual price of the rBST product will be partly determined by the way it 
is distributed to the farms and administered to the cow. What role does the 
veterinarian play in this context? How will the method of distribution and ad-
ministration impact the price of the product, and thus the profitability for farm-
ers? 
3. Some concern has been raised about the impact of the use of rBST on the breed-
ing programmes for dairy cows. How does the use of rBST interfere with cattle 
breeding? 
4. Some participants feel that the EU decision making process is not transparent 
and some issues are left out. How can the decision making process be broad-
ened, so that other information and data (particularly on socio-economic impact 
and animal health/welfare) are incorporated? 
5. By closely monitoring the socio-economic effects of rBST use in the United States 
we may see what may happen in the EU once rBST is approved (of course with 
the specific European conditions taken into account). Does the European per-
spective look like the developments in Wisconsin or in other states? 
6. Research on consumer attitudes towards rBST should focus on: 
- consumers in EU dairy export markets; 
- under different kinds of information supplied; 
- ifferences in consumption patterns and consumer behaviour between EU and 
USA; 
- more detailed consumer response questions in the Eurobarometer; 
- study differences between attitude and (eventual) behaviour. 
7. We should not only look at rBST for productivity growth, but we should also 
look at alternatives in the cost/benefit analysis of rBST. 
8. If rBST will be approved, what will be the effect of two milk streams (milk from 
treated and from untreated cows), and what kind of labelling may be intro-
duced? 
9. If rBST is approved, segmentation of the dairy market may appear: bulk produc-
tion with rBST for processing into whole milk powder, e.g. for cheap exports, 
and non-rBST milk for high value added products, for internal markets and some 
quality export markets. 
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Appendix 3 Information about biotechnology, supplied with 
Eurobarometer questions 
1. Plants 
'Scientists are trying to use biotechnology and genetic engineering to change 
plants, in ways that may be quicker or more precise than tradit ional breeding 
programmes, in order to make the plants more useful. For example make them resis-
tant to diseases or pests, make them ripen faster or give them the ability to grow in dry 
or salty soil. Please indicate to what extent you agree or disagree wi th each of the fo l -
lowing statements concerning plant research.' 
2. Animals 
'Another development is the application of biotechnology and genetic engineer-
ing to farm animals, to change them in quicker or more precise ways than tradit ional 
breeding programmes, in order to make them more useful: for example, make them 
resistant to disease, or grow faster, or produce more or better quality meat or milk. 
Please indicate to what extent you agree or disagree with each of the fol lowing state-
ments concerning such research on farm animals.' 
3. Micro-organisms (A) 
'Let us now talk about micro-organisms, such as the yeast we use to make bread, 
or beer, or yoghurt; or the micro-fungi we use to make medicines such as penicillin. 
Scientists know how to change these micro-organisms through biotechnology and 
genetic engineering, in order to improve their performance - that means, getting them 
to work faster or even to produce new products. Please indicate to what extent you 
agree or disagree wi th each of the fol lowing statements concerning research and 
micro-organisms.' 
4. Micro-organisms (B) 
'Some of these micro-organisms are used to break down sewage and other waste 
products and to turn them into materials harmless to the soil. Here again, scientists are 
trying, through biotechnology and genetic engineering, to improve these micro-organ-
isms. They are trying to make them work faster or to make them clean up oil-slicks or 
other contaminants in the environment. Please indicate to what extent you agree or 
disagree wi th each of the fol lowing statements concerning micro-organisms and the 
environment.' 
5. Food 
'These new methods of biotechnology and genetic engineering are also being 
applied to the production and processing of foods. Scientists say that they can improve 
the quality of food and drink - for example by making it higher in protein, or lower in 
fat, or making it keep longer, or taste better. Please indicate to what extent you agree 
or disagree wi th each of the fol lowing statements concerning such research on food. ' 
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6. Medicines and vaccines 
'Yet another application of biotechnology and genetic engineering is the devel-
opment of new medicines and vaccines to improve human health, for example, the 
production of human insulin for the treatment of diabetics. Please indicate to what 
extent you agree or disagree with each of the following statements concerning such 
research on medicines and vaccines.' 
7. Human beings 
'Science is also trying to apply some of the new methods of biotechnology and 
genetic engineering to human beings, or to their cells and tissues, for various purposes 
such as detecting, or curing diseases, and characteristics we might have inherited from 
our parents. Please indicate to what extent you agree or disagree with each of the 
following statements concerning such research on human beings, medicines and vac-
cines.' 
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Appendix 4 Support for various forms of biotechnological research 
In the Eurobarometer, the informants were asked to indicate whether they defi-
nitely agree, tend to agree or disagree, or definitely disagree with different three 
statements about different types of biotechnological research: 
'Such research is worthwhile and should be encouraged'; 
'Such research may involve risks to human health or to the environment'; 
'In any case, this research needs to be controlled by the government. 
In order to compare the support for the various technologies, we will look at the 
national breakdowns of means for each technology. These means are calculated by 
applying the coefficients +2, +1, -1 and-2 to the responses 'definitely agree', 'tend to 
agree', 'tend to disagree' and 'definitely disagree' respectively; the central point is 
therefore 0: below this point, negative responses predominate, and above, positive 
responses. 'Don't knows' are excluded from the calculation. This simplification will also 
make it easier to compare the opinions in different countries. 
The following table presents the national breakdown of means for each technol-
ogy for the statement 'Such research is worthwhile and should be encouraged'. 
Plants Farm Microorg Microorg Foods Medicine Human Means 
ani- (A) (6) vaccins beings of 
mals means 
Norway 
Denmark 
Netherlands 
W-Germany 
E-Germany 
Great Britain 
Luxembourg 
Belgium 
Ireland 
N-lreland 
France 
Greece 
Italy 
Spain 
Portugal 
Average, 
all countries 
0.67 
0.83 
0.86 
0.29 
0.86 
1.00 
0.57 
1.17 
0.93 
0.70 
1.01 
0.76 
0.82 
1.08 
0.94 
0.83 
-0.12 
-0.23 
-0.60 
-0.39 
0.14 
-0.23 
-0.26 
0.15 
0.13 
-0.30 
-0.11 
0.40 
0.12 
0.51 
0.29 
-0.04 
1.04 
1.07 
1.28 
0.68 
1.19 
1.22 
0.92 
1.36 
1.14 
0.94 
1.32 
0.89 
1.18 
1.21 
1.26 
1.11 
1.41 
1.60 
1.63 
1.15 
1.49 
1.53 
1.29 
1.61 
1.44 
1.24 
1.56 
1.53 
1.50 
1.41 
1.47 
1.46 
0.56 
0.17 
0.57 
-0.21 
0.30 
0.41 
0.13 
0.83 
0.62 
0.47 
0.53 
0.49 
0.52 
0.85 
0.86 
0.47 
1.59 
1.64 
1.56 
1.02 
1.48 
1.58 
1.54 
1.66 
1.59 
1.47 
1.61 
1.67 
1.53 
1.52 
1.63 
1.54 
0.64 
1.15 
1.00 
0.22 
0.57 
1.05 
1.05 
1.33 
1.21 
0.96 
1.36 
1.30 
0.88 
1.22 
1.40 
1.02 
0.83 
0.89 
0.90 
0.39 
0.86 
0.94 
0.75 
1.16 
1.01 
0.78 
1.04 
1.01 
0.94 
1.11 
1.12 
0.91 
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Appendix 5 Concern about the risk of using biotechnology 
'Such research may involve risks to human beings or to the environment', na-
tional breakdowns of means for each technology. 
Norway 
Denmark 
Netherlands 
W-Germany 
E-Germany 
Great Britain 
Luxembourg 
Belgium 
Ireland 
N-lreland 
France 
Greece 
Italy 
Spain 
Portugal 
Average, 
all countries 
Plants 
0.68 
1.09 
0.66 
1.03 
0.68 
0.34 
0.89 
0.27 
0.54 
0.68 
0.44 
1.05 
0.37 
0.22 
0.72 
0.65 
Farm 
ani-
mals 
0.72 
1.16 
1.10 
1.20 
0.86 
0.60 
1.02 
0.83 
0.83 
0.91 
0.83 
1.12 
0.54 
0.51 
0.96 
0.88 
Micro-org 
(A) 
0.60 
1.10 
0.69 
0.88 
0.57 
0.35 
0.95 
0.41 
0.53 
0.82 
0.37 
0.96 
0.13 
0.16 
0.66 
0.60 
Micro-org 
(B) 
0.29 
0.92 
0.42 
0.63 
0.38 
0.38 
0.65 
0.20 
0.50 
0.70 
0.28 
0.50 
-0.10 
0.15 
0.48 
0.41 
Foods 
0.68 
1.20 
0.68 
1.16 
0.87 
0.47 
0.98 
0.69 
0.59 
0.83 
0.60 
1.09 
0.40 
0.37 
0.75 
0.75 
Medicine 
aaccines 
0.29 
0.94 
0.59 
0.83 
0.47 
0.36 
0.61 
0.26 
0.45 
0.54 
-0.01 
0.15 
-0.14 
-0.04 
0.58 
0.39 
Human 
beings 
0.95 
1.21 
0.86 
1.11 
0.87 
0.69 
0.81 
0.66 
0.74 
0.81 
0.36 
0.48 
0.35 
0.24 
0.77 
0.73 
Means 
of 
means 
0.60 
1.09 
0.71 
0.98 
0.67 
0.46 
0.84 
0.47 
0.60 
0.76 
0.41 
0.76 
0.22 
0.23 
0.70 
0.63 
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Appendix 7 Intra-EU trade in dairy products in 1993 (million ECU) 
Table A7.1 Intra-EU trade in dairy products in 1993 (million ECU) 
Product Total value 
of exports 
11,964 
5,022 
1,744 
690 
1,205 
473 
877 
1,627 
Main exporters 
country 
Germany 
France 
Netherlands 
BelgVLux. 
Netherlands 
France 
Germany 
Netherlands 
Ireland 
BelgVLux. 
France 
Germany 
BelgVLux. 
Germany 
Ireland 
France 
Germany 
Netherlands 
France 
BelgVLux. 
Germany 
Germany 
BelgVLux. 
France 
value 
3,129 
2,467 
2,242 
1,421 
1,357 
1,228 
950 
438 
340 
299 
291 
151 
84 
662 
135 
122 
196 
145 
210 
207 
203 
749 
311 
291 
Main importers 
country 
Germany 
Italy 
Netherlands 
BelgVLux. 
Germany 
Italy 
Netherlands 
France 
Germany 
BelgVLux. 
Netherlands 
BelgVLux. 
Netherlands 
Italy 
Greece 
United Kingdom 
Netherlands 
Germany 
France 
BelgVLux. 
Italy 
BelgVLux 
France 
value 
2,240 
2,124 
1,691 
1,527 
1,479 
907 
365 
355 
331 
313 
155 
125 
455 
250 
141 
169 
139 
124 
116 
115 
654 
270 
265 
Dairy total 
of which: 
Cheese 
Butter 
WMP 
SMP 
Condensed milk 
Fresh dairy products 
and ice-cream 
Fresh milk 
Source: Eurostat Trade Statistics (EXMIS/LEI-DLO). 
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